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A B S T R A C T
Background
It is unclear whether blood pressure should be altered actively during the acute phase of stroke. This is an update of a Cochrane review
first published in 1997, and previously updated in 2001 and 2008.
Objectives
To assess the clinical effectiveness of altering blood pressure in people with acute stroke, and the effect of different vasoactive drugs on
blood pressure in acute stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (last searched in February 2014), the Cochrane Database of Systematic reviews
(CDSR) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, Issue 2), MEDLINE
(Ovid) (1966 to May 2014), EMBASE (Ovid) (1974 to May 2014), Science Citation Index (ISI, Web of Science, 1981 to May 2014)
and the Stroke Trials Registry (searched May 2014).
Selection criteria
Randomised controlled trials of interventions that aimed to alter blood pressure compared with control in participants within one week
of acute ischaemic or haemorrhagic stroke.
Data collection and analysis
Two review authors independently applied the inclusion criteria, assessed trial quality and extracted data. The review authors cross-
checked data and resolved discrepancies by discussion to reach consensus. We obtained published and unpublished data where available.
Main results
We included 26 trials involving 17,011 participants (8497 participants were assigned active therapy and 8514 participants received
placebo/control). Not all trials contributed to each outcome. Most data came from trials that had a wide time window for recruitment;
four trials gave treatment within six hours and one trial within eight hours. The trials tested alpha-2 adrenergic agonists (A2AA),
angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor antagonists (ARA), calcium channel blockers (CCBs), nitric
oxide (NO) donors, thiazide-like diuretics, and target-driven blood pressure lowering. One trial tested phenylephrine.
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At 24 hours after randomisation oral ACEIs reduced systolic blood pressure (SBP, mean difference (MD) -8 mmHg, 95% confidence
interval (CI) -17 to 1) and diastolic blood pressure (DBP, MD -3 mmHg, 95% CI -9 to 2), sublingual ACEIs reduced SBP (MD -
12.00 mm Hg, 95% CI -26 to 2) and DBP (MD -2, 95%CI -10 to 6), oral ARA reduced SBP (MD -1 mm Hg, 95% CI -3 to 2) and
DBP (MD -1 mm Hg, 95% CI -3 to 1), oral beta blockers reduced SBP (MD -14 mm Hg; 95% CI -27 to -1) and DBP (MD -1 mm
Hg, 95% CI -9 to 7), intravenous (iv) beta blockers reduced SBP (MD -5 mm Hg, 95% CI -18 to 8) and DBP (-5 mm Hg, 95% CI -
13 to 3), oral CCBs reduced SBP (MD -13 mmHg, 95% CI -43 to 17) and DBP (MD -6 mmHg, 95% CI -14 to 2), iv CCBs reduced
SBP (MD -32 mmHg, 95% CI -65 to 1) and DBP (MD -13, 95% CI -31 to 6), NO donors reduced SBP (MD -12 mmHg, 95% CI
-19 to -5) and DBP (MD -3, 95% CI -4 to -2) while phenylephrine, non-significantly increased SBP (MD 21 mmHg, 95% CI -13 to
55) and DBP (MD 1 mmHg, 95% CI -15 to 16).
Blood pressure lowering did not reduce death or dependency either by drug class (OR 0.98, 95% CI 0.92 to 1.05), stroke type (OR
0.98, 95% CI 0.92 to 1.05) or time to treatment (OR 0.98, 95% CI 0.92 to 1.05). Treatment within six hours of stroke appeared
effective in reducing death or dependency (OR 0.86, 95% CI 0.76 to 0.99) but not death (OR 0.70, 95% CI 0.38 to 1.26) at the end
of the trial. Although death or dependency did not differ between people who continued pre-stroke antihypertensive treatment versus
those who stopped it temporarily (worse outcome with continuing treatment, OR 1.06, 95% CI 0.91 to 1.24), disability scores at the
end of the trial were worse in participants randomised to continue treatment (Barthel Index, MD -3.2, 95% CI -5.8, -0.6).
Authors’ conclusions
There is insufficient evidence that lowering blood pressure during the acute phase of stroke improves functional outcome. It is reasonable
to withhold blood pressure-lowering drugs until patients are medically and neurologically stable, and have suitable oral or enteral access,
after which drugs can than be reintroduced. In people with acute stroke, CCBs, ACEI, ARA, beta blockers and NO donors each lower
blood pressure while phenylephrine probably increases blood pressure. Further trials are needed to identify which people are most likely
to benefit from early treatment, in particular whether treatment started very early is beneficial.
P L A I N L A N G U A G E S U M M A R Y
Drug interventions for deliberately altering blood pressure in acute stroke
Background: In people who have just had a stroke (a sudden brain attack due to either blockage or rupture of an artery in the brain),
very high and very low blood pressures may be harmful. Therefore, drugs that raise low blood pressure or lower high blood pressure
might be beneficial. Up to 50% of people admitted with acute stroke are taking blood pressure tablets on hospital admission and it is
not clear whether these medications should be continued or discontinued in the acute situation. This review looked at those trials that
deliberately altered blood pressure or compared continuing or stopping blood pressure-lowering tablets taken before stroke.
Study characteristics: This review is up-to-date to May 2014. We included 26 trials involving 17,011 participants: 24 trials assessed
lowering blood pressure, one trial tested raising blood pressure, and two trials assessed what to do with drugs taken before stroke. All
studies took place in hospitals that were used to treating people with stroke. Not all trials contributed information to all outcomes, and
we have used data that were available in publications.
Key results: There is insufficient evidence to say that lowering blood pressure saves lives or reduces disability in people with acute
stroke. Immediately restarting blood pressure-lowering drugs taken before the stroke may increase disability.
Conclusion: More research is needed to identify those people who are most likely to benefit from altering blood pressure in acute
stroke, the time window in which the treatment is likely to be of benefit, what types of stroke are likely to respond favourably, and the
environment in which such treatment may be best given in routine practice.
B A C K G R O U N D
Description of the condition
Stroke is the third most common cause of death and the most
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common cause of disability in the western world. Acute stroke,
whether due to infarction or haemorrhage, is associated with high
blood pressure in 75% of patients, of whom 50% have a previ-
ous history of high blood pressure (Britton 1986; Oppenheimer
1992). After a stroke, blood pressure falls in most patients over
a week although a third of patients remain hypertensive (Wallace
1981; Britton 1986; Harper 1994). A number of small studies
have assessed the relationship between blood pressure (Marshall
1959; Adams 1965; Droller 1965; Bourestom 1967;Marquarsden
1969; Carlberg 1993) and outcome. Ameta-analysis of these stud-
ies found that elevated blood pressure was associated with a poor
outcome (Willmot 2004). Data from 17,398 participants in the
International Stroke Trial identified a U-shaped relationship such
that both low and high blood pressure were associated indepen-
dently with increased early death and later death or dependency
(Leonardi-Bee 2002), a finding that has been replicated by others
(Castillo 2004; Vemmos 2004). High blood pressure is also asso-
ciated with an increased early recurrence of stroke (Leonardi-Bee
2002; Sprigg 2006).
The mechanisms underlying high blood pressure in stroke are
complex but pre-existing hypertension, hospitalisation stress, acti-
vation of the sympathetic renin-angiotensin-aldosterone, cortisol
and natriuretic peptide neuroendocrine systems, and the Cush-
ing reflex (raised blood pressure secondary to raised intracranial
pressure) all contribute (Myers 1982). In ischaemic stroke, high
blood pressure also appears to adversely affect outcome through
increasing the risk of cerebral oedema, but not haemorrhagic trans-
formation (Leonardi-Bee 2002). Haematoma expansion is related
to high blood pressure in people with intracerebral haemorrhage
(ICH) although this relationship may be confounded by stroke
severity and time to presentation (Fujii 1994; Kazui 1997; Fujii
1998; Bath 2003).
Description of the intervention
Although debated more than 29 years ago, it still remains unclear
whether high blood pressure should (Spence 1985) or should not
(Yatsu 1985) be treated acutely following stroke. Recent guidelines
recommend that acute lowering of blood pressure should be de-
layed for several days or even weeks unless blood pressure is greater
than 220/120 mmHg, blood pressure is greater than 200/100
mmHg with end organ involvement (hypertensive encephalopa-
thy, aortic dissection, cardiac ischaemia, pulmonary oedema, acute
renal failure), or blood pressure is greater than 200/120 mmHg
with primary ICH, are present (O’Connell 1994; EUSI 2004;
AHA-HS 2010; RCP 2012; AHA-IS 2013). Though the evidence
is weaker, guidelines now recommend that patients who have ele-
vated blood pressure and are otherwise eligible for treatment with
recombinant tissue plasminogen activator may have their blood
pressure lowered so that systolic blood pressure (SBP) is less than
or equal to 185 mmHg and diastolic blood pressure (DBP) is
less than or equal to 110 mmHg before thrombolysis using in-
travenous labetalol, nitroprusside or nicardipine and it should be
maintained below 180/105 mmHg for at least the first 24 hours
after therapy (AHA-IS 2013). Unfortunately, such guidelines are
inconsistent and are based on theoretical arguments and individ-
ual case reports, and not on the results of systematic overviews or
large intervention trials of blood pressure manipulation in acute
stroke. Nevertheless, a number of case reports and series have sug-
gested that active lowering of blood pressure in people with pri-
mary intracranial haemorrhage and ischaemic stroke may improve
(Dandapani 1995; Chamorro 1998) or worsen (Graham 1975;
Britton 1980; Fischberg 2000) outcome.
Low blood pressure is not common in acute stroke but it, like high
blood pressure, is associated with a poor outcome (Leonardi-Bee
2002). Possible reasons for low blood pressure include potentially
reversible conditions such as hypovolaemia, sepsis, impaired car-
diac output secondary to cardiac failure, arrhythmias or cardiac
ischaemia, and aortic dissection (Sprigg 2005). Guidelines recom-
mend that causes of hypotension in the setting of acute stroke
should be sought with the view to correcting reversible causes such
as hypovolaemia and cardiac arrhythmias (AHA-IS 2013). Since
cerebral autoregulation is lost following stroke (Strandgaard 1973;
Burke 1986; Paulson 1990), such that cerebral blood flowbecomes
dependent on systemic blood pressure, some researchers have hy-
pothesised that blood pressure should be increased to improve
cerebral perfusion (Sandercock 1992) and a case series (Rordorf
1997) and a pilot randomised trial of phenylephrine (Hillis 2003)
reporting this approach have been published.
How the intervention might work
Although the different drugs assessed work in a variety of ways, all
lower (or elevate - phenylephrine) blood pressure.
Why it is important to do this review
We are reviewing this topic in three parts (Bath 1997).
Part 1: this review
Assessment of trials in which the primary aim of the intervention
was to alter blood pressure in people with acute stroke with the
aim of improving clinical outcome.
A Cochrane review of blood pressure intervention in stroke pub-
lished in 2001 (BASC 2001) updated the original reviewpublished
in 1997. It was again updated in 2008 to include more informa-
tion from 13 trials published between 2003 and 2008 including
a total of 1153 participants (BASC 2009). With a relatively small
amount of data, there was insufficient evidence to evaluate the
effect of altering blood pressure during the acute phase of stroke.
The present review includes all new trials completed and pub-
lished since 2008. The total number of participants is now 17,011,
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a 14-fold increase since the review in 1997 and 2008. Although
many of the data are from trials testing blood pressure alteration
in the acute phase (≤ 48 hours), some recent trials have exam-
ined specific questions such as lowering blood pressure in ICH
(INTERACT pilot 2008; INTERACT-2 2013), with angiotensin
receptor antagonists (SCAST 2011), or glyceryl nitrate (ENOS
2014) or in the pre-hospital setting (PIL-FAST 2013; RIGHT
2013). Furthermore, two trials (COSSACS 2010; ENOS 2014)
have investigated whether to continue or stop temporarily pre-
stroke antihypertensive therapy. This systematic review includes
these data and provides up-to-date evidence.
Part 2: vasoactive drugs for acute stroke
Assessment of trials where vasoactive drugs were administered
to people with acute stroke and where clinical outcome was
measured. Drugs include: alpha receptor antagonists, angiotensin
converting enzyme inhibitors (ACEI), angiotensin II receptor
inhibitors (ARA), beta receptor antagonists, calcium channel
blockers (CCB), diuretics, magnesium, naftidrofuryl, nitric oxide
donors (nitrates), papaverine, pentoxifylline, prostacyclin, sero-
tonin receptor antagonists, sympathomimetics, theophylline (and
mimetics), thromboxane A2 antagonists, vinpocetine, and their
derivatives. Aggregated patient data are analysed separately for
drugs which lower and elevate blood pressure (BASC 2000).Work
on this analysis is ongoing.
Part 3: analysis of individual patient data from
the trials identified in parts 1 and 2
Work on this analysis is ongoing through the international Blood
pressure inAcute StrokeCollaboration. In brief, individual patient
data from the trials included in Part 1 and Part 2 are being collated
with the intention of extending analyses, particularly in subgroups
of participants and interventions.
O B J E C T I V E S
To assess the clinical effectiveness of altering blood pressure in
people with acute stroke, and the effect of different vasoactive
drugs on blood pressure in acute stroke.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published and unpublished randomised controlled trials (RCTs)
of vasoactive drugs in acute ischaemic stroke or acute intracerebral
haemorrhage (ICH) where the aim of the trial was to alter blood
pressure, and drug therapy was initiated within one week of stroke
onset. We excluded uncontrolled studies, confounded controlled
studies where two or more active interventions were compared,
and studies of people with subarachnoid haemorrhage.
Types of participants
Adults (age 18 or older) of either sex with acute ischaemic stroke
or ICH who were eligible for randomisation to either active treat-
ment, or placebo or open control.
Types of interventions
We sought RCTs evaluating single or multiple agents of deliberate
blood pressure lowering or elevation in acute stroke, regardless of
dosage or route of treatment, compared against placebo or open
control.We also included trials with two groups receiving different
doses of the same BP lowering agent, and studies assessing effects
of continuing or stopping pre-existing antihypertensive treatment.
Types of outcome measures
Primary outcomes
• Combined death or disability/dependency at end of trial (≥
one month after stroke). We defined death or dependency as the
modified Rankin Scale (mRS) > 2 (or > 3 as available).
Secondary outcomes
• Blood pressure when first measured after randomisation.
• Early case fatality (< one month).
• Late case fatality (≥ one month).
• Early neurological deterioration (< one month). As there is
no consensus on how early neurological deterioration should be
standardised, we used the trial-specific definition as a decrease in
the Scandinavian Stroke Scale (SSS) of > 5 points or a decrease in
consciousness part of the SSS by > 2 points (ENOS 2014),
increase in the National Institutes of Health Stroke Scale
(NIHSS) of 2 (Koch 2008) or more (CHHIPS 2009; COSSACS
2010; INTERACT-2 2013) or decline of 2 or more points in
Glasgow Coma Scale (GCS) (INTERACT-2 2013).
• Late disability or dependency (Barthel Index ≥ one month).
• Baseline and on-treatment blood pressure and heart rate.
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Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module. Our methods comprised electronic searches and assess-
ment of studies referenced in published systematic and non-sys-
tematic reviews. We applied no language restrictions.
Electronic searches
We searched the Cochrane Stroke Group Trials Register, (last
searched by theManagingEditor in February 2014), theCochrane
Database of Systematic reviews (CDSR) and theCochraneCentral
Register of Controlled Trials (CENTRAL) (The Cochrane Library
2014, Issue 2),MEDLINE (Ovid) (1966 toMay 2014) (Appendix
1), EMBASE (Ovid) (1974 to May 2014) (Appendix 2), Sci-
ence Citation Index (ISI, Web of Science, 1981 to May 2014) (
Appendix 3) and the Stroke Trials Registry (www.strokecenter.org/
trials/) (searched May 2014).
Searching other resources
We searched reviews of acute stroke relating to drugs that may
alter blood pressure, including: calcium channel blockers (CCBs)
(Horn 2001), nitric oxide (Bath 2002), pentoxifylline (Bath
2004a) and prostacyclin (Bath 2004b). In addition, we searched
reference lists of included trials and relevant papers. We contacted
principal investigators and researchers when we required addi-
tional information. For a previous version of this review (BASC
2001), we contacted the following pharmaceutical companies:
Bayer (nimodipine), Napp (pentoxifylline), Novartis (isradipine),
Lipha Sante (naftidrofuryl), Hoffmann la Roche (N-methyl-D-
aspartate), Hoechst (flunarizine) and UCB Pharma (piracetam).
Data collection and analysis
We extracted data using a standard proforma; KK entered data
into Review Manager (RevMan 2012) and PB checked the data.
Selection of studies
For this update, one review author (KK) screened the records ob-
tained from the electronic searches and excluded obviously irrel-
evant studies. We obtained the full paper copy of the remaining
studies and both review authors (KK and PB) selected trials for in-
clusion criteria detailed previously.We resolved any disagreements
by discussion.
Data extraction and management
We extracted data frompublished and unpublishedmaterial where
available. We recorded information on the method of randomi-
sation, concealment of allocation, blinding of treatment adminis-
tration, analysis (intention-to-treat, efficacy analysis), stroke type
(ischaemia, haemorrhage, or mixed), drug dose, route of admin-
istration (oral, sublingual, intravenous, transdermal) and timing,
blood pressure and heart rate before and during treatment, num-
bers of deaths, functional disability, quality of life, and length of
stay.
Assessment of risk of bias in included studies
We assessed the methodological quality of the trials using the fol-
lowing criteria.
• Method of randomisation.
• Balance of prognostic factors.
• Allocation concealment.
• Blinding of treatment administration.
• Intention-to-treat analysis.
• Blinding of outcome assessment.
• Follow-up.
We used the quality criteria to derive an overall assessment bias
score as ’low risk’ (all criteria met), moderate risk (one or more cri-
teria unclear) and high risk (one or more criteria absent) (Higgins
2011).
Measures of treatment effect
We calculated the weighted estimate of the typical treatment effect
across trials using RevMan 5 (RevMan 2012), odds ratios (OR)
using the Mantel-Haenszel random-effects model for binary data,
and mean difference (MD) using the inverse variance method for
continuous data, each with 95% confidence intervals (CI).
Unit of analysis issues
The primary outcome was based on the modified Rankin Scale
(mRS 0 to 6, where death = 6) assessed using the binary outcome of
combined death or dependency (mRS >1 or > 2 depending on trial
definition). The Barthel Index (BI) (disability measure of activities
of daily living) was also assessed (BI 100 to -5, where death = -5).
Where functional outcome was not assessed, we excluded the trial
from analysis of functional outcome.
Dealing with missing data
We attempted to collect missing data from trial investigators. In
instances where on-treatment blood pressure data were not pro-
vided or could not be obtained from study authors, we obtained
data (mean, SD) from graphs in the trial publication; where the
SD was not presented graphically, we used baseline data, a conser-
vative strategy. We excluded trials from individual analyses when
summary data were omitted in the trial publication.
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Assessment of heterogeneity
Weassessed heterogeneity betweenRCTs’ results using the I2 statis-
tic based on the DerSimonian-Laird formula.
Assessment of reporting biases
We examined reporting bias using funnel plots (Figure 1; Figure
2).
Figure 1. Funnel plot of comparison: 1 Blood pressure lowering therapy in acute stroke, outcome: 1.1 Death
or dependency, end of trial by intervention.
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Figure 2. Funnel plot of comparison: 1 Blood pressure lowering therapy in acute stroke, outcome: 1.23 SBP,
first after randomisation, by intervention.
Data synthesis
We performed statistical analysis using RevMan (RevMan 2012).
We reported outcomes as ORs with 95% CIs for dichotomous
data, and MD with 95% CI for continuous data. We used a
random-effects model to analyse individual results regardless of
whether there was heterogeneity or not; this is a conservative strat-
egy and takes account that the trials had heterogenous designs and
participant populations.
Subgroup analysis and investigation of heterogeneity
We assessed the primary outcomes in the following pre-specified
subgroups.
• Class or type of intervention.
• Type of stroke: ischaemic stroke or ICH.
• Stroke location: cortical or subcortical ischaemic stroke;
deep or superficial ICH. (The definition of deep haemorrhage
was not defined in all the trials and we therefore used the data as
given in the trials.)
• Timing of intervention: ultra-acute (≤ four hours) and pre-
hospital, hyper-acute (≤ six hours) and in hospital, acute (≤ 48
hours), sub-acute (≤ 168 hours).
We considered an I2 greater than 50% to infer significant het-
erogeneity. If significant heterogeneity was present, we looked for
potential causes, e.g. differences in trial design and study partici-
pants.
Sensitivity analysis
We based the analyses on all trials. We did not perform any sensi-
tivity analyses.
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R E S U L T S
Description of studies
The 26 included trials are summarised in Characteristics of
included studies, including details on baseline characteristics
(Figure 3).
Figure 3. Results of database search
Results of the search
The quantity of outcome data varied between studies:
• outcomes not universally collected;
• some data still to be published.;
• ’raw data’ available by personal communication.
If a trial used more than one dose of a particular drug then the
trial identifier is written as author followed by year and dose of the
drug. Referencing the whole trial was given by author and year.
For example the Fagan 1988 trial comprises: (Fagan 1988 120 mg;
Fagan 1988 240 mg).
Included studies
We identified 26 trials that fulfilled the inclusion criteria (Fagan
1988 120 mg/Fagan 1988 240 mg; Lisk 1993; Uzuner 1995;
Dyker 1997; Bath 2000; ACCESS2003;Hillis 2003; Rashid 2003
5 mg/Rashid 2003 5/10 mg/Rashid 2003 10 mg; Eames 2005;
ACCOST 2006; Willmot 2006; Eveson 2007; INTERACT pilot
2008; Koch 2008; CHHIPS 2009; PRoFESS 2009; COSSACS
2010; SCAST 2011; CATIS 2013; PIL-FAST 2013; RIGHT
2013; ICH-ADAPT 2013; INTERACT-2 2013; TAST 2013;
VENTURE2013; ENOS2014). Three trials comparedmore than
one drug against the control group (Lisk 1993; CHHIPS 2009;
ICH-ADAPT 2013) and two studies compared different doses
(Fagan 1988 120 mg/Fagan 1988 240 mg; Rashid 2003 5 mg/
Rashid 2003 5/10 mg/Rashid 2003 10 mg).
We obtained trial protocols and group data from published ma-
terial for the following studies (Fagan 1988 120 mg/Fagan 1988
240 mg; Lisk 1993; Hillis 2003; ACCESS 2003; Eames 2005;
Eveson 2007; INTERACT pilot 2008; Koch 2008; CHHIPS
2009; PRoFESS 2009; COSSACS 2010; SCAST 2011; CATIS
2013; ICH-ADAPT 2013; INTERACT-2 2013; PIL-FAST
2013; RIGHT 2013; TAST 2013; ENOS 2014), whilst individ-
ual patient data were provided by seven sets of authors (Lisk 1993;
Uzuner 1995; Dyker 1997; Bath 2000; Rashid 2003 5 mg/Rashid
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2003 5/10 mg/Rashid 2003 10 mg;Willmot 2006; ENOS 2014).
We obtained unpublished SBP, DBP and heart rate data for active
and control groups by contacting the authors for three trials (Hillis
2003; Eveson 2007; COSSACS 2010).
A variety of strategies and drug classes were used to lower blood
pressure.
• Alpha-2-adrenoceptor agonist, oral centrally-acting
(clonidine: two participants): one trial (Lisk 1993).
• Angiotensin converting enzyme-inhibitor (ACE-I)
(captopril, perindopril or lisinopril: 152 participants): five trials
(Lisk 1993; Dyker 1997; Eveson 2007; CHHIPS 2009;
PIL-FAST 2013).
• Angiotensin receptor antagonist (ARA), oral (candesartan
or telmisartan: 4190 participants): six trials (ACCESS 2003;
ACCOST 2006; PRoFESS 2009; SCAST 2011; TAST 2013;
VENTURE 2013).
• Beta-receptor antagonist (ß-RA) (labetalol: 56 participants):
one trial (CHHIPS 2009).
• Calcium channel blocker (CCB) (nimodipine or
nicardipine: 75 participants): three trials (Fagan 1988 120 mg/
Fagan 1988 240 mg; Lisk 1993; Uzuner 1995).
• Diuretic, oral thiazide-like (bendrofluazide: 18
participants): one trial (Eames 2005).
• Nitric oxide (NO) donor (transdermal glyceryl trinitrate
(GTN): 4197 participants): five trials (Bath 2000; Rashid 2003
5 mg/Rashid 2003 5/10 mg/Rashid 2003 10 mg; Willmot 2006;
RIGHT 2013; ENOS 2014).
• Intensive versus guideline blood pressure targets (7421
participants): five trials (INTERACT pilot 2008; Koch 2008;
CATIS 2013; ICH-ADAPT 2013; INTERACT-2 2013).
• Continue versus stop pre-stroke antihypertensive drugs
(2860 participants): two trials (COSSACS 2010; ENOS 2014).
One strategy was used to raise blood pressure.
• Sympathomimetic, intravenous (phenylephrine: nine
participants): one trial (Hillis 2003).
The trials recruited participants with only ischaemic stroke, mixed
stroke (ischaemic stroke and ICH), or only ICH.
• Ischaemic stroke: 12 trials (Fagan 1988 120 mg; Fagan
1988 240 mg; Lisk 1993; Dyker 1997; ACCESS 2003; Hillis
2003; Eames 2005; ACCOST 2006; Eveson 2007; PRoFESS
2009; CATIS 2013; TAST 2013; VENTURE 2013). In the
Fagan study (Fagan 1988 120 mg; Fagan 1988 240 mg)
participants were recruited with presumed ischaemic stroke
based on history and neurological examination.
• Mixed stroke: 10 trials (Uzuner 1995; Bath 2000; Rashid
2003 5 mg/Rashid 2003 5/10 mg/Rashid 2003 10 mg; Willmot
2006; CHHIPS 2009; COSSACS 2010; SCAST 2011;
PIL-FAST 2013; RIGHT 2013; ENOS 2014).
• ICH: four trials (INTERACT pilot 2008; Koch 2008;
ICH-ADAPT 2013; INTERACT-2 2013).
Trials recruited participants at different time frames after stroke:
• Ulta-acute (< four hours of onset)/pre-hospital: two trials
(PIL-FAST 2013; RIGHT 2013).
• Hyper-acute (< six hours)/hospital: two trials (INTERACT
pilot 2008; INTERACT-2 2013).
• Acute (< 48 hours): 11 trials (Uzuner 1995; ACCESS 2003;
CHHIPS 2009; COSSACS 2010; SCAST 2011; Eveson 2007;
Koch 2008; CATIS 2013; ICH-ADAPT 2013; VENTURE
2013; ENOS 2014).
• Sub-acute (< 168 hours): 10 trials (Lisk 1993; Dyker 1997;
Bath 2000; Hillis 2003; Rashid 2003 5 mg/Rashid 2003 5/10
mg/Rashid 2003 10 mg; Eames 2005; ACCOST 2006; Willmot
2006; PRoFESS 2009; TAST 2013).
• Timing unclear: one trial (Fagan 1988 120 mg/Fagan 1988
240 mg).
Trials variously defined enrolment blood pressure levels.
• Hypertension (SBP > 120 to 170 and ≤ 220 mm Hg): 21
trials (Lisk 1993; Dyker 1997; Bath 2000; ACCESS 2003;
Rashid 2003 5 mg/Rashid 2003 5/10 mg/Rashid 2003 10 mg;
Eames 2005; Willmot 2006; Eveson 2007; INTERACT pilot
2008; CHHIPS 2009; PRoFESS 2009; SCAST 2011;
ICH-ADAPT 2013; INTERACT-2 2013; PIL-FAST 2013;
TAST 2013; VENTURE 2013; ENOS 2014).
• Normotension (systolic BP < 140 mmHg): two trials (Hillis
2003; ACCOST 2006).
• No BP criteria: three trials (Fagan 1988 120 mg/Fagan
1988 240 mg; Uzuner 1995; COSSACS 2010).
Trials treated participants for varying lengths of time.
• For one day: one trial (ICH-ADAPT 2013).
• For up to two days: three trials (Uzuner 1995; Hillis 2003;
Koch 2008).
• For up to three days: one trial (Lisk 1993).
• For seven to 12 days: 13 trials (Bath 2000; Rashid 2003 5
mg/Rashid 2003 5/10 mg/Rashid 2003 10 mg; ACCESS 2003;
Eames 2005; Willmot 2006; INTERACT pilot 2008; SCAST
2011; ICH-ADAPT 2013; INTERACT-2 2013; PIL-FAST
2013; RIGHT 2013; VENTURE 2013; ENOS 2014).
• For 14 days: five trials (Dyker 1997; Eveson 2007;
CHHIPS 2009; COSSACS 2010; CATIS 2013).
• For 21 days: one trial (Fagan 1988 120 mg/Fagan 1988 240
mg).
• For 28 days: one trial (ACCOST 2006).
• For three months: one trial (TAST 2013).
• For up to 2.5 years: one trial (PRoFESS 2009); outcomes at
one to three months are used and longer-term follow-up data are
ignored.
The trials recruited from one or more centres.
• Single centre: 14 trials (Lisk 1993; Uzuner 1995; Dyker
1997; Bath 2000; Hillis 2003; Rashid 2003 5 mg/Rashid 2003
5/10 mg/Rashid 2003 10 mg; Eames 2005; ACCOST 2006;
Willmot 2006; Eveson 2007; Koch 2008; PIL-FAST 2013;
RIGHT 2013; TAST 2013).
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• Multicentre: 12 trials (Fagan 1988 120 mg; Fagan 1988
240 mg; ACCESS 2003; INTERACT pilot 2008; CHHIPS
2009; COSSACS 2010; PRoFESS 2009; SCAST 2011;
ICH-ADAPT 2013; CATIS 2013; INTERACT-2 2013;
VENTURE 2013; ENOS 2014).
A total of 17,011 participants received placebo or control treat-
ment across the studies. Several trials compared two or more ac-
tive treatment groups (8497 participants) with one control group
(8512 participants) (Fagan 1988 120 mg/Fagan 1988 240 mg;
Lisk 1993; Rashid 2003 5 mg/Rashid 2003 5/10 mg/Rashid 2003
10 mg).
One study reported on 19 participants from a larger RCT (Fagan
1988 120 mg/Fagan 1988 240 mg); further information on the
main study is not available.
One trial was performed in two stages: this review includes the first
phase, a double-blind comparison of candesartan versus placebo
(ACCOST2006), and excludes the second open-label comparison
of candesartan and an ACE-I.
One study expressly included patients with either ICH, who
were given intravenous nimodipine (treatment: eight participants;
placebo: three participants), or ischaemic stroke, who were given
oral nimodipine (treatment: 38 participants; placebo: 39 partic-
ipants) (Uzuner 1995); 10 participants (treatment: two partici-
pants; placebo: eight participants) treated with antihypertensive
agents for malignant hypertension, and two participants treated
with intravenous nimodipine for subarachnoid haemorrhage were
excluded.
Data from two trials were only available from published abstracts
(ACCOST 2006; VENTURE 2013).
Blood pressure measurements
Sixteen studies reported the method by which blood pressure
was measured, including equipment (manufacturer, model) and
patient posture (Lisk 1993; Dyker 1997; Bath 2000; Rashid
2003 5 mg/Rashid 2003 5/10 mg/Rashid 2003 10 mg; Eames
2005; Willmot 2006; Eveson 2007; Koch 2008; CHHIPS 2009;
PRoFESS 2009; COSSACS 2010; SCAST 2011; CATIS 2013;
RIGHT 2013; TAST 2013; ENOS 2014). The Fagan trial only
reported the average blood pressure measurements at, and for one
hour after, morning dosing over seven days of treatment (Fagan
1988 120 mg/Fagan 1988 240 mg); in the absence of individual
patient data, it is not possible to determine the blood pressure at
selected time points during treatment. Furthermore, this trial co-
administered beta blockers to some participants, although these
were always given at least two hours before or after nimodipine. In
ACCESS 2003, during the first three days blood pressure measure-
ments were performed by nurses as part of routine clinical care; on
day seven, automatic 24-hour blood pressure recording was per-
formed. The other nine trials (Fagan 1988 120 mg/Fagan 1988
240mg;Uzuner 1995;Hillis 2003; ACCOST2006; INTERACT
pilot 2008; INTERACT-2 2013; ICH-ADAPT 2013; PIL-FAST
2013; VENTURE 2013) made no mention of patient posture or
how blood pressure was measured.
Three trials recorded systolic but not diastolic BP after the first
intervention: (Koch 2008; ICH-ADAPT 2013; INTERACT-2
2013).
Outcomes
The trials reported a variety of outcomes.
• mRS or BI or both at ≥ one month: 15 trials (Bath 2000;
ACCESS 2003; Rashid 2003 5 mg/Rashid 2003 5/10 mg/
Rashid 2003 10 mg; Eames 2005; Willmot 2006; Eveson 2007;
INTERACT pilot 2008; CHHIPS 2009; PRoFESS 2009;
COSSACS 2010; SCAST 2011; CATIS 2013; INTERACT-2
2013; RIGHT 2013; ENOS 2014). Historically, trials
dichotomised outcome as death or dependency, defined as mRS
> 2, or mRS > 3, or BI < 60. Ordinal analysis of ordered
categorical data is statistically more efficient and provides
information on severity of outcome (Bath 2012) and recent trials
have used ordinal analysis of mRS data (INTERACT pilot 2008;
CHHIPS 2009; PRoFESS 2009; SCAST 2011; CATIS 2013;
INTERACT-2 2013; TAST 2013; ENOS 2014).
• Case fatality at ≥ one month: 15 trials (Bath 2000;
ACCESS 2003; Rashid 2003 5 mg/Rashid 2003 5/10 mg/
Rashid 2003 10 mg; Eames 2005; Willmot 2006; Eveson 2007;
INTERACT pilot 2008; CHHIPS 2009; PRoFESS 2009;
COSSACS 2010; SCAST 2011; CATIS 2013; INTERACT-2
2013; RIGHT 2013; ENOS 2014).
• Early neurological impairment (e.g. NIHSS, SSS) at < one
month: 11 trials (Lisk 1993; Dyker 1997; Hillis 2003; Eames
2005; Eveson 2007; INTERACT pilot 2008; CHHIPS 2009;
COSSACS 2010; CATIS 2013; ICH-ADAPT 2013;
INTERACT-2 2013).
• Hospital length of stay: four trials (CHHIPS 2009; CATIS
2013; RIGHT 2013; ENOS 2014).
Excluded studies
We excluded 66 studies because they lacked randomisation, were
irrelevant to the questions addressed in the current review, or
failed to provide blood pressure or outcome assessments (see
Characteristics of excluded studies).
Other studies
Eight studies are either awaiting assessment (MAPAS 2009;
ATTACI 2010; STABLE-ICAS 2010; ESH-CHL-SHOT 2013)
or are ongoing (ATACH-2 2011; ENCHANTED 2011; SETIN-
HYPERTENSION 2012; FAST-BP 2013) (Figure 3).
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Risk of bias in included studies
Computed tomography was used prior to entry in 10 trials to
identify people with ICH (Uzuner 1995; INTERACT pilot 2008;
Koch 2008; ICH-ADAPT 2013; INTERACT-2 2013) or to ex-
clude people with ICH (Lisk 1993; Dyker 1997; ACCESS 2003;
Hillis 2003; Eames 2005). Another study attempted to exclude
ICH through information from the history and neurological ex-
amination (Fagan 1988 120 mg/Fagan 1988 240 mg); it may
therefore have inadvertently included someparticipantswith ICH.
Statistical analysis
Four trials compared more than one treatment against a common
control group (Fagan 1988 120 mg/Fagan 1988 240 mg; Lisk
1993; Rashid 2003 5 mg/Rashid 2003 5/10 mg/Rashid 2003
10 mg; CHHIPS 2009). The most appropriate analysis in this
situation involves dividing the control group participants equally
between treatment groups to prevent control participants being
counted more than once and thereby artificially narrowing the
confidence intervals.
Allocation
We classified allocation concealment as ’low risk’, ’high risk’ or
’unclear risk’ according to the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Blinding
The method of randomisation was given for 23 trials (Dyker
1997; Bath 2000; ACCESS 2003; Rashid 2003 5 mg/Rashid
2003 5/10 mg/Rashid 2003 10 mg; Hillis 2003; Eames 2005;
ACCOST 2006; Willmot 2006; Eveson 2007; INTERACT pilot
2008; Koch 2008; CHHIPS 2009; PRoFESS 2009; COSSACS
2010; SCAST 2011; ICH-ADAPT 2013; INTERACT-2 2013;
PIL-FAST 2013; CATIS 2013; RIGHT 2013; TAST 2013;
VENTURE 2013; ENOS 2014). Two authors were unable to de-
scribe the method of randomisation (Lisk 1993; Uzuner 1995)
and one did not respond to our communication (Fagan 1988 120
mg/Fagan 1988 240 mg).
Participants and investigators were blinded to treatment as follows.
• Double-blind (participant and investigator blinded): 13
trials (Fagan 1988 120 mg; Lisk 1993; Dyker 1997; Bath 2000;
ACCESS 2003; CHHIPS 2009; Eames 2005; SCAST 2011;
ACCOST 2006; Eveson 2007; PRoFESS 2009; PIL-FAST
2013; TAST 2013).
• Single-blind (participant blinded): four trials (Rashid 2003
5 mg/Rashid 2003 5/10 mg/Rashid 2003 10 mg; Willmot 2006;
RIGHT 2013; ENOS 2014).
• Open-label: six trials (Rashid 2003 5 mg; Rashid 2003 5/10
mg; Rashid 2003 10 mg; Koch 2008; COSSACS 2010;
ICH-ADAPT 2013; INTERACT-2 2013; VENTURE 2013).
Incomplete outcome data
Sixteen trials were analysed by intention-to-treat (ITT) (Fagan
1988 120 mg/Fagan 1988 240 mg; Lisk 1993; Dyker 1997; Bath
2000; Rashid 2003 5 mg /Rashid 2003 5/10 mg/Rashid 2003
10 mg; Willmot 2006; INTERACT pilot 2008; Koch 2008;
CHHIPS 2009; PRoFESS 2009; COSSACS 2010; SCAST 2011
CATIS 2013; INTERACT-2 2013; RIGHT 2013; ENOS 2014).
One study excluded 10 participants from the analysis because they
had been treated with antihypertensive agents for concurrent ac-
celerated (malignant) hypertension (Uzuner 1995).
Cardiovascular data were analysed on a per-protocol basis and
outcomedata by intention-to-treat in one trial of lisinopril (Eveson
2007).
Selective reporting
We assessed selective reporting as low risk, high risk or unclear
risk according to the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We did not see evidence of selective
reporting in any of the trials.
Other potential sources of bias
One trial randomised participants before neuroimaging and those
having a non-ischaemic stroke were subsequently withdrawn from
the study (Eveson 2007). Two trials did not state the method of
analysis (Hillis 2003; Eames 2005). We did not find any other
potential risks to the validity of the included studies.
Effects of interventions
The Results section is split into three parts.
• Comparisons of BP lowering with control.
• Comparisons of continuing versus stopping temporarily
pre-stroke antihypertensive drugs.
• Comparisons of BP elevation with control.
Blood pressure lowering
Clinical outcomes
Twenty-one trials provided data on one or more outcomes relating
to treatment with:
• ACE-I (lisinopril): (Eveson 2007; CHHIPS 2009;
PIL-FAST 2013);
• ARA (candesartan, telmisartan): (ACCESS 2003; PRoFESS
2009; SCAST 2011; TAST 2013; VENTURE 2013);
• ß-RA (labetalol): (CHHIPS 2009);
• CCB (nimodipine): (Uzuner 1995);
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• NO donor (glyceryl trinitrate): (Bath 2000; Rashid 2003 5
mg/Rashid 2003 5/10 mg/Rashid 2003 10 mg; Willmot 2006;
RIGHT 2013; ENOS 2014);
• intensive blood pressure lowering: (INTERACT pilot
2008; Koch 2008; CHHIPS 2009; CATIS 2013; ICH-ADAPT
2013; INTERACT-2 2013);
• blood pressure elevation (phenylephrine): (Hillis 2003).
Death or dependency, end of trial
Drug class
Combined death or dependency was assessed using the mRS at
the end of follow-up. Data were available for 15,489 participants
recruited into 14 trials (Analysis 1.1). We observed no significant
difference between blood pressure lowering and control (OR 0.98;
95% CI 0.92 to 1.05), and heterogeneity was minimal. No indi-
vidual comparison within drug classes or BP lowering strategies
was significant (Analysis 1.1).
Stroke type
The effect of lowering blood pressure did not vary by stroke
subtype (ischaemic stroke, mixed stroke, ICH) across 14 trials
(Analysis 1.2).
Stroke location
The effect of lowering blood pressure did not vary by stroke lo-
cation (ICH deep or not, ischaemic stroke cortical or subcortical)
across six trials with 11951 participants (Analysis 1.2). Although
there was insufficient evidence to assess heterogeneity, blood pres-
sure lowering in deep ICH almost reached significance (OR 0.86;
95% CI 0.73 to 1.00, P value = 0.06) (Analysis 1.3).
Time to treatment
Data from 15 trials involving 15,520 participants were available.
There was significant reduction in death or dependency if treat-
ment was administered during the hyperacute period and in hos-
pital (OR 0.87; 95% CI 0.76 to 0.99, P value = 0.03). Recruit-
ment of participants later than this was associated with no benefit
(Analysis 1.4).
Death, early and end of trial
There was no overall effect of treatment on early death or death
at end of trial (Analysis 1.5; Analysis 1.8). When considering
subgroups, no differences existed when analysed by drug class
(Analysis 1.5; Analysis 1.8), stroke type (Analysis 1.6; Analysis
1.9), or time to treatment (Analysis 1.7; Analysis 1.10).
Barthel Index (disability), end of trial
We assessed the BI at the end of follow-up in two trials with 4350
participants (Analysis 1.11). Although we observed no significant
difference between blood pressure lowering and control (OR 0.63;
95% CI -3.28 to -4.54) (Analysis 1.11) and did not vary with
stroke type (Analysis 1.12), BI scores were lower if treatment was
started within six hours of stroke onset (Analysis 1.13).
Neurological deterioration, early
There was no overall difference in the rate of early neurological de-
terioration across seven trials (Analysis 1.14). Subgroup differences
were not present when analysed by drug class or intensity (Analysis
1.14), or stroke type (Analysis 1.15). However, subgroup differ-
ences were apparent when assessed by time to treatment (Analysis
1.16); specifically, an increase in neurological deterioration was
seen in participants with acute stroke (≤ 48 hours post stroke)
(OR 1.39; 95% CI 1.07 to 1.81, P value = 0.01) but not when
trials specifically treated earlier during the ultra-acute and hyper-
acute periods.
Quality of life
Quality of life, assessed using the EQ-5D and transformed into a
Health Utility Status, was assessed in three trials (Analysis 1.17;
Analysis 1.18). HealthUtility scores were higher/better with blood
pressure lowering (MD 0.02; 95% CI 0.01 to 0.04). However,
heterogeneity was apparent between studies (I2 = 76.0%) with a
significant result in INTERACT-2 2013, but not ENOS 2014.
When broken down into stroke types, participants with ICH in
INTERACT-2 2013 treated with blood pressure lowering tended
to report a better quality of life (Analysis 1.18). When assessed
by time to treatment, Health Utility Status scores were higher in
participants treated≤ six hours (MD 0.06; 95% CI 0.03 to 0.08),
but not when treated later (Analysis 1.19).
Length of stay
Length of stay was not influenced by lowering blood pressure and
there were no subgroup differences by type of intervention, stroke
type or time to treatment (Analysis 1.20; Analysis 1.21; Analysis
1.22).
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Haemodynamic measures
Blood pressure
The effect of different blood pressure-lowering strategies on blood
pressure after the first dose are summarised in Analysis 1.23 and
Analysis 1.29, and in Table 1. Altogether, 24 trials studied 15,432
participants; most participants received an ARA, a NO donor or
intensive blood pressure lowering. The focus for the following
comments are on systolic rather than diastolic blood pressure. The
magnitude of blood pressure reduction varied between -4.6/-2.5
mmHg for oral ARA (primarily candesartan and telmisartan) and
-13.7/-7.9 mmHg for ACE-Is. When assessed by stroke type, het-
erogeneity was present; slightly larger reductions in blood pres-
sure were seen in participants with ICH (-11.8/-5.1 mmHg) with
mixed stroke intermediate (-7.9/-3.0mmHg) and ischaemic stroke
least (-7.0/-3.1 mmHg) (Analysis 1.22; Analysis 1.30). Similarly,
the magnitude of reduction varied by time to randomisation or
treatment (I2 = 89%); a graded decrease was seen by time with the
largest reduction occurring in participants treated during the ultra-
acute/pre-hospital (-16.0/-15.0 mmHg), hyper-acute/hospital (-
13.4/-7.5 mmHg), acute (-8.2/-2.8 mmHg) and sub-acute (-7.3/
-4.9 mmHg) periods.
The effect of the various types of intervention over the first week
are summarised in Table 2.
Heart rate
Thirteen trials reported heart rate measurements (Lisk 1993;
Uzuner 1995; Dyker 1997; Bath 2000; Rashid 2003 5 mg/Rashid
2003 5/10 mg/Rashid 2003 10 mg; Eames 2005; Willmot 2006;
Eveson 2007; PRoFESS 2009; ICH-ADAPT 2013; RIGHT
2013; TAST 2013; ENOS 2014). The heart rate for glyceryl trini-
trate increased at day one (MD 4.5 bpm; 95% CI 2 to 8) (Analysis
1.37) (Table 3). Intravenous CCBs reduced heart rate at day one
(Uzuner 1995) (Analysis 1.37).
Continuing versus stopping pre-stroke
antihypertensive drugs
Two trials tested whether pre-stroke antihypertensives should be
continued in the immediate post-stroke period, or stopped tem-
porarily (COSSACS 2010; ENOS 2014). The total number of
participants numbered 2860.
Clinical outcomes
Death or dependency, end of trial
There was no significant difference in mRS at day 90 between
those participants assigned to continue or stop antihypertensives
(OR1.06; 95%CI0.91 to 1.24) (Analysis 2.1).Within subgroups,
the effect of continuing versus stopping antihypertensives did not
differ by stroke types or time to treatment across both trials (
Analysis 2.2 and Analysis 2.3).
Death, early and at the end of trial
The rates of death at the end of treatment, and at the end of trial,
did not differ between the treatment groups (Analysis 2.4 and
Analysis 2.7). No significant differences were observed by stroke
types or time to treatment (Analysis 2.5; Analysis 2.6; Analysis
2.8; Analysis 2.9).
Barthel Index
Barthel Index scores were lower in participants assigned to con-
tinue treatment (MD -3.18; 95% CI -0.55 to -5.80, P value =
0.02) (Analysis 2.10).
Neurological deterioration, early
The rate of death at the end of treatment did not differ between
the treatment groups (Analysis 2.11).
Quality of life
Quality of life, assessed using the EQ-5D and transformed into a
Health Utility Status, was lower (i.e. worse) in participants ran-
domised to continue pre-stroke antihypertensive drugs (MD -
0.03; 95% CI -0.05 to -0.01, P value = 0.008) (Analysis 2.12).
Haemodynamic measures
Blood pressure
Blood pressure was lower by -7.9/-1.2 mmHg at the first mea-
surement after randomisation in participants randomised to con-
tinue treatment with the reduction in systolic BP much greater in
COSSACS 2010 than in ENOS 2014 (Analysis 2.14). By the end
of treatment, blood pressure was lower by -11.3/-6.4 mmHg in
the continue group.
Heart rate
Data were only available for ENOS 2014. Heart rate was signifi-
cantly lower by 3.2 bpm by end of treatment in those who were
randomised to continue treatment (Analysis 2.21).
Blood pressure elevation therapy in acute stroke
Phenylephrine
13Interventions for deliberately altering blood pressure in acute stroke (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Phenylephrine non-significantly increased systolic blood pressure
at 24 hours (MD 21 mmHg; 95% CI -13 to 55 mmHg), but
had no significant effect on diastolic blood pressure (Hillis 2003) (
Analysis 3.4). Insufficient datawere available on clinical outcomes.
D I S C U S S I O N
Twenty-six trials, involving 17,011 participants with stroke, as-
sessed the effects of deliberate blood pressure alteration.
Blood pressure lowering
The results come from 24 trials that studied 15,432 participants.
Clinical outcomes
Overall, lowering blood pressure did not improve outcome,
whether assessed as death, combined death or dependency, neuro-
logical deterioration or quality of life. These findings were main-
tained irrespective of type of intervention (drug class, intensity
of lowering) or type of stroke. However, when assessed by time
to treatment, very early blood pressure lowering (before hospital
presentation or within six hours of stroke onset) was associated
with reduced death or dependency, and improved quality of life
(INTERACT-2 2013; RIGHT 2013).
Haemodynamic effects
All the studied antihypertensive drug classes lowered blood pres-
sure during the period of treatment. Reductions in blood pressure
after the first treatment varied between -4.6/-2.5 mmHg for oral
ARA and -21.0/-7.9 mmHg for ACE-I. Slightly larger reductions
in blood pressure were seen in participants with ICH (-11.8/-5.1
mmHg) than in those with ischaemic stroke (-7.0/-3.1 mmHg).
The largest reductions were seen if treatment was started very
early before hospital presentation (-16.0/-15.0 mmHg); smaller
reductions occurred if treatment was started beyond 48 hours after
stroke onset (-7.3/-4.9 mmHg).
Discussion
A variety of hypotheses can be postulated for why functional out-
come was better if blood pressure lowering was started very early
after stroke. First, the magnitude of blood pressure lowering may
be important since the greatest improvement in outcome occurred
when treatment was started early. Second, the type of intervention
may be important since improved outcome was seen with early in-
tensive blood pressure lowering (INTERACT-2 2013), and early
nitrate administration (RIGHT 2013; ENOS 2014). Conversely,
apparent hazardwas seenwithARAdrugs (SCAST2011; Jusufovic
2014).
Perhaps surprisingly, stroke type may not be particularly relevant
since differential effects on outcome were not seen for ischaemic
stroke versus ICH.
In summary, very early treatment with an appropriate agent or
target blood pressure may be the most important strategy to test in
the future, irrespective of stroke type. Importantly, systolic blood
pressure should not be lowered excessively (> 20%), at least in
ischaemic stroke, since trials of intravenous CCBs found that these
worsened outcome (Bridgers 1991; Wahlgren 1994).
Continue versus stop pre-stroke antihypertensive
drugs
The results come from two trials that studied 2860 participants
(COSSACS 2010; ENOS 2014).
Clinical outcomes
The findings were mixed with some comparisons, in particular
dependency (mRS), death, and neurological deterioration, neutral
for the comparison of continue versus stop pre-stroke antihyper-
tensive drugs. In contrast, measures of disability (BI) and quality of
life (EQ-5D, transformed into a Health Utility Status) were worse
in participants randomised to continue treatment immediately.
Haemodynamic effects
Immediately continuing antihypertensive drugs taken before
stroke was associated with a lower blood pressure by -7.9/-1.2
mmHg at the first measurement after randomisation, and -11.3/-
6.4 mmHg by end-of-treatment.
Discussion
The discrepancy in findings for two measures of functional out-
come,mRS andBI, is challenging to explain. First, itmay represent
chance such that no difference exists between the interventions.
Second, it could reflect outcome bias since it is not possible to test
this question in a double-blind placebo-controlled design. Never-
theless, both trials used blinded outcome assessment for both mRS
and BI. Further, since a majority of stroke physicians tend to con-
tinue treatment in routine practice (Bath 2000b), the result seen
across the two results is counter-intuitive. Last, the difference may
be real in which case mRS, usually considered to be the optimal
functional outcome in stroke trials (Lees 2012), failed to detect a
difference in contrast to a comparison of BI scores.
If continuing drugs immediately is, indeed, hazardous, then the
two trials do not identify the cause. Drugs that attenuate stress
hormones, in particular that down-regulate the renin-angiotensin-
aldosterone-system (RAAS) were commonly taken before stroke,
e.g. ACE-I, ARA and ß-receptor antagonists. Initiating these drugs
in the acute phase of stroke has been associated with harm (BEST
1988; SCAST 2011), so it can be postulated that continuing these
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during the acute phase of stroke is potentially harmful. Alterna-
tively, continuing drugs in people who are dysphagic and who do
not have safe enteral access for feeding may be hazardous through
aspiration of these drugs and then the development of pneumonia.
The ENOS trial gives some support for this hypothesis (ENOS
2014).
The main implication for clinicians is that it is reasonable to with-
hold BP-lowering drugs until patients are medically and neurolog-
ically stable, and have suitable oral or enteral access, after which
drugs can then be reintroduced.
General
An important problem with some of the trials was the absence of
detailed information on howblood pressure wasmeasured.Hence,
the quality of blood pressure readings is unknown. It is essential
that future trials describe in detail how blood pressure is measured
by including the following information.
1. Equipment: manufacturer, model, measurement method
(mercury, anaeroid or oscillometry, and manual or automatic),
and whether the equipment has been independently validated,
and if so by whom.
2. Measurer: who measured blood pressure, and how they
were trained, assessed, re-trained and re-assessed.
3. Measurements: the number of readings at each time point,
site of measurement (brachial, finger, etc) and what position the
person was in (supine, sitting, standing).
Little is known about the effect of blood pressure altering in older
people with acute stroke, who comprise the largest group of pa-
tients, including those with ischaemic stroke who need throm-
bolysis. Of the trials, only two had mean age over 75 years con-
tributing to a total of 98 participants (CHHIPS 2009; RIGHT
2013). The number and proportion of older people is likely to in-
crease with population ageing. As the variation in response by in-
dividuals to blood pressure modulating agents increases with age,
e.g. related to concurrent isolated systolic hypertension or cardiac
dysfunction, it may be inappropriate to assume that the effects of
changing blood pressure seen in younger populations will neces-
sarily be the same in older ones.
This review is Part 1 of the Blood pressure in Acute Stroke Collab-
oration and reports only those trials that specifically set out to alter
blood pressure in people with acute stroke. Part 2 of the project as-
sesses all RCTs in acute stroke where vasoactive drugs were admin-
istered and includes all those studies covered in Part 1. Although
progress has been made in the number and quality of stroke trials
in the last few years, a substantial number of questions remain.
The number of participants included in this review is very small
in comparison to the global burden of stroke (about 15,000,000
per year worldwide). At present, any benefit of treatment is small,
and additional data are required to recommend changes to rou-
tine clinical practice. The centres that took part in the trials were
interested and familiar with the management of acute stroke. To
extrapolate these results in routine clinical practice to less special-
ist centres could result in greater hazard or completely negate any
potential benefit. Therefore, there is a need for new centres to par-
ticipate in trials. Further evidence is needed on:
• how to select participants;
• the influence of age, time of onset, stroke subtype, severity,
choice of drug, dose, route of administration and blood pressure
variability, on response to active changes in blood pressure.
Recent guidelines based on the non-systematic analysis of (largely)
observational data recommend that hypertension should not be
treated for up to two weeks after an ischaemic stroke unless se-
vere hypertension, hypertensive encephalopathy, heart failure, car-
diac ischaemia, aortic dissection, or continued intracerebral bleed-
ing are present (O’Connell 1994; EUSI 2004; AHA-HS 2010;
AHA-IS 2013). Persistent hypertension after two weeks should
be treated since the risk of stroke in people with cerebrovascu-
lar disease is dependent on systolic and diastolic blood pressure
(Rodgers 1996). In PROGRESS 2001, perindopril (with or with-
out indapamide) reduced the risk of stroke among both hyperten-
sive and non-hypertensive participants with a history of stroke or
transient ischaemic attack. Further, evidence from the Heart Out-
comes Prevention Evaluation (HOPE) trial suggests that an ACE-
I may reduce stroke and other vascular events in people with prior
cerebrovascular disease (HOPE 2000). Overall, lowering blood
pressure in people with chronic stroke reduces the subsequent risk
of recurrence (Rashid 2003).
Summary of main results
In this updated review, blood pressure lowering did not improve
functional outcome. However, early initiation of treatment might
be beneficial, and further studies are required to test this spe-
cific question. Immediately continuing pre-stroke antihyperten-
sive drugs appears to be associated with a worse functional out-
come and lower quality of life; hence, it is reasonable to delay
treatment until patients are stable and have oral or enteral access
to allow safe administration of drugs.
Overall completeness and applicability of
evidence
The included trials are an excellent start to answering the question
of optimal blood pressure management in acute stroke. The lack
of a definitive result based on data frommore than 16,000 partici-
pants confirms that the question is complex and future trials need
to refine trial design, especially focusing on very early treatment.
Quality of the evidence
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The quality of the included studies was variable. Methods of ran-
domisation and allocation concealment were not always clear. Not
all trials contributed to each outcome. Details of blood pressure
recording including equipment, number of readings and patient
positioning were not provided in some studies. Trials in the last
decade were more standardised compared with earlier ones when
reporting baseline stroke characteristics, primary and secondary
outcomes. Outcome assessment was blinded in recent large RCTs
and clearly reported in trial protocols. Trials were largely not rep-
resentative of unselected stroke populations around the world -
participants tended to be younger, have fewer comorbidities and
be conscious, so that poor outcomes were less common thanmight
be expected.
Potential biases in the review process
This review follows an extensive literature search by both the
Cochrane Stroke ReviewGroup, and the authors, and without any
language restrictions. Hence the risk of study inclusion bias is low.
Agreements and disagreements with other
studies or reviews
The limited data mean that we can draw no firm conclusions, as
shown in other reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The lack of definitive results for blood pressure lowering, and
very limited data for raising blood pressure, mean that no firm
recommendations can be made.
There is no evidence to support the routine policy of immediately
continuing prestroke antihypertensive drugs; treatmentmay be re-
started once patients have stabilised medically and neurologically,
and once safe feeding or enteral access is available.
The very limited data related to blood pressure elevation mean
that no recommendations can be made.
Implications for research
Large randomised controlled trials (RCTs) of blood pressure low-
ering are needed to:
• test the effect of ultra-acute/pre-hospital lowering of blood
pressure in RCTs;
• test the effect of hyper-acute/hospital lowering of blood
pressure in RCTs. Two trials are important examples of ongoing
studies (ATACH-2 2011; ENCHANTED 2011);
• determine the effects on long-term survival (≥ one year);
• determine the effects on quality of life and cost-
effectiveness.
An individual patient data (IPD) meta-analysis is required to:
• identify subgroups of patients who are likely to benefit or
be harmed, e.g. by age, sex, race-ethnicity group, baseline blood
pressure, history of hypertension, stroke type (ischaemic stroke,
ICH);
• identify what type of treatment is required, e.g. drug class,
route, dose of administration.
The ongoing ’Blood pressure in Acute Stroke Collaboration’ is
performing an IPDmeta-analysis and includesmany of the quoted
trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ACCESS 2003
Methods Double-blind, placebo-controlled
Method of randomisation not known
Participants Germany, multicentre
339 participants. T: 173, C: 166
Age T: 68 years, C: 67.8 years
Male T: 50%, C: 52%
Inclusion: IS
100% CT
Enrolment within 24 to 36 hours after admission
Interventions T: candesartan 4 mg po on day 1 and dose was increased to 8 or 16 mg if BP exceeded 160
mmHg SBP or 100 mmHg DBP
C: matching placebo
Rx: 7 days
Outcomes BP measured by a nurse or automatically
Case fatality and disability using BI 3 months
Notes Exclusion: age > 85 years, > 70% stenosis of internal carotid artery, disorders in conscious-
ness, cardiac failure, unstable angina, malignant hypertension, and high grade aortic or
mitral stenosis
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Unclear
ACCOST 2006
Methods Double-blind, placebo-controlled
Method of randomisation not known
Participants UK, single centre
38 participants, T: 19, C: 19
Age: not given
Inclusion: IS with BP > 120/70
Enrolment within 72 hours
Interventions T: candesartan 4 mg once daily
C: matching placebo
Rx: 28 days
Dose was increased to 8 mg or 2 placebo if BP criteria not met. Target BP not reported
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ACCOST 2006 (Continued)
Outcomes BP methodology not given
All-cause mortality and mortality due to vascular causes
90 days: NIHSS, mRS, BI
Notes Exclusion criteria: not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was an abstract only. The author re-
ported the study as being prospective, dou-
ble-blind and placebo-controlled
Allocation concealment (selection bias) Unclear risk No further information available
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk This was an abstract only. The authors de-
scribed the study as being double-blind, al-
though it was unclear who was blinded and
how
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk This was an abstract only. The authors de-
scribed the study as being double-blind, al-
though it was unclear who was blinded and
how
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was an abstract only. The authors de-
scribed the study as being double-blind, al-
though it was unclear who was blinded and
how
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This was an abstract only. 38 participants
were enrolled into this trial, insufficient
data to assess attrition
Selective reporting (reporting bias) Unclear risk This was an abstract only
Other bias Unclear risk This was an abstract only
Bath 2000
Methods Double-blind, placebo-controlled
Randomisation by computer (with minimisation on age andmean arterial BP, baseline SSS,
hours from onset presence of a visible stroke lesion on CT)
Participants UK, single centre
37 participants. T: 16, C: 21
Age T: 76 years, C: 72 years
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Bath 2000 (Continued)
Male T: 6, C: 12
Inclusion: IS or ICH
100% CT
Enrolment within 5 days
Interventions T: transdermal GTN (Schwarz Pharma) 5 mg once daily
C: matching placebo
Rx: 12 days
Outcomes 24-hour ambulatory BP (Spacelabs 90207, measured 3 times/hour during the day, hourly
during the night) at days 0, 1 and 8
Rankin scale, BI and case fatality at 3 months
Notes Exclusion: taking part in another trial
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Adequate
CATIS 2013
Methods Single blind, blinded end-point
Randomisation central and stratified by participating hospitals and use of antihyperten-
sives. Randomisation schedules generated using SAS PROCPLAN in SAS and concealed
until eligible participant was ready for enrolment
Participants China, multicentre
4071 participants, T: 2038, C: 2033
Males T: 62.1 years, C: 61.8 years
Male T: 1317, C: 1287
Inclusion: IS confirmed by CT or MRI with SBP between 140 to 220 mmHg
Enrolment within 48 hours
FU: losses - T: 50 participants, C: 46 participants
Interventions T: early intensive lowering of BP (target BP 140/90 mmHg)
C: stop pre-existing antihypertensive drugs
Rx: 14 days
Outcomes BP measured supine using a standard sphygmomanometer and using 1 of 4 cuff sizes
(paediatric, regular, adult, large adult, or thigh) based on arm circumference. After ran-
domisation, 3 BP measurements every 2 hours on day 1, every 4 hours on day 2 and 3
and three times a day until hospital discharge or death
Primary outcomes: BP at days 1, 7, 14; death and major disability at day 14
Secondary outcomes: death and major disability at day 14 and 90
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CATIS 2013 (Continued)
Notes Exclusion: severe heart failure, myocardial infarction, unstable angina, atrial fibrillation,
aortic dissection, cerebrovascular stenosis, or resistant hypertension, deep coma, treat-
ment with iv rtPA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate
Allocation concealment (selection bias) Low risk Central randomisation ensured allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Treating clinicians and nurses were not
blinded to treatment group assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Although participants were masked to
treatment allocation, treating clinicians
and nurses were not blinded to treatment
group assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by investigators
centrally masked to all clinical details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Very fewparticipants (96 among 4071) lost
to follow up; no differences between trial
groups
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported;
no difference in reporting between groups
Other bias Low risk No other biases found
CHHIPS 2009
Methods Double-blind, placebo-controlled
Block randomisation (6 per block) by secure Internet centrally to receive either active
treatment or placebo in 2:1 ratio
Participants UK, multicentre
179 participants, T: 113, C: 59
Labetalol arm: 56 participants
Mean age T: 74 years; C: 74 years
Males T: 34 (61%), C: 31 (53%)
Lisinopril arm: 57 participants
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CHHIPS 2009 (Continued)
Mean age: 75 years; C: 74 years
Males T: 30 (53%), C: 31 (53%)
Inclusion: neuroradiologically confirmed stroke patients 12 hours of stroke onset, hy-
pertensive (SBP > 160), non dysphagic ischaemic and haemorrhagic stroke within 36
hours of stroke onset and hypertensive, dysphagic ischaemic and haemorrhagic stroke
patients within 36 hours of stroke onset
Interventions Non-dysphagic patients: T: oral labetalol 50 mg or lisinopril 5 mg orally; C: matching
oral placebo
Dysphagic patients: either of:
T: iv labetalol 50 mg
C: sublingual placebo
T: 5 mg sl lisinopril
C: intravenous placebo
T: sublingual placebo
C: intravenous placebo
Rx: 14 days
Outcomes BP changes at 24 hours and 2 weeks. BPmeasured in the brachial artery every 30minutes
for 8 hours post treatment using a validated A&D UA-767 blood pressure monitor and
appropriate cuff
Primary outcomes: death or dependency mRS and BI at 14 days following stroke onset
Secondary outcomes: NIHSS at 72 hours, mRS and NIHSS day 14, stroke recurrence
over 2 weeks, death, quality of life, discharge disposition at 3 months
Notes Exclusion: hypertensive encephalopathy, co-existing cardiac or vascular emergency, SBP
> 200 mm Hg and/or diastolic blood pressure > 120 mm Hg with ICH, pre-existing
antihypertensive treatment in patients without dysphagia, NIHSS section 1a≥ 2 points,
premorbid mRS > 3, any coexisting life-threatening condition with a life expectancy of
< 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate
Allocation concealment (selection bias) Low risk Central randomisation ensured allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Treatment assignment was blinded. Both
active and placebo tablets were identical in
shape, size and colour. Similarly, the vials
of labetalol and placebo were identical in
size, shape and colour
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CHHIPS 2009 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatment assignment was blinded. Both
active and placebo tablets were identical in
shape, size and colour. Similarly, the vials
of labetalol and placebo were identical in
size, shape and colour
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by investigators
centrally masked to all clinical details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differences between trial groups
Selective reporting (reporting bias) Low risk All outcomes were reported; no differences
between trial groups
Other bias Low risk No other biases found
COSSACS 2010
Methods Prospective, open-label, blinded-endpoint
Randomisation (1:1) with a block size of 4 centrally by secure Internet
Allocation to continue or stop treatment was done by computer with stratification by
age at entry (< 75 years and > 75 years)
Participants UK, multicentre
763 participants. T: 379, C: 384
Mean age T: 74 years, C: 74 years
Males T: 210, C: 216
Inclusion: non-dysphagic ischaemic or haemorrhagic stroke within 48 hours of last dose
of antihypertensive drugs
Interventions T: continue pre-existing antihypertensive medications
C: stop pre-existing antihypertensive drugs
Rx: 14 days
Outcomes BP measured by use of a UA-767 BP monitor (A&D Medical, San Jose, CA, USA). BP
calculated throughout the treatment period as mean of 2 sets of 3 supine readings taken
10 minutes apart
Primary outcome: death or dependency at 2 weeks
Secondary outcomes: BP changes at admission and 2 weeks; NIHSS, BI at 2 weeks;
death, recurrent stroke, quality of life at 2 weeks
Discharge disposition at 2 weeks and 6 months
Notes Exclusion: hypertensive encephalopathy; coexisting cardiac or vascular urgency; SBP
greater than 200 mm Hg or DBP greater than 120 mm Hg associated with known
primary ICH; contraindications to stopping or indications for continuing antihyperten-
sive treatment; dysphagia; impaired consciousness (NIHSS section 1a score ≥ 2 points)
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COSSACS 2010 (Continued)
; women of childbearing potential; premorbid dependency (mRS > 3 points); any coex-
isting life-threatening condition with an estimated life expectancy of less than 6 months;
and no evidence of stroke on neuroimaging
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised using a com-
puter and the method of random sequence
generation was described
Allocation concealment (selection bias) Low risk Central web-based allocation ensured allo-
cation concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Treatment was open-label, therefore partic-
ipants and clinicians knew whether treat-
ment was either to stop or continue
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Treatment was open-label, therefore partic-
ipants and clinicians knew whether treat-
ment was either to stop or continue. How-
ever all participants were to receive best
medical care and there was no difference in
care between treatment groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by investigators
centrally masked to all clinical details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differences between trial groups
Selective reporting (reporting bias) Low risk All outcomes were reported; no differences
between trial groups
Other bias Low risk No other biases found
Dyker 1997
Methods Double-blind, placebo-controlled
Method of randomisation not known
Participants UK, single centre
28 participants. T: 14, C: 14
Mean age 70 years
Males T: 9, C: 8
Inclusion: ischaemic strokes with mild to moderate hypertension (170 to 250/95 to 120
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Dyker 1997 (Continued)
mmHg)
100% CT on entry
Enrolment within 1 week
Patients admitted on prescribed antihypertensive therapy had treatment discontinued for
at least 48 hours before entry into the study
Interventions T: perindopril 4 mg po once daily
C: matching placebo
Rx: 15 days
Outcomes BPmeasured semi-automatically pre-treatment and hourly at 10 hours repeated at 24 hours
and at 2 weeks
Neurological impairment: NIHSS made at baseline and day 15
Notes Exclusion: severe carotid disease
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Adequate
Eames 2005
Methods Double-blind, placebo-controlled, parallel group study
Block randomisation (4 per block)
Participants UK, single centre
37 participants. T: 18, C: 19
Age: 68 years
Male: 86%
Inclusion: neuroradiologically diagnosed ischaemic stroke with 24 hour BP > 130/80
mmHg or daytime mean BP > 135/85 mmHg
Enrolment within 96 hours of stroke onset
Interventions T: bendrofluazide 2.5 mg po daily
C: matching placebo
Rx: 7 days
Outcomes Casual and non-invasive beat-to-beat arterial BP level, cerebral blood flow velocity, ECG
and transcutaneous carbon dioxide levels within 70 20 hours of cerebral infarction and
7 days later were measured.
24-hour BP monitoring with Spacelabs 90207 and brachial artery BP with validated semi-
automatic BP monitor (Omron 711)
Notes Exclusion: history of previous stroke, dysphagia, symptoms lasting < 24 hours, or presented
> 76 hours after symptom onset (to allow for 24 hour BP monitoring to be performed prior
to randomisation)
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Eames 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Adequate
ENOS 2014
Methods Single-blind, parallel-group, partial factorial study
Randomisation via password protected, data-encrypted website, with: stratification by
prior antihypertensive treatment and country; minimisation by sex, age, stroke severity,
time to treatment and total anterior circulation syndrome
Participants International (23 countries), multicentre (173 sites)
4011 participants. T: 2000; C: 2011
Age T: 70 years, C: 70 years
Male T: 1147 (57%), C:1150 (57%)
Inclusion: haemorrhagic or ischaemic stroke; motor deficit in arm and/or leg; SBP be-
tween 140 to 220 mmHg
Enrolment: < 48 hours of onset
Interventions Factor 1:
T: Transdermal GTN 5 mg
C: No GTN
Blinding with a gauze dressing applied over GTN patch or equivalent area of skin
Factor 2 (in relevant participants):
T: Continue pre-stroke antihypertensive therapy
C: Stop pre-stroke antihypertensive therapy
Rx: 7 days
Outcomes Primary outcome: mRS at day 90
Secondary outcomes:
• BP and HR measured with validated automated blood pressure monitor (Omron
HEM-705CP or HEM-757, Illinois, USA)
• Days 1 to 7: BP, HR
• Day 7: Recurrent stroke
• Discharge: Length of stay; disposition
• Day 90: Death or dependency (mRS 3 to 6); BI; QoL (EQ-5D, EQ-VAS);
MMSE; TICS; Animal naming; Zung depression
Notes Exclusions: GCS < 8; pure sensory stroke; preceding dependency (mRS 3 to 5); con-
founding neurological or psychiatric disease; stroke mimic; severe liver or renal dysfunc-
tion; severe concomitant medical conditions: pregnant or breastfeeding; planned surgical
intervention; previous participation in ENOS 2014; definite need for, or contradiction
to, nitrates and/or prestroke antihypertensive therapy
Risk of bias
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ENOS 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation
Allocation concealment (selection bias) Low risk Central web-based allocation ensured allo-
cation concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk GTN was given in a single-blind design
as no manufacturer was able to supply
placebo patches. Participants were blinded
with placement of a gauze dressing over an
area of skin out of view (e.g. back or shoul-
ders) with or without GTN patch a under-
neath. The continue versus stop arm was
open-label
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk GTN was given in a single-blind design
as no manufacturer was able to supply
placebo patches. Participants were blinded
with placement of a gauze dressing over an
area of skin out of view (e.g. back or shoul-
ders) with or without GTN patch a under-
neath. The continue versus stop arm was
open-label. All participants were to receive
best medical care and there was no differ-
ence in care between treatment groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by investigators
centrally masked to all clinical details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differences between trial groups
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported;
no differences between trial groups
Other bias Low risk No other biases found
Eveson 2007
Methods Double-blind, placebo-controlled, parallel-group study
Randomisation by numbered identical study packs
Participants UK, single centre
40 participants. T: 18, C: 22
Age T: 73 years, C: 75 years
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Eveson 2007 (Continued)
Male: 63%
Inclusion: acute IS within previous 24 hours with mean SBP level ≥ 140 mmHg or
DBP level ≥ 90 mmHg
Randomisation done before neuroimaging; participants with non-IS were withdrawn
from the study
Interventions T: lisinopril 5 mg po once daily
C: matching placebo
Rx: 14 days
Dose was increased to 10 mg or 2 placebo on day 7 if SBP ≥ 140 mmHg or DBP ≥
90mmHg
Outcomes Casual brachial artery BP monitoring at 5-minute intervals during a 30-minute period
with a validated monitor (A&D UA 767)
NIHSS score at day 14, BI and mRS at day 14 and day 90
Notes Exclusion: severe carotid stenosis, significant aortic stenosis, cardiac failure, MI within
past 6 months, dysphagia, dehydration, adverse reactions to ACEI, and pre-stroke mRS
score > 2
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Adequate
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Fagan 1988 120 mg
Methods Double-blind, placebo-controlled
Randomisation technique not stated
Intention-to-treat analysis
FU: no losses
Participants USA, multicentre
19 participants, T: 10, C: 9
Age > 45 years, no genders given
IS diagnosed on history and neurological examination
Enrolment times not given
Interventions T: nimodipine (Miles Pharmaceuticals, USA) 120 mg/day (20 mg 4 hourly) po
C: matching placebo
Rx for 21 days
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Fagan 1988 120 mg (Continued)
Outcomes Brachial BP before and 30 and 60 minutes after each morning dose for 7 days
BP methodology not stated
Notes Exclusion: concurrent calcium channel antagonists, antihypertensive agents (other than
beta blockers)
Part of a larger unpublished trial to evaluate the safety and efficacy of nimodipine
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Inadequate
Fagan 1988 240 mg
Methods Double-blind, placebo-controlled
Randomisation technique not stated
Intention-to-treat analysis
FU: no losses
Participants USA, multicentre
19 participants, T: 10, C: 9
Age > 45 years, no genders given
IS diagnosed on history and neurological examination
Enrolment times not given
Interventions T: nimodipine (Miles Pharmaceuticals, USA) 240 mg/day (40 mg 4 hourly) po
C: matching placebo
Rx: for 21 days
Outcomes Brachial BP before and 30 and 60 minutes after each morning dose for 7 days
BP methodology not stated
Notes Exclusion: concurrent calcium channel antagonists,antihypertensive agents (other than beta
blockers)
Part of a larger unpublished trial to evaluate the safety and efficacy of nimodipine
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Inadequate
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Hillis 2003
Methods Pilot randomised controlled trial
Method of randomisation: 2:1 to BP elevation or conventional management
FU: no losses
Participants USA, single centre
15 participants T: 9, C: 6
Age T: 59 years, C: 68 years
Male T: 2, C: 2
Inclusion: IS > 20% diffusion perfusion mismatch; quantifiable, stable or worsening apha-
sia; hemispatial neglect or hemiparesis
Enrolment: up to 7 days from the onset of stroke symptoms
Prior antihypertensive medication was discontinued prior to initiation
Interventions T: intravenous phenylephrine was titrated to reach 10% to 20% increase MAP and contin-
ued for maximum of 72 hours. After 24 hours the participants were started on midodrine
(up to 10 mg), fludrocortisone(up to 0.2 mg) and sodium chloride tablets with simulta-
neous weaning of intravenous phenylephrine. By 4 weeks, midodrine, fludrocortisone and
sodium chloride were tapered providing no clinical deterioration
C: conventional management
Outcomes BP measurement method not given
NIHSS and cognitive tests on day 1, day 3 and 6 to 8 weeks
Notes Exclusion: CI or inability to tolerateMRI, cardiac ejection fraction < 25%, recent congestive
heart failure, myocardial ischaemia, unstable angina, bradycardia, allergy to gadolinium,
haemorrhage seen on initial CT, agitation requiring ongoing sedation, or MAP > 140 with
no intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Unclear
ICH-ADAPT 2013
Methods Open-label, blinded-endpoint randomised trial
Block randomisation (6 per block), stratified by onset to treatment time (≤ 6 and 6 to
24 hours)
Treatment allocation using a random number generator before trial commencement
Treatment assignment in sealed, opaque envelopes at the site
Participants Canada, multicentre
75 participants, T: 39, C: 36
Mean age T: 70.7 years, C: 68.7 years
Male T: 26, C: 28
Inclusion: spontaneous ICH confirmed by CT and elevated BP ≥ 150 mm Hg (≥ 2
readings, ≥ 5 minutes apart)
Enrolment: within 24 hours of symptom onset
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ICH-ADAPT 2013 (Continued)
Rx: 1 day
FU: no losses
Interventions T: early intensive BP lowering of BP (SBP target < 150 mm Hg) with iv Labetalol/
hydralazine/enalapril
C: guideline based management of BP (target SBP 180 mm Hg)
At 24 hours, both groups received perindopril 4 mg daily and or previous antihyperten-
sives po or ng as per investigators discretion
Outcomes Primary: perihaematoma relative CBF, as measured with CT perfusion 2 hours after
initiation of antihypertensive therapy
Secondary: continuous non-invasive BP and HR monitoring for minimum 24 hours
(BP methodology not stated); NIHSS at 2 hours; mRS, NIHSS at 24 hours, day 30 and
90; BI at day 30 and 90
Notes Exclusion: secondary ICH, planned surgical resection, or CIs to CT perfusion e.g. con-
trast allergy or renal impairment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate
Allocation concealment (selection bias) Low risk Randomisation by sequential numbered
packs (allocation have been generated ran-
domly)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Treatment was open-label, therefore partic-
ipants and clinicians knew whether treat-
ment was either to stop or continue
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was open-label, therefore partic-
ipants and clinicians knew whether the as-
signed treatment was intensive or guide-
line-recommended management of BP
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Images were measured centrally by readers
blinded to treatment and clinical outcomes
Clinical assessment were performed by in-
vestigators masked to image analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differences between treatment groups
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported;
no differences between trial groups
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ICH-ADAPT 2013 (Continued)
Other bias Low risk No other biases found
INTERACT pilot 2008
Methods Open, blinded outcome, randomised trial
Randomisation done with minimisation through a password protected Internet-based sys-
tem
Intention-to-treat analysis
Participants International, multicentre
404 participants, T: 203, C: 201
Age 63 years
Male 65%
Inclusion: spontaneous ICH confirmed by CT and elevated SBP ( ≥ 2 measurements of
150 to 220 mmHg, recorded ≥ 2 minutes apart)
100% CT
Enrolment: within 6 hours of ICH onset
FU: no losses
Interventions T: early intensive lowering of BP (target SBP 140 mmHg)
C: standard guideline based management of BP (target SBP 180 mmHg)
Both groups received oral as well as intravenous agents for lowering BP
Rx: for 7 days
Outcomes Proportional change in haematoma volume at 24 hours
BP methodology not stated
Notes Exclusion: indication for intensive lowering of BP, CI to intensive lowering of BP, ICH
secondary to structural cerebral abnormality or use of thrombolytic agent, IS within 30
days, deep coma (3 to 5 on the GCS), pre-stroke disability or medical illness, and early
planned decompressive neurosurgical intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Adequate
INTERACT-2 2013
Methods Open, blinded outcome, randomised trial
Randomisation done with minimisation through a password protected Internet based
system
Participants International, multicentre
2839 participants, T: 1382, C: 1412
Mean age T: 63 years, C:64.1 years
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INTERACT-2 2013 (Continued)
Male T: 64.2%, C: 61.7%
Inclusion: spontaneous ICH confirmed by CT and elevated SBP ( ≥ 2 measurements
of 150 to 220 mmHg, recorded ≥ 2 minutes apart)
100% CT
Enrolment: within 6 hours of ICH onset
FU: no losses
Interventions T: intensive lowering of BP (target SBP 140 mmHg)
C: standard guideline based management of BP (target SBP 180 mmHg)
Both groups received oral as well as intravenous agents for lowering BP
Rx: for 7 days
Outcomes Primary: mRS at day 90
Secondary: combined death and dependency at day 90 in participants treated < 4 hours
of ICH onset; recurrent stroke; haematoma expansion and cerebral oedema at 24 and
72 hours; BP during 7 days of treatment (BP methodology not stated); length of stay;
discharge disposition; BI, QoL (EuroQoL), MMSE, Zung depression at day 90 (BP
methodology not stated)
Notes Exclusion: indication for intensive lowering of BP, CI to intensive lowering of BP, ICH
secondary to structural cerebral abnormality or use of thrombolytic agent, IS within 30
days, deep coma (3 to 5 on the GCS), pre-stroke disability or medical illness, and early
planned decompressive neurosurgical intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by secure Internet system
Allocation concealment (selection bias) Low risk Central web-based allocation ensured allo-
cation concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Treatment was open-label, therefore partic-
ipants and clinicians knew whether the as-
signed treatment was intensive or guide-
line-recommended management of BP
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Treatment was open-label, therefore partic-
ipants and clinicians knew whether the as-
signed treatment was intensive or guide-
line-recommended management of BP. All
participants were to receive best medical
care and there was no differences in care
between the 2 treatment groups
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INTERACT-2 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by investigators
centrally masked to all clinical details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No difference between trial groups
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported;
no differences between trial groups
Other bias Low risk No other biases found
Koch 2008
Methods Open-label, blinded outcome, randomised trial
Allocation concealment by numbered envelopes in random sequence
Participants USA, single centre
42 participants: T: 21, C: 21
Mean age T: 61 years, C: 60 years
Male T: 9, C: 14
Inclusion: CT confirmed spontaneous supratentorial ICH
Enrolment: within 8 hours of ICH onset
Rx: 2 days
Interventions T: intensive lowering of BP (target MAP < 110 mm Hg)
C: guideline based management of BP (target MAP 110 to 130 mm Hg)
Outcomes BP; monitored every 15minutes for the first 3 hours, every 30minutes from 3 to 6 hours,
and hourly from 6 to 48 hours. BP measured with automated cuff sphygmomanometry
NIHSS, GCS at 24 and 48 hours
Haematoma and oedema growth between baseline and 24 hours
mRS day 90
Notes Exclusion: inability to consent, head injury, comatose, coagulopathy (platelet count < 50,
000 or INR ≥ 1.8), MAP < 110 mmHg, ICH secondary to other causes (arteriovenous
malformations, trauma, aneurysm) or needing surgical evacuation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation has been stratified by cen-
tre, but method of random sequence gen-
eration was not described
Allocation concealment (selection bias) Low risk Allocation have been done randomly
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Koch 2008 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Treatment was open-label, therefore partic-
ipants and clinicians knew whether the as-
signed treatment was intensive or guide-
line-recommended management of BP
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Treatment was open-label, therefore partic-
ipants and clinicians knew whether the as-
signed treatment was intensive or guide-
line-recommended management of BP
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by investigators
centrally masked to all clinical details
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for; no differ-
ences between trial groups
Selective reporting (reporting bias) Low risk All outcomes reported; no difference be-
tween treatment groups
Other bias Low risk No other biases found
Lisk 1993
Methods Double-blind, placebo-controlled
Randomisation technique not stated
Intention-to-treat analysis
FU: no losses
Participants USA, single centre
Mean age 66 years, range 46 to 83 years, 4 male, 12 female
IS, 14 participants had MCA territory infarct
100% CT pre-entry
Enrolment within 72 hours
Baseline SBP 170 to 220 mmHg and DBP 95 to 120 mmHg, or mean BP 120 to 140
mmHg
History of previous hypertension (current treatment or clinical evidence of end organ
damage)
Interventions T 1: nicardipine hydrochloride 20 mg po tds (5 participants)
T 2: captopril 12.5 mg po tds (3 participants)
T 3. clonidine hydrochloride 0.1 mg tds (2 participants)
C: matching dextrose/starch capsule tds (6 participants)
Rx: for 3 days
Outcomes Supine BP at baseline then every 10 minutes for first hour, then hourly for 6 hours, then
4 hourly
BP measured using an automatic monitor (Space Labs, model IEC 601-1)
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Lisk 1993 (Continued)
Neurological impairment: NIHSS at baseline and daily SPECT at baseline and at 3 days
Notes Exclusion: coma, significant neurological deficit from previous stroke, brain stem stroke,
acute MI, severe heart failure or cardiac conduction defect, history of angioedema or col-
lagen vascular disease, liver dysfunction
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Inadequate
PIL-FAST 2013
Methods Double-blind parallel-group external pilot controlled trial
Both active and control group tablets were blister packed and placed in identical boxes.
Each box had a unique study number according to the randomisation code (intervention
and control in 1:1 ratio)
Participants UK, single centre
14 participants. T: 6 C: 8
Median age 73 years
Male T: 7, C: 7
Inclusion: conscious (“A” on AVPU scale),≥ 40 years with new unilateral arm weakness
thought to be due to be acute stroke and SBP > 160 mmHg on 2 consecutive seated or
lying readings taken 5 to 10 minutes apart
Enrolment within 3 hours of symptom onset
FU: not completed for 1 participant
Interventions T: lisinopril (Modepharma) 5mg sublingual and second dose of 5mg givenpo, sublingual
or via nasogastric tube
C: matched placebo (Haupt Pharma Wuelfing)
Rx: 7 days
Outcomes BP measured seated or supine 5 to 10 minutes apart before randomisation
Primary: feasibility-recruitment rate, compliance with data collection
Secondary: change in BP for 7 days (BP measurement methodology during study sched-
ule not given); NIHSS at days 3 and 7; BI, mRS, renal function, death at day 7
Notes Exclusion: age < 40 years; females, pregnant, lactating or at risk of pregnancy; females <
56 years of age consented by a relative; suspected stroke without unilateral arm weakness;
unable to establish whether stroke onset time was within the last 3 hours; SBP < 160
mm Hg; reduced level of consciousness below “A” on AVPU scale; patient not being
transported to PIL-FAST trial site; absence of participant or next of kin consent; known
to be taking ACE inhibitor or angiotensin II receptor blocker medication already; known
sensitivity to lisinopril or other ACE inhibitor medication; pulse > 120 bpm; seizure;
hypoglycaemia; unable to walk independently prior to stroke; obvious understanding or
memory problems when next of kin is absent; significant head trauma or brain surgery in
44Interventions for deliberately altering blood pressure in acute stroke (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PIL-FAST 2013 (Continued)
the last 3months; known renal failure, liver failure (or currently jaundiced); uncontrolled
heart failure (breathlessness at rest); receiving palliative care for known malignancy;
participating in a clinical trial assessing a study drug
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list created by independent
statistician
Allocation concealment (selection bias) Low risk Both lisinopril and placebo were supplied
in identical boxes and each box was pack-
aged into a secondary trial pack. Each pack
carried a unique study number linked to
the randomisation code
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by investigators
centrally masked to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for, both groups
have similar dropout rates; clinical reason-
ing given
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported
Other bias Low risk No other biases evident
PRoFESS 2009
Methods Double-blind, 2 x 2 factorial trial
Randomisation done by central telephone system
Participants International (35 countries), multicentre (695 centres)
1360 participants. T: 647 , C: 713
Mean age T: 66.8 years, C: 67.1 years
Male T: 64.9%, C: 65.1%
Inclusion: IS
Enrolment within 72 hours
FU: no losses
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PRoFESS 2009 (Continued)
Interventions T: telmisartan 80 mg once daily
C: placebo
Rx: 2.5 years
Outcomes Primary: BP, HR at days 7, 30 and 90 (BP and HR recorded using validated semiauto-
matic monitor - Omron 705CP)
Secondary: mRS day 30, haemorrhagic transformation of the infarct, cerebral oedema,
recurrent stroke, MI, composite vascular events (vascular death, non-fatal stroke, or MI)
, death at days 7, 30 and 90
Notes Exclusion: mRS > 3, using or needing ARA at time of randomisation, known severe
renal insufficiency or renal artery stenosis, hyperkalaemia, uncorrected volume or sodium
depletion, known severe coronary artery disease or recent MI, patients scheduled for
carotid endarterectomy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate
Allocation concealment (selection bias) Low risk Central allocation ensured allocation con-
cealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Endpoint adjudication committee blinded;
independent safety committee blinded
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported
Other bias Low risk None
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Rashid 2003 10 mg
Methods Open-label, blinded-endpoint dose comparison controlled trial
Randomisation by minimisation (age, gender, SSS, mean arterial pressure)
FU: no losses
Participants UK, single centre
90 participants. T: 20, C: 30
Mean age T: 70.8 years, C: 73.9 years
Male T: 28, C: 13
Inclusion: IS or ICH
Enrolment within 72 hours of ictus
Clinical stroke subtype at baseline and CT scanning within a week of stroke onset
Any antihypertensive medication was stopped at the time of admission and recommenced
after 10 days once the trial treatment phase was completed
Interventions T: transdermal GTN 10 mg once daily
C: no patch
Rx: 10 days
Outcomes 24 hour ambulatory BP monitoring during day and hourly during night at days 0, 1, 4, 5
and 10
mRS, BI, QoL at 3 months
Notes Exclusion: SBP > 230 mmHg or < 100 mmHg, DBP > 130 mmHg or < 60 mmHg, HR >
130 bpm or < 50 bpm, mild stroke, coma, pre-morbid dependence, or presence of illnesses
that could confound neurological or functional evaluation (such as pre-existing neurologic
or psychiatric disorders)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Adequate
Rashid 2003 5 mg
Methods Open-label, blinded-endpoint dose comparison controlled trial
Randomisation by minimisation (age, gender, SSS, mean arterial pressure)
FU: no losses
Participants UK, single centre
90 participants. T: 20, C: 30
Mean age T: 70.8 years, C: 73.9 years
Male T: 28, C: 13
Inclusion: IS or ICH
Enrolment within 72 hours of ictus
Clinical stroke subtype at baseline and CT scanning within a week of stroke onset
Any antihypertensive medication was stopped at the time of admission and recommenced
after 10 days once the trial treatment phase was completed
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Rashid 2003 5 mg (Continued)
Interventions T: transdermal GTN 5 mg once daily
C: no patch
Rx: 10 days
Outcomes 24 hour ambulatory BP monitoring during day and hourly during night at days 0, 1, 4, 5
and 10
mRS, BI, QoL at 3 months
Notes Exclusion: SBP > 230 mmHg or < 100 mmHg, DBP > 130 mmHg or < 60 mmHg, HR >
130 bpm or < 50 bpm, mild stroke, coma, pre-morbid dependence, or presence of illnesses
that could confound neurological or functional evaluation (such as pre-existing neurologic
or psychiatric disorders)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Adequate
Rashid 2003 5/10 mg
Methods Open-label, blinded-endpoint dose comparison controlled trial
Randomisation by minimisation (age, gender, SSS, mean arterial pressure)
FU: no losses
Participants UK, single centre
90 participants. T: 20, C: 30
Mean age T: 70.8 years, C: 73.9 years
Male T: 28, C: 13
Inclusion: IS or ICH
Enrolment within 72 hours of ictus
Clinical stroke subtype at baseline and CT scanning within a week of stroke onset
Any antihypertensive medication was stopped at the time of admission and recommenced
after 10 days once the trial treatment phase was completed
Interventions T: transdermal GTN 5/10 mg once daily
C: no patch
Rx: 10 days
Outcomes 24 hour ambulatory BP monitoring during day and hourly during night at days 0, 1, 4, 5
and 10, mRS, BI, QoL at 3 months
Notes Exclusion: SBP > 230 mmHg or < 100 mmHg, DBP > 130 mmHg or < 60 mmHg, HR >
130 bpm or < 50 bpm, mild stroke, coma, pre-morbid dependence, or presence of illnesses
that could confound neurological or functional evaluation (such as pre-existing neurologic
or psychiatric disorders)
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Rashid 2003 5/10 mg (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Adequate
RIGHT 2013
Methods Single-blind, blinded-endpoint
Randomisation (1:1)
Intervention in double non-opaque envelopes carried in ambulance: outer envelope -
case report form; inner envelope - gauze dressing +/- GTN patch
Participants UK, single centre
41 participants. T: 25, C: 16
Mean age T: 79 years, C: 81 years
Male T: 15 (60%), C: 7 (43.8%)
Inclusion: positive FAST test
Enrolmentwithin 4hours of symptomonset (wake-up stroke defined as onset at bedtime)
FU: no losses
Interventions T: GTN patch
C: No GTN patch
Blinding: gauze dressing covering patch or similar area of skin
Outcomes Primary: SBP at 2 hours (BP measured in the ambulance using a semiautomatic sphyg-
momanometer and in hospital with Omron 705 CP or 705 CP II)
Secondary: 15minutes: SBP,DBP,HR;Day 7: SSS, recurrent stroke, death, hypotension,
neurological deterioration (5 point reduction in SSS); Day 90: mRS, BI, EQ-5D, EQ-
VAS, MMSE, Zung Depression Scale
Notes Exclusion: definite need or CI for GTN; GCS ≤ 8; blood glucose < 2.5 mmol/L; non-
ambulatory prior to symptom onset
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Simple randomisation equally distributed
with equal distribution between treatment
and control groups
Allocation concealment (selection bias) Low risk Adequate. The opaque envelope contain-
ing the gauze dressing with or without
GTN was opened only after informed
consent was obtained; thus the research
paramedic did not know or was not able
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RIGHT 2013 (Continued)
to guess treatment allocation unless the
opaque envelope was opened
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk GTN was given in a single-blind design
as no manufacturer was able to supply
placebo patches. Participants were blinded
with placement of a gauze dressing over an
area of skin out of view (e.g. back or shoul-
ders) with or without GTN patch a under-
neath
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk GTN was given in a single-blind design
as no manufacturer was able to supply
placebo patches. Participants were blinded
with placement of a gauze dressing over an
area of skin out of view (e.g. back or shoul-
ders) with or without GTN patch a under-
neath. All participants were to receive best
medical care and there was no difference in
care between treatment groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed by investigators
blinded to all clinical details
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants have been accounted for;
no differences between trial groups
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Low risk No other biases found
SCAST 2011
Methods Double-blind, placebo-controlled, blinded-endpoint
Randomisation (1:1) by secure Internet website with both participants and investigators
masked to treatment allocation
Participants International (9 countries), multicentre (146 sites)
2029 participants. T: 1017, C: 1012
Mean age T: 70.8 years, C: 71.0 years
Male T: 60%, C: 56%
Inclusion: IS or ICH
Enrolment within 30 hours of stroke onset and elevated SBP > 140 mm Hg
FU: 25 losses
Interventions T: candesartan (Astra Zeneca), doses increasing from 4 mg on day 1 to 16 mg on days
3 to 7
C: placebo
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SCAST 2011 (Continued)
Rx: 7 days
Outcomes BP measured twice with validated automated blood pressure monitor (UA-767 Plus 30,
A&D Medical, San Jose, CA, USA)
Primary: composite of vascular death, nonfatal MI or non-fatal stroke in first 6 months;
mRS at 6 months
Secondary: SSS at day 7 and BI; death from all causes; vascular death; recurrent stroke;
MI; stroke progression
Notes Exclusion: CI to, or current treatment with ARA; markedly reduced consciousness (SSS
consciousness score ≤ 2); clear indication for an ARA during treatment period; clear
indication for antihypertensive treatment during the acute phase of stroke; premorbid
modified mRS ≥ 4; life expectancy of 12 months or less; patient unavailable for follow-
up; pregnancy or breastfeeding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done by secure Inter-
net system
Allocation concealment (selection bias) Low risk Both candesartan and placebo tablets were
identical in appearance. Central web-based
allocation ensured allocation concealment.
If Internet was not available, investigators
used the drug pack with the lowest pack
number
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differences between trial groups
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported;
no differences between trial groups
Other bias Unclear risk No other biases found
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TAST 2013
Methods Double-blind, blinded outcome
Randomisation (2:1) by computerised minimisation (age, sex, SBP, SSS, time to first
Xenon scan and cortical features according to OCSP classification); randomisation and
minimisation were carried out by a single investigator who had no contact with the trial
participants or trial data. Randomisation sequence was generated by trial pharmacist
Participants UK, single centre
19 participants. T: 12, C: 7
Mean age T: 71.9 years, C: 68.3 years
Male: T: 10 (83%), C: 4 (57%)
Inclusion:CT confirmed or suspected IS
Enrolment within 5 days and elevated SBP > 140 mm Hg
FU: no losses
Interventions T: telmisartan 80 mg daily administered orally or by nasogastric tube
C: placebo
Rx: 90 days
Outcomes Primary: change in ipsilateral hemispheric CBF
Secondary: BP; CBF velocity; CPP; ZFP; mRS at day 90. BP was measured using Om-
ronHEM- 705CP (Omron, 705IT, Kyoto, Japan) semiautomatic sphygmomanometer
with participants supine or sitting; measurements were taken in the unaffected arm and
done in duplicate with the average of the two readings recorded in the database
Notes Exclusion: CI to telmisartan or xenon CT scanning, or no enteral access
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised after core
data entry was complete by computer and
minimised on key prognostic variables
Allocation concealment (selection bias) Unclear risk All validations made with treatment alloca-
tion blinded
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
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TAST 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for; no differ-
ences between trial groups
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Low risk No other biases evident
Uzuner 1995
Methods Double-blind, placebo-controlled
Randomisation technique not stated
Per-protocol analysis
FU: no losses
Participants Turkey, single centre
100 participants. T: 50, C: 50
100% CT pre-entry
Enrolment within 24 hours
IS: 41 male, 36 female
Mean age 63 years
ICH: 3 male, 8 female
Mean age 65 years
Interventions T IS: nimodipine 180 mg/day (60 mg tds) po
T ICH: nimodipine 2 mg/h iv
C: matching po or iv placebo
Rx: for 2 days
Outcomes BP and HR at baseline, 5, 15, 30 and 60 minutes, then every hour for 23 hours (day 1)
, then every 2 hours for 24 hours (day 2). BP measured supine using unstated automatic
device; LOS; GCS
Notes Exclusion: 10 participants (T 2, C 8) treated with antihypertensive agents for malignant
hypertension and 2 participants with subarachnoid haemorrhage (treated with iv nimodip-
ine) were excluded from our analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Inadequate
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VENTURE 2013
Methods Prospective, open-labelled, blinded-endpoint
Randomisation by computer
Participants South Korea, multicentre (30 sites)
405 participants, T: 203, C: 202
Interventions T: valsartan 80 mg po once daily titrated up to 320 mg
C: no valsartan
Inclusion: IS and SBP 150 to 185 mm Hg
Enrolment: within 24 hours
Rx: 7 days
Outcomes BP methodology not known
Primary: mRS at 90 days
Secondary: early neurological deterioration during the first 7 days; death at day 90
Notes Exclusion: not known
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was an abstract only. The authors de-
scribe the study as being randomised open-
labelled and blinded-endpoint
Allocation concealment (selection bias) Unclear risk No further information available
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial was published as an abstract only.
The authors describe the study as being
open-labelled and blinded-endpoint
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The trial was published as an abstract only.
The authors describe the study as being
open-labelled and blinded-endpoint
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The trial was published as an abstract
only. The authors describe the study was
prospective, open-labelled and blinded-
endpoint
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient sufficient datawere provided in
the abstract to assess attrition
Selective reporting (reporting bias) Unclear risk This was an abstract only
Other bias Unclear risk This was an abstract only
54Interventions for deliberately altering blood pressure in acute stroke (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Willmot 2006
Methods Participant- and measurement-blinded RCT
Randomisation by computer (with minimisation on age, sex, baseline SBP, baseline SSS,
hours from onset, presence of a visible stroke lesion on CT)
FU: no losses
Participants UK, single centre
18 participants. T: 12, C: 6
Age T: 69 years, C: 70 years
Male T: 2, C: 3
Inclusion: IS or ICH, previously independent adult patients with a clinical stroke syndrome
and limb weakness
100% CT
Enrolment: within 5 days of ictus
Prior antihypertensive medication was discontinued at the time of admission
Interventions T: transdermal GTN 5 mg (Transiderm-Nitro5, Novartis Pharmaceuticals) once daily
C: no patch
Rx: 7 days
Outcomes BP was measured immediately before the baseline xenon CT scan and immediately after
the post-treatment scan
Peripheral SBP and DBP was measured in the non-hemiparetic arm with a validated digital
readout oscillometric device (Omron HEM-705CP, Omron Corp, Toyoko, Japan)
Central BP was assessed by applanation tonometry of the left radial artery and using the
pulse wave analysis (PWA) system (Sphygmocor, Sydney, Australia)
Notes Exclusion: requirement for or CI to nitrate therapy, had a definite need for prior antihy-
pertensive therapy or vasoactive drugs, unable to co-operate with scanning
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Adequate
ACEI: Angiotensin converting enzyme Inhibitors
ARA: Angiotensin receptor antagonist
AVPU: Alert, Voice, Pain, Unresponsive (AVPU) scale
BI: Barthel Index
BP: blood pressure
bpm: beats per minute
CI: contraindication
C: control group
CBF: cerebral blood flow
CPP: cerebral perfusion pressure
CT: computed tomography
DBP: diastolic blood pressure
ECG: electrocardiogram
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EQ-5d: European Quality of life-5 dimensions questionnaire
FU: follow up
GCS: Glasgow coma scale
GTN: glycerol trinitrate
HR: heart rate
ICH: intracerebral haemorrhage
INR: International Normalised Ratio
IS: ischaemic stroke
iv: intravenous
LOS: length of stay in hospital
MAP: mean arterial pressure
MCA: middle cerebral artery
MI: myocardial infarction
MMSE: mini mental state examination
MRI: magnetic resonance imaging
mRS: modified Rankin Scale
NIHSS: National Institutes of Health Stroke Scale
OCSP: Oxford Community Stroke Project classification
po: orally
QoL: quality of life
RCT: randomised controlled trial
rtPA: recombinant tissue plasminogen activator
Rx: treatment
SBP: systolic blood pressure
SSS: Scandinavian stroke scale
T: treatment group
tds: three times daily
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ACCELERATE 2013 Single-arm, non-blinded trial with all participants enrolled to receive iv clevidipine
Alem 2005 Recruitment of participants was within 3 months and not in the acute stage; compared bendrofluazide and
indapamide
ATACH 2006 Prospective open-label study; used single agent intravenous nicardipine comparing 3 tiers of BP lowering
Beer 2012 Trial aim not to alter BP, but assess the effect of irbesartan on infarct size and cerebral blood flow
BEST 1988 Trial aim not about altering BP, but to assess the effect of beta blockers in acute stroke
BIAS 2012 Trial aim not about altering BP, but to assess the effect of neuro and cardioprotective effects of propranolol
BLAST 2007 Withdrawn before recruitment
Bougousslavsky 1990 Trial aim not to alter BP, but to assess the effect of nimodipine on functional outcome
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(Continued)
Bridgers 1991 Aim of the trial was not to alter BP, but to test the effect of nimodipine in acute stroke
Bursztyn 1985 Head-to-head comparison of nifedipine + betablocker + thiazide versus nifedipine alone
Canwin 1993 Trial aim not about altering BP, but to assess the effect of nimodipine in acute stroke
CAPON 1983 Concealment, treatment losses, exclusion criteria, stroke criteria not available
Carlsson 1993 BP and outcome data not available
Chandra 1995 Head-to-head comparison study comparing intravenous versus oral nimodipine
CHERISH 2010 Head-to-head comparison study comparing cilnidipine versus losartan
Csiba 2012 No data available
Dalal 1995 Tested nimodipine as a neuroprotectant
FIST 1996 Aim not to alter BP, but assessed the effect of flunarizine on functional outcome
Gelmers 1984 Not placebo controlled
Gelmers 1988 Trial tested nimodipine in neurological outcome and survival
German-Austrian 1994 Trial aim not to alter BP, but to assess effect of nimodipine in neurological and functional outcome
Hartmann 2005 Head-to-head comparison study comparing urapidil versus nifedipine
HASTE 2010 No trial design or data available
Heiss 1990 Study compared morphological and functional effect between nimodipine and placebo
Infield 1999 Assessed the effect of nimodipine on cerebral perfusion and outcome
Inzhutova 2007 Study aim not to alter BP, but to assess effect on humoral endothelial dysfunction markers in ischaemic
stroke
Kaste 1994 Trial tested the effect of nimodipine on functional outcome, not BP
Koenig 2006 A retrospective chart review of induced hypertension
Kornhuber 1993 Study assessed the effect of flunarizine on functional outcome, not BP
Kwon 2013 Head-to head comparison between amlodipine and losartan
Lamsudin 1995 Assessed functional outcome with nimodipine, not BP
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(Continued)
Limburg 1990 Trial tested the effect of death and dependency of flunarizine
Lowe 1989 Comparison of death and disability with oral nimodipine versus placebo
Marin Gámez 1988 Published in Spanish. Very little known about treatment group, large number of participants excluded after
randomisation
Martinez-Vila 1990 Trial tested the effect of nimodipine on mortality and functional outcome
Marzan 2004 A retrospective evaluation of induced hypertension
Matias Guiu 1988 Study tested nicardipine on cognitive impairment
Meier 1991 BP data not available
Mohr 1992 Aim not to alter BP, but tested the effect of nimodipine on death and functional outcome
MOSES 2005 Head-to-head comparison study comparing eprosartan and nitrendipine
Nag 1998 BP data reported 4 weeks after treatment
Naidech 2003 BP data not available
Nakamura 2007 Head-to-head comparison study comparing perindopril versus candesartan versus conventional antihyper-
tensive therapy
Nazir 2004 SBP and DBP data not available
Nazir 2005 SBP and DBP data not available
NEST 1993 Significant number of participants excluded after randomisation and outcomes not presented in the pub-
lication
NICE 2010 Trial aim not to alter BP, but to evaluate nimodipine in preventing cognitive impairment after acute
ischaemic stroke
Ning 2007 Trial aim not to alter BP, but to assess the effect of nimodipine in treating perifocal oedema and neurological
function after ICH
Oczkowski 1989 Not relevant
PACI 1989 Tested effect of nimodipine on functional outcome and mortality, not BP
Popa 1995 Pre-stroke antihypertensive drugs discontinued (nifedipine, clonidine, furosemide or acetazolamide or
both)
Powers 1999 BP data not available
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Roitberg 2008 Head-to-head comparison between nicardipine and nitroprusside
Rordorf 1997 Retrospective study of induced hypertension
Rosenbaum 1990 Feasibility and safety study
Rosselli 1992 Article published in Italian; only abstract available, insufficient details
Sherman 1986 Trial tested effect of nimodipine versus placebo on clinical outcome, not BP
Shibuya 2005 Study compared clinical outcome between fasudil and placebo
Sze 1998 Not relevant; trial tested the effect of nimodipine on memory
TOPS 2013 Non-randomised study investigating the effects of olmesartan post-stroke
TRUST 1990 Primary aim not to alter BP
Wang 2006 Non-randomised study
Wimalaratna 1994 Study aim not to alter BP
Wityk 2008 No comparator, all participants received intervention to induce hypertension
Yao 1991 Article published in Chinese; nimodipine trial; preliminary study, insufficient details
Yordanov 1984 No details of control group
BP: blood pressure
DBP: diastolic blood pressure
ICH: intracerebral haemorrhage
iv: intraveous
SBP: systolic blood pressure
Characteristics of studies awaiting assessment [ordered by study ID]
ATTACI 2010
Methods Prospective, single centre
Participants Elderly people (> 65 years) with ischaemic stroke
Interventions Antihypertensive medications added to existing BP medications either morning, afternoon or bedtime
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ATTACI 2010 (Continued)
Outcomes BP
Notes Size: 200 participants
Contact person: Dr N Hosomi
Department of Clinical Neuroscience and Therapeutics,
Hiroshima University Graduate School of Biomedical and Health Sciences,
Hiroshima, Japan
ESH-CHL-SHOT 2013
Methods Factorial 3 x 2 arm, phase 4 study
Participants People with recent stroke or TIA
Interventions Randomisation to one of 3 BP targets:
• < 145 to 135 mm Hg
• < 135 to 125 mm Hg
• < 125 mm Hg
Random allocation to 1 of 2 lipid-lowering targets:
• LDL-C between 2.8 and 1.8 mmol/L
• < 1.8 mmol/L
Outcomes Recurrent stroke
Time to recurrent stroke
Composite vascular events: cardiovascular death, non-fatal stroke, non-fatal MI and cardiac failure
Cognitive impairment and dementia
Notes Size: 7500 participants
Funding: Instituto Auxologico Italiano, Italy
MAPAS 2009
Methods Single centre, randomised, open-label, parallel assignment
Participants Non-thrombolysed acute ischaemic stroke patients within 6 hours of ictus onset
Interventions T1: infusion up to 1 litre of saline and/or norepinephrine
T2: infusion of esmolol or sodium nitroprusside
Outcomes Primary: mRS at day 90
Secondary: treatment feasibility of the antihypertensive treatment, comparing the SBP range for the 24-hour period
Notes Size: 240
Funding: Hospital de Clinicas de Porto Alegre, Brazil
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STABLE-ICAS 2010
Methods Phase 4 study
Participants People with subacute ischaemic stroke due to symptomatic severe intracranial atherosclerosis
Interventions Intensive BP lowering (SBP < 120 mm Hg) compared with modest BP control (SBP < 140mm Hg)
Outcomes Primary outcomes: ischaemic lesion volume change in the whole forebrain on fluid attenuation inversion recovery
(FLAIR) magnetic resonance imaging (MRI); difference between final ischaemic lesions volume and base ischaemic
lesions of both hemisphere on FLAIR MRI
Secondary outcomes: Ischaemic lesion volume change in the territory of symptomatic intracranial disease on FLAIR
MRI
difference between final ischaemic lesions volume and base ischaemic lesions in the territory of symptomatic in-
tracranial disease on FLAIR MRI; participants with new ischaemic lesion in the whole forebrain on FLAIR MRI;
cardiovascular events; vascular death; number of adverse events and adverse drug reactions
Notes Size: 156 participants
Funding: Asan Medical Center, South Korea
BP: blood pressure
LDL-C: low-density lipoprotein cholesterol
MI: myocardial infarction
mRS: modified Rankin Scale
SBP: systolic blood pressure
TIA: transient ischaemic attack
Characteristics of ongoing studies [ordered by study ID]
ATACH-2 2011
Trial name or title Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH II)
Methods Multicentre, prospective, open-label, phase 3 randomised trial
Participants People with supratentorial intracerebral haemorrhage
Interventions Early intensive BP lowering with nicardipine iv, or management according to current American Heart Asso-
ciation guidelines
Outcomes Primary outcome: combining death and dependency, according to a 4 to 6 score on the mRS at 90 days
Secondary outcomes: all cause and cause-specific early neurological deterioration during the first 24 hours;
haematoma expansion at 24 hours; quality of life at 3 months
Starting date 2011
Contact information Prof Adnan I Qureshi
University of Minnesota, MMC 295, 420 Delaware St. SE., Minneapolis MN 55455, USA
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ATACH-2 2011 (Continued)
Notes Size: 1280 participants
Funding: National Institutes of Health, USA
ENCHANTED 2011
Trial name or title Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
Methods Prospective, international, multicentre, open-label, blinded-endpoint quasi-factorial randomised trial
Participants People with ischaemic stroke within 4.5 hours of ictus and SBP ≤ 185mm Hg
Interventions • standard dose rtPA or low dose rtPA
• intensive BP lowering to SBP 140 to 150 mm Hg, or SBP to < 180 mm Hg
Outcomes Primary outcome: death and dependency, according to a 2 to 6 score on the mRS
Secondary outcomes: early neurological deterioration during the first 72 hours; symptomatic intracerebral
haemorrhage during the first 7 days; day 90: discharge: quality of life; length of stay; disposition; mortality
Starting date 2012
Contact information Prof Craig Anderson, The George Institute, PO BoxM 201, Misssenden Road, Sydney NSW2050, Australia
Notes Size: 3300
Sponsor: National Health and Medical Research Council of Australia (NHMRC)
FAST-BP 2013
Trial name or title Field Administration of Stroke Therapy-Blood Pressure Lowering (FAST-BP)
Methods Single centre, prospective, open-label, safety and feasibility study
Participants People with ischaemic stroke or intracerebral haemorrhage
Interventions T1: GTN 5 mg/24 hour patch
T2: GTN 10 mg/24 hour patch
T3: GTN 5 mg/24 hour patch plus single metered dose 0.4 mg sublingual GTN
Outcomes Primary outcome: mean BP change 15 minutes after treatment
Secondary outcomes: early neurological deterioration (two point or greater worsening in GCS) during the
first hour; SBP less than 120 mm Hg; serious adverse events at 90 days
Starting date 2013
Contact information Dr Nerses Sanossian, Keck School of Medicine of University of South California, 1520 San Pablo St, Los
Angeles, CA90033, USA
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FAST-BP 2013 (Continued)
Notes Size: 45
Sponsor: University of California Los Angeles, USA
SETIN-HYPERTENSION 2012
Trial name or title Safety and Efficacy of Therapeutic Induced Hypertension in Acute Non-cardioembolic Ischemic Stroke
Methods Multicentre, prospective, randomised, open-label, phase 3 study
Participants Acute ischaemic stroke, confirmed by DWI within 24 hours of onset of ictus, or people who show a 2-point
or more increase in NIHSS including one or more increase in the motor score of the affected arm or leg or
clear evidence of symptom worsening judged by the investigator confirmed by DWI performed within 24
hours of symptom aggravation
Interventions T: iv phenylephrine
C: no phenylephrine
Outcomes Primary outcome: NIHSS between day 0 and day 7
Secondary outcomes: Day 7: infarct growth or new ischaemic lesion on MRI; Day 90: mRS, BI; symp-
tomatic intracerebral haemorrhage or cerebral oedema, MI, death from any cause during the first 3 months;
intracerebral haemorrhage on follow up MRI and side effects (headache, arrhythmia, chest pain, dysuria, or
gastrointestinal haemorrhage) up to 3 months
Starting date 2012
Contact information Prof Oh Young Bang
Samsung Medical Centre, South Korea
Notes Size: 170
Sponsor: Samsung Medical Centre
BI: Barthel Index
BP: blood pressure
DWI: Diffusion-weighted imaging
GCS: Glasgow Coma Score
GTN: glyceryl trinitrate
iv: intravenous
MI: myocardial infarction
MRI: magnetic resonance imaging
mRS: modified Rankin Score
NIHSS: National Institutes of Health Stroke Scale
rtPA: recombinant tissue plasminogen activator
SBP: systolic blood pressure
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D A T A A N D A N A L Y S E S
Comparison 1. Blood pressure lowering therapy in acute stroke
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or dependency, end of
trial by intervention
16 15489 Odds Ratio (IV, Random, 95% CI) 0.98 [0.92, 1.05]
1.1 ACE inhibitors 2 126 Odds Ratio (IV, Random, 95% CI) 1.12 [0.53, 2.36]
1.2 ARA(po) 3 3737 Odds Ratio (IV, Random, 95% CI) 1.07 [0.93, 1.23]
1.3 Beta-blockers 1 86 Odds Ratio (IV, Random, 95% CI) 1.03 [0.42, 2.55]
1.4 Nitric oxide donor 7 4194 Odds Ratio (IV, Random, 95% CI) 0.97 [0.86, 1.10]
1.5 Low BP target 4 7346 Odds Ratio (IV, Random, 95% CI) 0.95 [0.86, 1.04]
2 Death or dependency, end of
trial by stroke type
16 15366 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.92, 1.05]
2.1 Ischaemic stroke 8 11015 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.92, 1.08]
2.2 Combined Ischaemic
stroke and Intracerebral
haemorrhage
5 142 Odds Ratio (M-H, Random, 95% CI) 1.31 [0.64, 2.65]
2.3 Intracerebral haemorrhage 7 4209 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.21]
3 Death or dependency, end of
trial by stroke location
6 11950 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.87, 1.01]
3.1 Intracerebral
haemorrhage, deep
3 2536 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.73, 1.00]
3.2 Intracerebral
haemorrhage, superficial
3 851 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.77, 1.35]
3.3 Ischaemic stroke, cortical 4 6180 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.81, 1.09]
3.4 Ischaemic stroke,
subcortical
4 2383 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.76, 1.27]
4 Death or dependency, end of
trial by time to treatment
16 15489 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.92, 1.05]
4.1 Ultra-acute/pre-hospital 1 41 Odds Ratio (M-H, Random, 95% CI) 0.36 [0.09, 1.43]
4.2 Hyper-acute 3 3506 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.76, 0.99]
4.3 Acute 7 10440 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.94, 1.11]
4.4 Subacute 6 1502 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.84, 1.31]
5 Death, early by intervention 16 10050 Odds Ratio (IV, Random, 95% CI) 0.97 [0.74, 1.28]
5.1 ACE inhibitors (po) 4 164 Odds Ratio (IV, Random, 95% CI) 0.51 [0.06, 4.34]
5.2 ARA (po) 2 1379 Odds Ratio (IV, Random, 95% CI) 0.45 [0.05, 3.97]
5.3 Beta-blockers 1 86 Odds Ratio (IV, Random, 95% CI) 0.25 [0.02, 2.93]
5.4 Calcium channel blockers
(po)
1 77 Odds Ratio (IV, Random, 95% CI) 0.65 [0.17, 2.50]
5.5 Calcium channel blockers
(iv)
1 11 Odds Ratio (IV, Random, 95% CI) 2.69 [0.10, 73.20]
5.6 Nitric oxide donor 7 4189 Odds Ratio (IV, Random, 95% CI) 0.79 [0.37, 1.72]
5.7 Low BP target 2 4144 Odds Ratio (IV, Random, 95% CI) 1.10 [0.66, 1.83]
6 Death, early by stroke type 13 9925 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.76, 1.35]
6.1 Ischaemic stroke 6 8844 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.73, 1.38]
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6.2 Combined ischaemic
stroke and intracerebral
haemorrhage
6 373 Odds Ratio (M-H, Random, 95% CI) 0.72 [0.25, 2.05]
6.3 Intracerebral haemorrhage 3 708 Odds Ratio (M-H, Random, 95% CI) 1.27 [0.61, 2.61]
7 Death, early by time to treatment 15 10028 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.79, 1.36]
7.1 Ultra-acute/prehospital 2 47 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.09, 14.29]
7.2 Hyper-acute 1 270 Odds Ratio (M-H, Random, 95% CI) 1.55 [0.59, 4.05]
7.3 Acute 6 8182 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.78, 1.41]
7.4 Subacute 7 1529 Odds Ratio (M-H, Random, 95% CI) 0.40 [0.11, 1.42]
8 Death, end of trial by
intervention
20 15818 Odds Ratio (IV, Random, 95% CI) 0.95 [0.84, 1.06]
8.1 ACE inhibitors (po) 4 165 Odds Ratio (IV, Random, 95% CI) 0.47 [0.15, 1.48]
8.2 ARA (po) 5 4120 Odds Ratio (IV, Random, 95% CI) 0.92 [0.59, 1.44]
8.3 Beta-blockers 1 86 Odds Ratio (IV, Random, 95% CI) 0.57 [0.17, 1.89]
8.4 Nitric oxide donor 7 4197 Odds Ratio (IV, Random, 95% CI) 0.86 [0.72, 1.04]
8.5 Low BP target 4 7250 Odds Ratio (IV, Random, 95% CI) 1.04 [0.87, 1.25]
9 Death, end of trial by stroke type 20 15750 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.84, 1.07]
9.1 Ischaemic stroke 10 11238 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.78, 1.16]
9.2 Combined ischaemic
stroke and intracerebral
haemorrhage
7 328 Odds Ratio (M-H, Random, 95% CI) 0.59 [0.29, 1.22]
9.3 Intracerebral haemorrhage 6 4184 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.82, 1.18]
10 Death, end of trial by time to
treatment
20 15818 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.75, 1.08]
10.1 Ultra-acute/pre-hospital 2 52 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.11, 2.07]
10.2 Hyper-acute 3 3506 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.38, 1.26]
10.3 Acute 8 10708 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.77, 1.22]
10.4 Subacute 8 1552 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.39, 2.15]
11 Barthel Index, end of trial, by
intervention
2 4350 Mean Difference (IV, Random, 95% CI) 0.63 [-3.28, 4.54]
11.1 ARA 1 339 Mean Difference (IV, Random, 95% CI) -1.90 [-6.46, 2.66]
11.2 Nitric oxide donor 1 4011 Mean Difference (IV, Random, 95% CI) 2.20 [-0.20, 4.60]
12 Barthel Index, end of trial, by
stroke type
2 4310 Mean Difference (IV, Random, 95% CI) 1.33 [-1.04, 3.69]
12.1 Ischaemic stroke 2 3681 Mean Difference (IV, Random, 95% CI) 0.84 [-3.21, 4.89]
12.2 Intracerebral
haemorrhage
1 629 Mean Difference (IV, Random, 95% CI) 0.90 [-5.18, 6.98]
13 Barthel Index, end of trial, by
time to treatment
2 4350 Mean Difference (IV, Random, 95% CI) -5.43 [-14.19, 3.33]
13.1 Ultra-acute 1 273 Mean Difference (IV, Random, 95% CI) -18.0 [-25.66, -10.
34]
13.2 Acute 2 4077 Mean Difference (IV, Random, 95% CI) 0.30 [-2.64, 3.24]
14 Early neurological
deterioration, by intervention
7 7575 Odds Ratio (M-H, Random, 95% CI) 1.07 [0.92, 1.24]
14.1 ACE inhibitors 1 86 Odds Ratio (M-H, Random, 95% CI) 1.59 [0.30, 8.41]
14.2 Beta-blockers 1 86 Odds Ratio (M-H, Random, 95% CI) 0.53 [0.03, 8.74]
14.3 Nitric oxide donor 2 4052 Odds Ratio (M-H, Random, 95% CI) 1.14 [0.66, 1.98]
14.4 Low BP target 4 3351 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.80, 1.18]
15 Early neurological
deterioration, by stroke type
7 7507 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.91, 1.24]
15.1 Ischaemic stroke 2 3349 Odds Ratio (M-H, Random, 95% CI) 0.58 [0.09, 3.82]
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15.2 Combined ischaemic
stroke and intracerebral
haemorrhage
1 172 Odds Ratio (M-H, Random, 95% CI) 1.23 [0.31, 4.95]
15.3 Intracerebral
haemorrhage
6 3986 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.22]
16 Early neurological
deterioration, by time to
treatment
7 7575 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.87, 1.30]
16.1 Ultra-acute 1 41 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.13, 2.32]
16.2 Hyper-acute 3 3506 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.77, 1.13]
16.3 Acute 4 4028 Odds Ratio (M-H, Random, 95% CI) 1.39 [1.07, 1.81]
17 Quality of life (EuroQol) at
end of trial, by intervention
3 6881 Mean Difference (IV, Fixed, 95% CI) 0.02 [0.01, 0.04]
17.1 Nitric oxide donor 2 4052 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.01, 0.03]
17.2 Low BP target 1 2829 Mean Difference (IV, Fixed, 95% CI) 0.05 [0.02, 0.08]
18 Quality of life (EuroQoL) at
end of trial, by stroke type
3 7502 Mean Difference (IV, Random, 95% CI) 0.03 [-0.01, 0.07]
18.1 Ischaemic stroke 2 4038 Mean Difference (IV, Random, 95% CI) 0.13 [-0.14, 0.40]
18.2 Intracerebral
haemorrhage
3 3464 Mean Difference (IV, Random, 95% CI) 0.02 [-0.03, 0.08]
19 Quality of life (EuroQoL)
at end of trial, by time to
treatment
3 6867 Mean Difference (IV, Random, 95% CI) 0.05 [-0.00, 0.11]
19.1 Ultra-acute 1 27 Mean Difference (IV, Random, 95% CI) 0.29 [0.07, 0.51]
19.2 Hyperacute 2 3102 Mean Difference (IV, Random, 95% CI) 0.06 [0.03, 0.08]
19.3 Acute 1 3738 Mean Difference (IV, Random, 95% CI) 0.0 [-0.02, 0.02]
20 Length of stay, by intervention 4 8295 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.30, 0.28]
20.1 ACE inhibitors 1 86 Mean Difference (IV, Fixed, 95% CI) -0.13 [-2.11, 1.85]
20.2 Beta-blockers 1 86 Mean Difference (IV, Fixed, 95% CI) 0.21 [-1.76, 2.18]
20.3 Nitric oxide donor 2 4052 Mean Difference (IV, Fixed, 95% CI) -0.31 [-1.76, 1.14]
20.4 Low BP target 1 4071 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.31, 0.31]
21 Length of stay, by stroke type 3 8194 Mean Difference (IV, Random, 95% CI) -0.00 [-0.30, 0.29]
21.1 Ischaemic stroke 2 7393 Mean Difference (IV, Random, 95% CI) -0.03 [-0.33, 0.28]
21.2 Combined ischaemic
and Intracerebral haemorrhage
1 172 Mean Difference (IV, Random, 95% CI) 0.20 [-1.20, 1.60]
21.3 Intracerebral
haemorrhage
1 629 Mean Difference (IV, Random, 95% CI) 2.60 [-1.49, 6.69]
22 Length of stay, by time to
treatment
4 8295 Mean Difference (IV, Random, 95% CI) -0.01 [-0.30, 0.29]
22.1 Ultra-acute 2 314 Mean Difference (IV, Random, 95% CI) -1.88 [-6.58, 2.83]
22.2 Acute 3 7981 Mean Difference (IV, Random, 95% CI) 0.00 [-0.29, 0.30]
23 SBP, first after randomisation,
by intervention
24 15432 Mean Difference (IV, Random, 95% CI) -9.83 [-12.11, -7.56]
23.1 ACE inhibitors(po) 5 123 Mean Difference (IV, Random, 95% CI) -13.68 [-20.03, -7.
32]
23.2 ACE inhibitors (s/l) 1 42 Mean Difference (IV, Random, 95% CI) -4.00 [-17.55, 5.55]
23.3 ARA (po) 3 3408 Mean Difference (IV, Random, 95% CI) -4.59 [-7.71, -1.48]
23.4 A2AA(po) 1 4 Mean Difference (IV, Random, 95% CI) -13.67 [-41.48, 14.
14]
23.5 Beta-blockers (po) 1 44 Mean Difference (IV, Random, 95% CI) -11.5 [-20.29, -2.71]
23.6 Beta-blockers (iv) 1 41 Mean Difference (IV, Random, 95% CI) -16.40 [-27.40, -5.
40]
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23.7 Calcium channel
blockers (po)
3 106 Mean Difference (IV, Random, 95% CI) -7.62 [-17.21, 1.96]
23.8 Calcium channel
blockers (iv)
1 11 Mean Difference (IV, Random, 95% CI) -9.76 [-24.42, 4.90]
23.9 Nitric oxide donor 7 4192 Mean Difference (IV, Random, 95% CI) -9.25 [-14.54, -3.96]
23.10 Thiazide-like diuretic
(po)
1 40 Mean Difference (IV, Random, 95% CI) -20.0 [-38.60, -1.40]
23.11 Low BP target 5 7421 Mean Difference (IV, Random, 95% CI) -11.39 [-15.30, -7.
49]
24 SBP, first after randomisation
by stroke type
22 15659 Mean Difference (IV, Random, 95% CI) -8.77 [-11.04, -6.50]
24.1 Ischaemic stroke 10 9256 Mean Difference (IV, Random, 95% CI) -6.99 [-8.61, -5.38]
24.2 Combined ischaemic
stroke and intracerebral
haemorrhage
9 2466 Mean Difference (IV, Random, 95% CI) -7.89 [-12.43, -3.36]
24.3 Intracerebral
haemorrhage
4 3937 Mean Difference (IV, Random, 95% CI) -11.77 [-15.25, -8.
30]
25 SBP, first after randomisation
by time to treatment
17 15211 Mean Difference (IV, Random, 95% CI) -9.67 [-12.14, -7.20]
25.1 Ultra-acute/prehospital 2 55 Mean Difference (IV, Random, 95% CI) -15.98 [-30.43, -1.
53]
25.2 Hyper-acute 3 3506 Mean Difference (IV, Random, 95% CI) -13.38 [-15.41, -11.
35]
25.3 Acute 6 10120 Mean Difference (IV, Random, 95% CI) -7.23 [-9.83, -4.63]
25.4 Subacute 7 1530 Mean Difference (IV, Random, 95% CI) -7.26 [-10.02, -4.50]
26 SBP, at day 1 18 14203 Mean Difference (IV, Random, 95% CI) -8.33 [-10.97, -5.69]
26.1 ACE inhibitors (po) 5 120 Mean Difference (IV, Random, 95% CI) -7.90 [-16.83, 1.03]
26.2 ACE inhibitors (s/l) 1 42 Mean Difference (IV, Random, 95% CI) -12.0 [-25.60, 1.60]
26.3 ARA (po) 2 2368 Mean Difference (IV, Random, 95% CI) -0.50 [-2.52, 1.51]
26.4 A2AA (po) 1 4 Mean Difference (IV, Random, 95% CI) -21.83 [-66.12, 22.
46]
26.5 Beta-blockers(po) 1 44 Mean Difference (IV, Random, 95% CI) -14.00 [-27.28, -0.
72]
26.6 Beta-blockers (iv) 1 43 Mean Difference (IV, Random, 95% CI) -5.0 [-18.44, 8.44]
26.7 Calcium channel
blockers (po)
2 84 Mean Difference (IV, Random, 95% CI) -13.23 [-43.36, 16.
91]
26.8 Calcium channel
blockers (iv)
1 11 Mean Difference (IV, Random, 95% CI) -31.90 [-64.73, 0.
93]
26.9 Nitric oxide donor 7 4183 Mean Difference (IV, Random, 95% CI) -12.10 [-19.06, -5.
14]
26.10 Low BP target 3 7304 Mean Difference (IV, Random, 95% CI) -10.04 [-12.47, -7.
61]
27 SBP, at day 7 11 15151 Mean Difference (IV, Random, 95% CI) -6.74 [-9.39, -4.10]
27.1 ACE inhibitors 1 11 Mean Difference (IV, Random, 95% CI) -26.0 [-43.00, -7.00]
27.2 ARA(po) 4 3747 Mean Difference (IV, Random, 95% CI) -5.74 [-7.44, -4.03]
27.3 Thiazide-like diuretic
(po)
1 37 Mean Difference (IV, Random, 95% CI) -15.0 [-34.25, 4.25]
27.4 Nitric oxide donor 2 4052 Mean Difference (IV, Random, 95% CI) -1.16 [-2.63, 0.31]
27.5 Low BP target 3 7304 Mean Difference (IV, Random, 95% CI) -7.62 [-11.69, -3.56]
28 SBP, at end of treatment 20 15684 Mean Difference (IV, Random, 95% CI) -8.02 [-10.07, -5.97]
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28.1 ACE inhibitors (po) 4 123 Mean Difference (IV, Random, 95% CI) -17.37 [-23.42, -11.
31]
28.2 ACE inhibitors (s/l) 1 42 Mean Difference (IV, Random, 95% CI) -1.5 [-12.20, 9.20]
28.3 ARA (po) 5 3785 Mean Difference (IV, Random, 95% CI) -7.37 [-10.19, -4.56]
28.4 A2AA (po) 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
28.5 Beta-blockers (po) 1 44 Mean Difference (IV, Random, 95% CI) -3.20 [-13.17, 6.77]
28.6 Beta-blockers (iv) 1 43 Mean Difference (IV, Random, 95% CI) -13.00 [-25.21, -4.
79]
28.7 Calcium channel
blockers (po)
1 77 Mean Difference (IV, Random, 95% CI) -7.80 [-17.12, 1.52]
28.8 Calcium channel
blockers (iv)
1 11 Mean Difference (IV, Random, 95% CI) -9.20 [-25.73, 7.33]
28.9 Nitric oxide donor 4 4101 Mean Difference (IV, Random, 95% CI) -1.05 [-2.50, 0.39]
28.10 Thiazide-like diuretic
(po)
1 37 Mean Difference (IV, Random, 95% CI) 3.0 [-11.74, 17.74]
28.11 Low BP target 5 7421 Mean Difference (IV, Random, 95% CI) -10.06 [-13.58, -6.
55]
29 DBP, first after randomisation
by intervention
17 12397 Mean Difference (IV, Random, 95% CI) -3.86 [-5.07, -2.64]
29.1 ACE inhibitors(po) 5 123 Mean Difference (IV, Random, 95% CI) -4.23 [-9.68, 1.21]
29.2 ACE inhibitors (s/l) 1 42 Mean Difference (IV, Random, 95% CI) 2.20 [-5.50, 9.90]
29.3 ARA (po) 3 3408 Mean Difference (IV, Random, 95% CI) -2.48 [-4.35, -0.61]
29.4 A2AA 1 4 Mean Difference (IV, Random, 95% CI) -2.10 [-15.43, 11.
23]
29.5 Beta-Blockers (po) 1 43 Mean Difference (IV, Random, 95% CI) -5.40 [-13.01, 2.21]
29.6 Beta-Blockers (iv) 1 41 Mean Difference (IV, Random, 95% CI) -17.5 [-25.32, -9.68]
29.7 Calcium channel
blockers (po)
1 77 Mean Difference (IV, Random, 95% CI) -3.30 [-9.28, 2.68]
29.8 Calcium channel
blockers (iv)
1 11 Mean Difference (IV, Random, 95% CI) -12.90 [-31.35, 5.
55]
29.9 Nitric oxide donor 6 4173 Mean Difference (IV, Random, 95% CI) -3.39 [-4.25, -2.52]
29.10 Low BP target 2 4475 Mean Difference (IV, Random, 95% CI) -6.43 [-12.10, -0.75]
30 DBP, first after randomisation
by stroke type
16 14952 Mean Difference (IV, Random, 95% CI) -3.73 [-4.69, -2.76]
30.1 Ischaemic stroke 6 7500 Mean Difference (IV, Random, 95% CI) -3.53 [-4.20, -2.87]
30.2 Combined ischaemic
stroke and Intracerebral
haemorrhage
10 6419 Mean Difference (IV, Random, 95% CI) -2.85 [-4.26, -1.44]
30.3 Intracerebral
haemorrhage
2 1033 Mean Difference (IV, Random, 95% CI) -6.80 [-11.99, -1.60]
31 DBP, first after randomisation
by time to treatment
16 10977 Mean Difference (IV, Random, 95% CI) -3.80 [-5.06, -2.54]
31.1 Ultra-acute/prehospital 2 55 Mean Difference (IV, Random, 95% CI) 1.39 [-7.71, 10.48]
31.2 Hyper-acute 2 677 Mean Difference (IV, Random, 95% CI) -6.48 [-12.55, -0.41]
31.3 Acute 6 10076 Mean Difference (IV, Random, 95% CI) -3.11 [-4.26, -1.97]
31.4 Subacute 7 169 Mean Difference (IV, Random, 95% CI) -3.88 [-7.98, 0.22]
32 DBP, at day 1 16 11361 Mean Difference (IV, Random, 95% CI) -3.05 [-4.20, -1.91]
32.1 ACE inhibitors (po) 4 96 Mean Difference (IV, Random, 95% CI) -3.24 [-8.95, 2.47]
32.2 ACE inhibitors (s/l) 1 42 Mean Difference (IV, Random, 95% CI) -2.0 [-9.70, 5.70]
32.3 ARA (po) 2 2368 Mean Difference (IV, Random, 95% CI) 1.00 [-3.47, 1.48]
32.4 A2AA (po) 1 4 Mean Difference (IV, Random, 95% CI) 0.17 [-26.77, 27.11]
32.5 Beta-blockers (po) 1 43 Mean Difference (IV, Random, 95% CI) -1.0 [-8.99, 6.99]
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32.6 Beta-blockers (iv) 1 41 Mean Difference (IV, Random, 95% CI) -5.0 [-13.21, 3.21]
32.7 Calcium channel
blockers (po)
2 84 Mean Difference (IV, Random, 95% CI) -6.10 [-14.08, 1.89]
32.8 Calcium channel
blockers (iv)
1 11 Mean Difference (IV, Random, 95% CI) -12.90 [-31.35, 5.
55]
32.9 Nitric oxide donor 7 4197 Mean Difference (IV, Random, 95% CI) -3.31 [-4.17, -2.44]
32.10 Low BP target 2 4475 Mean Difference (IV, Random, 95% CI) -5.34 [-9.02, -1.65]
33 DBP, at day 7 10 12686 Mean Difference (IV, Random, 95% CI) -2.90 [-3.96, -1.83]
33.1 ACE inhibitors 1 11 Mean Difference (IV, Random, 95% CI) -18.0 [-33.10, -2.90]
33.2 ARA(po) 5 4152 Mean Difference (IV, Random, 95% CI) -2.47 [-3.24, -1.70]
33.3 Nitric oxide donor 1 4011 Mean Difference (IV, Random, 95% CI) -1.10 [-2.00, -0.20]
33.4 Thiazide-like diuretic
(po)
1 37 Mean Difference (IV, Random, 95% CI) -5.0 [-16.00, 6.00]
33.5 Low BP target 2 4475 Mean Difference (IV, Random, 95% CI) -4.49 [-6.18, -2.80]
34 DBP, at end of treatment 15 13050 Mean Difference (IV, Random, 95% CI) -3.95 [-5.15, -2.75]
34.1 ACE inhibitors (po) 4 123 Mean Difference (IV, Random, 95% CI) -6.06 [-11.18, -0.95]
34.2 ARA (po) 6 4190 Mean Difference (IV, Random, 95% CI) -3.61 [-5.61, -1.61]
34.3 ACE inhibitors (s/l) 1 42 Mean Difference (IV, Random, 95% CI) 0.0 [-7.70, 7.70]
34.4 Beta-blockers (po) 1 43 Mean Difference (IV, Random, 95% CI) 0.90 [-7.48, 9.28]
34.5 Beta-Blockers (iv) 1 41 Mean Difference (IV, Random, 95% CI) -16.40 [-24.22, -8.
58]
34.6 Calcium channel
blockers (po)
1 77 Mean Difference (IV, Random, 95% CI) -9.40 [-15.50, -3.30]
34.7 Calcium channel
blockers (iv)
1 11 Mean Difference (IV, Random, 95% CI) -2.90 [-21.35, 15.
55]
34.8 Nitric oxide donor 1 4011 Mean Difference (IV, Random, 95% CI) -1.10 [-2.00, -0.20]
34.9 Thiazide-like diuretic
(po)
1 37 Mean Difference (IV, Random, 95% CI) -4.0 [-13.03, 5.03]
34.10 Low BP target 2 4475 Mean Difference (IV, Random, 95% CI) -4.24 [-5.62, -2.86]
35 HR at baseline 15 5841 Mean Difference (IV, Random, 95% CI) 0.07 [-0.86, 0.99]
35.1 ACE inhibitors (po) 3 61 Mean Difference (IV, Random, 95% CI) 0.22 [-5.31, 5.75]
35.2 ARA(po) 2 1379 Mean Difference (IV, Random, 95% CI) -0.34 [-1.57, 0.90]
35.3 A2AA (po) 1 2 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
35.4 Calcium channel
blockers (po)
2 79 Mean Difference (IV, Random, 95% CI) -3.60 [-9.47, 2.27]
35.5 Nitric oxide donor 7 4197 Mean Difference (IV, Random, 95% CI) 2.26 [-1.26, 5.77]
35.6 Thiazide-like diuretic
(po)
1 37 Mean Difference (IV, Random, 95% CI) -4.0 [-10.50, 2.50]
35.7 Calcium channel
blockers (iv)
1 11 Mean Difference (IV, Random, 95% CI) 5.30 [-4.21, 14.81]
35.8 Low BP target 1 75 Mean Difference (IV, Random, 95% CI) -3.0 [-10.53, 4.53]
36 HR, first after randomisation 6 4196 Mean Difference (IV, Random, 95% CI) 2.74 [-1.13, 6.61]
36.1 ACE inhibitors (po) 2 39 Mean Difference (IV, Random, 95% CI) -0.58 [-9.89, 8.72]
36.2 ARA(po) 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.3 Calcium channel
blockers (po)
2 82 Mean Difference (IV, Random, 95% CI) 1.28 [-21.89, 24.46]
36.4 A2AA (po) 1 3 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.5 Nitric oxide donor 3 4061 Mean Difference (IV, Random, 95% CI) 3.95 [-1.03, 8.93]
36.6 Calcium channel
blockers (iv)
1 11 Mean Difference (IV, Random, 95% CI) 10.0 [0.71, 19.29]
37 HR, at day 1 10 4333 Mean Difference (IV, Random, 95% CI) 2.35 [-1.06, 5.76]
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37.1 ACE inhibitors (po) 2 39 Mean Difference (IV, Random, 95% CI) 0.03 [-40.45, 40.51]
37.2 Calcium channel
blockers (po)
2 83 Mean Difference (IV, Random, 95% CI) -2.56 [-7.71, 2.59]
37.3 A2AA (po) 1 3 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
37.4 Nitric oxide donor 7 4197 Mean Difference (IV, Random, 95% CI) 4.53 [1.46, 7.60]
37.5 Calcium channel
blockers (iv)
1 11 Mean Difference (IV, Random, 95% CI) -16.90 [-27.35, -6.
45]
38 HR, at day 7 4 5449 Mean Difference (IV, Random, 95% CI) 0.47 [-0.24, 1.19]
38.1 Thiazide-like diuretic
(po)
1 37 Mean Difference (IV, Random, 95% CI) 0.0 [-6.14, 6.14]
38.2 ARA(po) 1 1360 Mean Difference (IV, Random, 95% CI) 0.10 [-1.07, 1.27]
38.3 Nitric oxide donor 2 4052 Mean Difference (IV, Random, 95% CI) 0.72 [-0.20, 1.63]
39 HR, at end of treatment 4 4124 Mean Difference (IV, Random, 95% CI) 0.70 [-0.21, 1.61]
39.1 ACE inhibitors 1 35 Mean Difference (IV, Random, 95% CI) 2.40 [-62.22, 67.02]
39.2 Thiazide- like diuretic 1 37 Mean Difference (IV, Random, 95% CI) 0.0 [-6.14, 6.14]
39.3 Nitric oxide donor 2 4052 Mean Difference (IV, Random, 95% CI) 0.72 [-0.20, 1.63]
Comparison 2. Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or dependency, end of
trial by C/S
2 2860 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.91, 1.24]
2 Death or dependency, end of
trial by stroke type C/S
2 2841 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.91, 1.24]
2.1 Ischaemic stroke 1 1832 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.87, 1.28]
2.2 Combined ischaemic
stroke and intracerebral
haemorrhage
1 763 Odds Ratio (M-H, Random, 95% CI) 1.10 [0.82, 1.48]
2.3 Intracerebral haemorrhage 1 246 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.55, 1.65]
3 Death or dependency, end of
trial by time to treatment
2 2860 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.91, 1.24]
3.1 Ultra-acute 1 143 Odds Ratio (M-H, Random, 95% CI) 1.34 [0.69, 2.61]
3.2 Acute 2 2717 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.89, 1.23]
4 Death early, by C/S 2 2860 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.55, 2.00]
5 Death early, by stroke type C/S 2 2841 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.56, 1.87]
5.1 Ischaemic stroke 1 1832 Odds Ratio (M-H, Random, 95% CI) 1.37 [0.79, 2.36]
5.2 Combined ischaemic
stroke and intracerebral
haemorrhage
1 763 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.17, 1.98]
5.3 Intracerebral haemorrhage 1 246 Odds Ratio (M-H, Random, 95% CI) 0.53 [0.09, 2.92]
6 Death early, by time to treatment
C/S
2 2860 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.60, 1.93]
6.1 Ultra-acute 1 143 Odds Ratio (M-H, Random, 95% CI) 5.68 [0.27, 120.37]
6.2 Acute 2 2717 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.61, 1.76]
7 Death, end of trial by C/S 2 2860 Odds Ratio (M-H, Random, 95% CI) 1.15 [0.92, 1.43]
8 Death end of trial, by stroke type
C/S
2 2839 Odds Ratio (M-H, Random, 95% CI) 1.18 [0.94, 1.47]
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8.1 Ischaemic stroke 1 1832 Odds Ratio (M-H, Random, 95% CI) 1.24 [0.96, 1.61]
8.2 Combined ischaemic
stroke and intracerebral
haemorrhage
1 763 Odds Ratio (M-H, Random, 95% CI) 1.13 [0.67, 1.91]
8.3 Intracerebral haemorrhage 1 244 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.45, 1.71]
9 Death, end of trial by time to
treatment C/S
2 2860 Odds Ratio (M-H, Random, 95% CI) 1.14 [0.92, 1.42]
9.1 Ultra-acute 1 143 Odds Ratio (M-H, Random, 95% CI) 1.87 [0.68, 5.15]
9.2 Acute 2 2717 Odds Ratio (M-H, Random, 95% CI) 1.12 [0.89, 1.40]
10 Barthel Index, end of trial, by
C/S
2 2860 Mean Difference (IV, Random, 95% CI) -3.18 [-5.80, -0.55]
11 Early neurological
deterioration, by C/S
1 2097 Odds Ratio (M-H, Random, 95% CI) 1.27 [0.89, 1.82]
12 Quality of life (EuroQol) at
end of trial, by C/S
2 2860 Mean Difference (IV, Random, 95% CI) -0.03 [-0.05, -0.01]
13 Length of stay, by C/S 1 2097 Mean Difference (IV, Random, 95% CI) 1.20 [-0.87, 3.27]
14 SBP, first after randomisation,
by C/S
2 2860 Mean Difference (IV, Random, 95% CI) -3.11 [-4.75, -1.46]
15 SBP, at day 1 by C/S 2 2860 Mean Difference (IV, Random, 95% CI) -3.11 [-4.75, -1.46]
16 SBP, at end of treatment by C/S 2 2860 Mean Difference (IV, Random, 95% CI) -11.30 [-15.20, -7.
40]
17 DBP, at baseline by C/S 2 2860 Mean Difference (IV, Random, 95% CI) -0.69 [-1.65, 0.27]
18 DBP at day 1, by C/S 2 2860 Mean Difference (IV, Random, 95% CI) -1.16 [-2.24, -0.08]
19 DBP, at end of treatment by
C/S
2 2860 Mean Difference (IV, Random, 95% CI) -6.45 [-9.28, -3.61]
20 HR, at day 1 1 2097 Mean Difference (IV, Fixed, 95% CI) 0.60 [-0.70, 1.90]
21 HR, at end of treatment 1 2097 Mean Difference (IV, Fixed, 95% CI) -3.20 [-4.51, -1.89]
Comparison 3. Blood pressure elevation therapy in acute stroke
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death early, by intervention 1 15 Odds Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Phenylephrine (iv) 1 15 Odds Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Death early, by stroke type 1 15 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Ischaemic stroke 1 15 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Death end of trial, by
intervention
1 15 Odds Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Phenylephrine (iv) 1 15 Odds Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 SBP, at baseline 1 15 Mean Difference (IV, Random, 95% CI) -27.5 [-50.83, -4.17]
4.1 Phenylephrine (iv) 1 15 Mean Difference (IV, Random, 95% CI) -27.5 [-50.83, -4.17]
5 SBP, first after randomisation 1 15 Mean Difference (IV, Random, 95% CI) 20.60 [-13.31, 54.
51]
6 SBP, at day 1 1 15 Mean Difference (IV, Random, 95% CI) 20.60 [-13.31, 54.
51]
7 DBP, at baseline 1 15 Mean Difference (IV, Random, 95% CI) -8.30 [-19.13, 2.53]
8 DBP, first after randomisation 1 15 Mean Difference (IV, Random, 95% CI) 0.5 [-14.86, 15.86]
9 DBP, at day 1 1 15 Mean Difference (IV, Random, 95% CI) 0.5 [-14.86, 15.86]
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Analysis 1.1. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 1 Death or
dependency, end of trial by intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 1 Death or dependency, end of trial by intervention
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors
CHHIPS 2009 35/57 17/29 0.5 % 1.12 [ 0.45, 2.79 ]
Eveson 2007 7/18 8/22 0.3 % 1.11 [ 0.31, 4.03 ]
Subtotal (95% CI) 75 51 0.8 % 1.12 [ 0.53, 2.36 ]
Total events: 42 (Treatment), 25 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
2 ARA(po)
PRoFESS 2009 195/647 211/713 8.0 % 1.03 [ 0.81, 1.30 ]
SCAST 2011 348/1000 331/1004 12.6 % 1.09 [ 0.90, 1.31 ]
VENTURE 2013 46/187 42/186 1.9 % 1.12 [ 0.69, 1.80 ]
Subtotal (95% CI) 1834 1903 22.4 % 1.07 [ 0.93, 1.23 ]
Total events: 589 (Treatment), 584 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
3 Beta-blockers
CHHIPS 2009 34/56 18/30 0.5 % 1.03 [ 0.42, 2.55 ]
Subtotal (95% CI) 56 30 0.5 % 1.03 [ 0.42, 2.55 ]
Total events: 34 (Treatment), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
4 Nitric oxide donor
Bath 2000 8/16 6/18 0.2 % 2.00 [ 0.50, 8.00 ]
ENOS 2014 1205/2000 1227/2011 26.9 % 0.97 [ 0.85, 1.10 ]
Rashid 2003 10 mg 13/20 6/10 0.2 % 1.24 [ 0.26, 5.91 ]
Rashid 2003 5 mg 12/20 6/10 0.2 % 1.00 [ 0.21, 4.71 ]
Rashid 2003 5/10 mg 12/20 6/10 0.2 % 1.00 [ 0.21, 4.71 ]
RIGHT 2013 13/25 12/16 0.2 % 0.36 [ 0.09, 1.43 ]
0.2 0.5 1 2 5
Favours BP lowering Favours control
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(. . . Continued)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Willmot 2006 5/12 2/6 0.1 % 1.43 [ 0.18, 11.09 ]
Subtotal (95% CI) 2113 2081 28.0 % 0.97 [ 0.86, 1.10 ]
Total events: 1268 (Treatment), 1265 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.26, df = 6 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
5 Low BP target
CATIS 2013 683/2038 681/2033 25.4 % 1.00 [ 0.88, 1.14 ]
INTERACT pilot 2008 95/203 95/201 2.8 % 0.98 [ 0.66, 1.45 ]
INTERACT-2 2013 719/1399 785/1430 19.7 % 0.87 [ 0.75, 1.01 ]
Koch 2008 13/21 11/21 0.3 % 1.48 [ 0.43, 5.05 ]
Subtotal (95% CI) 3661 3685 48.3 % 0.95 [ 0.86, 1.04 ]
Total events: 1510 (Treatment), 1572 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.53, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Total (95% CI) 7739 7750 100.0 % 0.98 [ 0.92, 1.05 ]
Total events: 3443 (Treatment), 3464 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.12, df = 16 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 2.15, df = 4 (P = 0.71), I2 =0.0%
0.2 0.5 1 2 5
Favours BP lowering Favours control
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Analysis 1.2. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 2 Death or
dependency, end of trial by stroke type.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 2 Death or dependency, end of trial by stroke type
Study or subgroup BP lowering Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke
CATIS 2013 683/2038 681/2033 25.7 % 1.00 [ 0.88, 1.14 ]
CHHIPS 2009 44/64 19/35 0.6 % 1.85 [ 0.79, 4.33 ]
ENOS 2014 985/1664 1015/1678 22.7 % 0.95 [ 0.83, 1.09 ]
Eveson 2007 7/18 8/22 0.3 % 1.11 [ 0.31, 4.03 ]
PRoFESS 2009 195/647 211/713 8.0 % 1.03 [ 0.81, 1.30 ]
RIGHT 2013 8/16 10/11 0.1 % 0.10 [ 0.01, 0.98 ]
SCAST 2011 285/843 284/860 10.7 % 1.04 [ 0.85, 1.27 ]
VENTURE 2013 46/187 42/186 1.9 % 1.12 [ 0.69, 1.80 ]
Subtotal (95% CI) 5477 5538 70.0 % 1.00 [ 0.92, 1.08 ]
Total events: 2253 (BP lowering), 2270 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.93, df = 7 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
2 Combined Ischaemic stroke and Intracerebral haemorrhage
Bath 2000 8/16 6/18 0.2 % 2.00 [ 0.50, 8.00 ]
Rashid 2003 10 mg 13/20 6/10 0.2 % 1.24 [ 0.26, 5.91 ]
Rashid 2003 5 mg 12/20 6/10 0.2 % 1.00 [ 0.21, 4.71 ]
Rashid 2003 5/10 mg 12/20 6/10 0.2 % 1.00 [ 0.21, 4.71 ]
Willmot 2006 5/12 2/6 0.1 % 1.43 [ 0.18, 11.09 ]
Subtotal (95% CI) 88 54 0.9 % 1.31 [ 0.64, 2.65 ]
Total events: 50 (BP lowering), 26 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.60, df = 4 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
3 Intracerebral haemorrhage
CHHIPS 2009 14/18 3/7 0.1 % 4.67 [ 0.72, 30.11 ]
ENOS 2014 204/310 204/319 4.1 % 1.08 [ 0.78, 1.51 ]
INTERACT pilot 2008 95/203 95/201 2.8 % 0.98 [ 0.66, 1.45 ]
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(. . . Continued)
Study or subgroup BP lowering Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
INTERACT-2 2013 719/1399 785/1430 19.9 % 0.87 [ 0.75, 1.01 ]
Koch 2008 13/21 11/21 0.3 % 1.48 [ 0.43, 5.05 ]
RIGHT 2013 3/5 1/1 0.0 % 0.47 [ 0.01, 16.89 ]
SCAST 2011 63/144 47/130 1.8 % 1.37 [ 0.84, 2.23 ]
Subtotal (95% CI) 2100 2109 29.1 % 1.01 [ 0.84, 1.21 ]
Total events: 1111 (BP lowering), 1146 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.71, df = 6 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.08 (P = 0.93)
Total (95% CI) 7665 7701 100.0 % 0.98 [ 0.92, 1.05 ]
Total events: 3414 (BP lowering), 3442 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 16.40, df = 19 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.56, df = 2 (P = 0.76), I2 =0.0%
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Analysis 1.3. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 3 Death or
dependency, end of trial by stroke location.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 3 Death or dependency, end of trial by stroke location
Study or subgroup Favours experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intracerebral haemorrhage, deep
ENOS 2014 53/100 56/100 1.9 % 0.89 [ 0.51, 1.55 ]
INTERACT pilot 2008 13/88 18/99 1.0 % 0.78 [ 0.36, 1.70 ]
INTERACT-2 2013 568/1070 614/1079 20.8 % 0.86 [ 0.72, 1.02 ]
Subtotal (95% CI) 1258 1278 23.7 % 0.86 [ 0.73, 1.00 ]
Total events: 634 (Favours experimental), 688 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
2 Intracerebral haemorrhage, superficial
ENOS 2014 146/203 144/210 3.4 % 1.17 [ 0.77, 1.79 ]
INTERACT-2 2013 100/210 111/223 4.2 % 0.92 [ 0.63, 1.34 ]
RIGHT 2013 3/4 1/1 0.0 % 0.78 [ 0.02, 32.37 ]
Subtotal (95% CI) 417 434 7.6 % 1.02 [ 0.77, 1.35 ]
Total events: 249 (Favours experimental), 256 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
3 Ischaemic stroke, cortical
CATIS 2013 439/1571 442/1601 24.9 % 1.02 [ 0.87, 1.19 ]
ENOS 2014 696/1013 716/1012 16.7 % 0.91 [ 0.75, 1.10 ]
RIGHT 2013 7/13 8/8 0.1 % 0.07 [ 0.00, 1.42 ]
SCAST 2011 157/476 176/486 8.5 % 0.87 [ 0.66, 1.13 ]
Subtotal (95% CI) 3073 3107 50.2 % 0.94 [ 0.81, 1.09 ]
Total events: 1299 (Favours experimental), 1342 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.31, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.86 (P = 0.39)
4 Ischaemic stroke, subcortical
CATIS 2013 48/362 54/329 3.4 % 0.78 [ 0.51, 1.19 ]
ENOS 2014 266/584 276/596 11.5 % 0.97 [ 0.77, 1.22 ]
RIGHT 2013 0/2 2/3 0.0 % 0.12 [ 0.00, 4.61 ]
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Study or subgroup Favours experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SCAST 2011 64/242 57/265 3.6 % 1.31 [ 0.87, 1.98 ]
Subtotal (95% CI) 1190 1193 18.5 % 0.98 [ 0.76, 1.27 ]
Total events: 378 (Favours experimental), 389 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.38, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 0.13 (P = 0.90)
Total (95% CI) 5938 6012 100.0 % 0.94 [ 0.87, 1.01 ]
Total events: 2560 (Favours experimental), 2675 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.45, df = 13 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 1.65, df = 3 (P = 0.65), I2 =0.0%
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Analysis 1.4. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 4 Death or
dependency, end of trial by time to treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 4 Death or dependency, end of trial by time to treatment
Study or subgroup BP lowering Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ultra-acute/pre-hospital
RIGHT 2013 13/25 12/16 0.2 % 0.36 [ 0.09, 1.43 ]
Subtotal (95% CI) 25 16 0.2 % 0.36 [ 0.09, 1.43 ]
Total events: 13 (BP lowering), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
2 Hyper-acute
INTERACT pilot 2008 95/203 95/201 2.8 % 0.98 [ 0.66, 1.45 ]
INTERACT-2 2013 719/1399 785/1430 19.7 % 0.87 [ 0.75, 1.01 ]
ENOS 2014 74/144 78/129 1.9 % 0.69 [ 0.43, 1.12 ]
Subtotal (95% CI) 1746 1760 24.4 % 0.87 [ 0.76, 0.99 ]
Total events: 888 (BP lowering), 958 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
3 Acute
CHHIPS 2009 69/113 35/59 1.0 % 1.08 [ 0.57, 2.04 ]
CATIS 2013 683/2038 681/2033 25.5 % 1.00 [ 0.88, 1.14 ]
SCAST 2011 348/1000 331/1004 12.6 % 1.09 [ 0.90, 1.31 ]
Eveson 2007 7/18 8/22 0.3 % 1.11 [ 0.31, 4.03 ]
VENTURE 2013 46/187 42/186 1.9 % 1.12 [ 0.69, 1.80 ]
Koch 2008 13/21 11/21 0.3 % 1.48 [ 0.43, 5.05 ]
ENOS 2014 1131/1856 1149/1882 25.0 % 1.00 [ 0.87, 1.14 ]
Subtotal (95% CI) 5233 5207 66.5 % 1.02 [ 0.94, 1.11 ]
Total events: 2297 (BP lowering), 2257 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.18, df = 6 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
4 Subacute
Bath 2000 8/16 6/18 0.2 % 2.00 [ 0.50, 8.00 ]
Rashid 2003 10 mg 13/20 6/10 0.2 % 1.24 [ 0.26, 5.91 ]
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(. . . Continued)
Study or subgroup BP lowering Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rashid 2003 5/10 mg 12/20 6/10 0.2 % 1.00 [ 0.21, 4.71 ]
Rashid 2003 5 mg 12/20 6/10 0.2 % 1.00 [ 0.21, 4.71 ]
Willmot 2006 5/12 2/6 0.1 % 1.43 [ 0.18, 11.09 ]
PRoFESS 2009 195/647 211/713 8.0 % 1.03 [ 0.81, 1.30 ]
Subtotal (95% CI) 735 767 8.8 % 1.05 [ 0.84, 1.31 ]
Total events: 245 (BP lowering), 237 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.00, df = 5 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 7739 7750 100.0 % 0.98 [ 0.92, 1.05 ]
Total events: 3443 (BP lowering), 3464 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 10.14, df = 16 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 6.71, df = 3 (P = 0.08), I2 =55%
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Analysis 1.5. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 5 Death, early by
intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 5 Death, early by intervention
Study or subgroup Active group Control group Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors (po)
Dyker 1997 0/12 0/12 Not estimable
PIL-FAST 2013 0/6 0/8 Not estimable
CHHIPS 2009 0/57 1/29 0.7 % 0.17 [ 0.01, 4.18 ]
Eveson 2007 1/18 1/22 0.9 % 1.24 [ 0.07, 21.24 ]
Subtotal (95% CI) 93 71 1.7 % 0.51 [ 0.06, 4.34 ]
Total events: 1 (Active group), 2 (Control group)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 ARA (po)
PRoFESS 2009 0/647 1/713 0.7 % 0.37 [ 0.01, 9.02 ]
TAST 2013 1/12 1/7 0.9 % 0.55 [ 0.03, 10.37 ]
Subtotal (95% CI) 659 720 1.6 % 0.45 [ 0.05, 3.97 ]
Total events: 1 (Active group), 2 (Control group)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
3 Beta-blockers
CHHIPS 2009 1/56 2/30 1.3 % 0.25 [ 0.02, 2.93 ]
Subtotal (95% CI) 56 30 1.3 % 0.25 [ 0.02, 2.93 ]
Total events: 1 (Active group), 2 (Control group)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
4 Calcium channel blockers (po)
Uzuner 1995 4/38 6/39 4.1 % 0.65 [ 0.17, 2.50 ]
Subtotal (95% CI) 38 39 4.1 % 0.65 [ 0.17, 2.50 ]
Total events: 4 (Active group), 6 (Control group)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
5 Calcium channel blockers (iv)
Uzuner 1995 2/8 0/3 0.7 % 2.69 [ 0.10, 73.20 ]
Subtotal (95% CI) 8 3 0.7 % 2.69 [ 0.10, 73.20 ]
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Study or subgroup Active group Control group Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total events: 2 (Active group), 0 (Control group)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
6 Nitric oxide donor
Willmot 2006 0/12 0/6 Not estimable
Rashid 2003 5/10 mg 0/20 2/10 0.8 % 0.08 [ 0.00, 1.92 ]
Rashid 2003 10 mg 0/20 2/10 0.8 % 0.08 [ 0.00, 1.92 ]
Rashid 2003 5 mg 2/20 2/10 1.7 % 0.44 [ 0.05, 3.74 ]
ENOS 2014 61/2000 58/2011 56.6 % 1.06 [ 0.74, 1.53 ]
RIGHT 2013 2/21 1/12 1.2 % 1.16 [ 0.09, 14.29 ]
Bath 2000 2/16 1/21 1.2 % 2.86 [ 0.24, 34.66 ]
Subtotal (95% CI) 2109 2080 62.2 % 0.79 [ 0.37, 1.72 ]
Total events: 67 (Active group), 66 (Control group)
Heterogeneity: Tau2 = 0.22; Chi2 = 6.17, df = 5 (P = 0.29); I2 =19%
Test for overall effect: Z = 0.59 (P = 0.56)
7 Low BP target
CATIS 2013 25/2038 25/2033 24.2 % 1.00 [ 0.57, 1.74 ]
ICH-ADAPT 2013 7/37 4/36 4.3 % 1.87 [ 0.50, 7.03 ]
Subtotal (95% CI) 2075 2069 28.5 % 1.10 [ 0.66, 1.83 ]
Total events: 32 (Active group), 29 (Control group)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Total (95% CI) 5038 5012 100.0 % 0.97 [ 0.74, 1.28 ]
Total events: 108 (Active group), 107 (Control group)
Heterogeneity: Tau2 = 0.0; Chi2 = 10.68, df = 14 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 2.99, df = 6 (P = 0.81), I2 =0.0%
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Analysis 1.6. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 6 Death, early by
stroke type.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 6 Death, early by stroke type
Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke
CATIS 2013 25/2038 25/2033 25.8 % 1.00 [ 0.57, 1.74 ]
Dyker 1997 0/12 0/12 Not estimable
ENOS 2014 49/1644 48/1678 49.1 % 1.04 [ 0.70, 1.56 ]
Eveson 2007 1/18 1/22 1.0 % 1.24 [ 0.07, 21.24 ]
PRoFESS 2009 0/647 1/713 0.8 % 0.37 [ 0.01, 9.02 ]
RIGHT 2013 0/16 1/11 0.7 % 0.21 [ 0.01, 5.71 ]
Subtotal (95% CI) 4375 4469 77.4 % 1.00 [ 0.73, 1.38 ]
Total events: 75 (Active), 76 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.29, df = 4 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
2 Combined ischaemic stroke and intracerebral haemorrhage
Bath 2000 2/16 1/21 1.3 % 2.86 [ 0.24, 34.66 ]
CHHIPS 2009 1/113 3/59 1.5 % 0.17 [ 0.02, 1.64 ]
PIL-FAST 2013 1/6 1/8 0.9 % 1.40 [ 0.07, 28.12 ]
Rashid 2003 10 mg 0/20 2/30 0.8 % 0.28 [ 0.01, 6.10 ]
Rashid 2003 5 mg 2/20 2/30 1.9 % 1.56 [ 0.20, 12.05 ]
Rashid 2003 5/10 mg 0/20 2/30 0.8 % 0.28 [ 0.01, 6.10 ]
Subtotal (95% CI) 195 178 7.3 % 0.72 [ 0.25, 2.05 ]
Total events: 6 (Active), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.23, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
3 Intracerebral haemorrhage
ENOS 2014 10/310 10/319 10.1 % 1.03 [ 0.42, 2.51 ]
ICH-ADAPT 2013 7/37 4/36 4.6 % 1.87 [ 0.50, 7.03 ]
RIGHT 2013 2/5 0/1 0.6 % 2.14 [ 0.06, 77.54 ]
Subtotal (95% CI) 352 356 15.3 % 1.27 [ 0.61, 2.61 ]
Total events: 19 (Active), 14 (Control)
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Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 4922 5003 100.0 % 1.02 [ 0.76, 1.35 ]
Total events: 100 (Active), 101 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.91, df = 13 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.78, df = 2 (P = 0.68), I2 =0.0%
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Analysis 1.7. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 7 Death, early by
time to treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 7 Death, early by time to treatment
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ultra-acute/prehospital
PIL-FAST 2013 0/6 0/8 Not estimable
RIGHT 2013 2/21 1/12 1.2 % 1.16 [ 0.09, 14.29 ]
Subtotal (95% CI) 27 20 1.2 % 1.16 [ 0.09, 14.29 ]
Total events: 2 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
2 Hyper-acute
ENOS 2014 12/144 7/126 8.0 % 1.55 [ 0.59, 4.05 ]
Subtotal (95% CI) 144 126 8.0 % 1.55 [ 0.59, 4.05 ]
Total events: 12 (Experimental), 7 (Control)
Heterogeneity: not applicable
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.88 (P = 0.38)
3 Acute
CATIS 2013 25/2038 25/2033 23.8 % 1.00 [ 0.57, 1.74 ]
CHHIPS 2009 1/113 3/59 1.4 % 0.17 [ 0.02, 1.64 ]
ENOS 2014 56/1856 52/1882 50.5 % 1.09 [ 0.75, 1.61 ]
Eveson 2007 1/18 1/22 0.9 % 1.24 [ 0.07, 21.24 ]
ICH-ADAPT 2013 7/37 4/36 4.2 % 1.87 [ 0.50, 7.03 ]
Uzuner 1995 6/46 6/42 5.0 % 0.90 [ 0.27, 3.04 ]
Subtotal (95% CI) 4108 4074 85.8 % 1.05 [ 0.78, 1.41 ]
Total events: 96 (Experimental), 91 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.37, df = 5 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
4 Subacute
Bath 2000 2/16 1/21 1.2 % 2.86 [ 0.24, 34.66 ]
Dyker 1997 0/12 0/12 Not estimable
PRoFESS 2009 0/647 1/713 0.7 % 0.37 [ 0.01, 9.02 ]
Rashid 2003 10 mg 0/20 2/10 0.8 % 0.08 [ 0.00, 1.92 ]
Rashid 2003 5 mg 2/20 2/10 1.6 % 0.44 [ 0.05, 3.74 ]
Rashid 2003 5/10 mg 0/20 2/10 0.8 % 0.08 [ 0.00, 1.92 ]
Willmot 2006 0/12 0/6 Not estimable
Subtotal (95% CI) 747 782 5.0 % 0.40 [ 0.11, 1.42 ]
Total events: 4 (Experimental), 8 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 4.33, df = 4 (P = 0.36); I2 =8%
Test for overall effect: Z = 1.42 (P = 0.16)
Total (95% CI) 5026 5002 100.0 % 1.03 [ 0.79, 1.36 ]
Total events: 114 (Experimental), 107 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 10.69, df = 12 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 2.85, df = 3 (P = 0.42), I2 =0.0%
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Analysis 1.8. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 8 Death, end of trial
by intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 8 Death, end of trial by intervention
Study or subgroup Active group Control group Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors (po)
CHHIPS 2009 4/57 6/29 0.8 % 0.29 [ 0.07, 1.12 ]
Dyker 1997 0/14 0/14 Not estimable
Eveson 2007 1/18 1/22 0.2 % 1.24 [ 0.07, 21.24 ]
PIL-FAST 2013 1/4 1/7 0.1 % 2.00 [ 0.09, 44.35 ]
Subtotal (95% CI) 93 72 1.1 % 0.47 [ 0.15, 1.48 ]
Total events: 6 (Active group), 8 (Control group)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.77, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
2 ARA (po)
ACCESS 2003 5/173 12/166 1.2 % 0.38 [ 0.13, 1.11 ]
PRoFESS 2009 5/647 6/713 1.0 % 0.92 [ 0.28, 3.02 ]
SCAST 2011 84/1017 78/1012 13.5 % 1.08 [ 0.78, 1.49 ]
TAST 2013 1/12 1/7 0.2 % 0.55 [ 0.03, 10.37 ]
VENTURE 2013 2/187 0/186 0.1 % 5.03 [ 0.24, 105.42 ]
Subtotal (95% CI) 2036 2084 16.0 % 0.92 [ 0.59, 1.44 ]
Total events: 97 (Active group), 97 (Control group)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.60, df = 4 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.37 (P = 0.71)
3 Beta-blockers
CHHIPS 2009 7/56 6/30 1.0 % 0.57 [ 0.17, 1.89 ]
Subtotal (95% CI) 56 30 1.0 % 0.57 [ 0.17, 1.89 ]
Total events: 7 (Active group), 6 (Control group)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
4 Nitric oxide donor
Bath 2000 3/16 1/21 0.2 % 4.62 [ 0.43, 49.30 ]
ENOS 2014 233/2000 263/2011 39.2 % 0.88 [ 0.73, 1.06 ]
Rashid 2003 10 mg 0/20 1/10 0.1 % 0.15 [ 0.01, 4.15 ]
Rashid 2003 5 mg 2/20 1/10 0.2 % 1.00 [ 0.08, 12.56 ]
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Study or subgroup Active group Control group Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Rashid 2003 5/10 mg 1/20 1/10 0.2 % 0.47 [ 0.03, 8.46 ]
RIGHT 2013 4/25 6/16 0.6 % 0.32 [ 0.07, 1.38 ]
Willmot 2006 0/12 0/6 Not estimable
Subtotal (95% CI) 2113 2084 40.6 % 0.86 [ 0.72, 1.04 ]
Total events: 243 (Active group), 273 (Control group)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.95, df = 5 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
5 Low BP target
CATIS 2013 68/1988 54/1987 10.6 % 1.27 [ 0.88, 1.82 ]
INTERACT pilot 2008 21/203 25/201 3.7 % 0.81 [ 0.44, 1.50 ]
INTERACT-2 2013 166/1399 170/1430 26.8 % 1.00 [ 0.79, 1.25 ]
Koch 2008 3/21 3/21 0.5 % 1.00 [ 0.18, 5.63 ]
Subtotal (95% CI) 3611 3639 41.4 % 1.04 [ 0.87, 1.25 ]
Total events: 258 (Active group), 252 (Control group)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 7909 7909 100.0 % 0.95 [ 0.84, 1.06 ]
Total events: 611 (Active group), 636 (Control group)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.39, df = 18 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.04, df = 4 (P = 0.40), I2 =1%
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Analysis 1.9. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 9 Death, end of trial
by stroke type.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 9 Death, end of trial by stroke type
Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke
ACCESS 2003 5/173 12/166 1.2 % 0.38 [ 0.13, 1.11 ]
CATIS 2013 68/1988 54/1987 10.7 % 1.27 [ 0.88, 1.82 ]
Dyker 1997 0/14 0/14 Not estimable
ENOS 2014 186/1644 212/1678 31.9 % 0.88 [ 0.72, 1.09 ]
Eveson 2007 1/18 1/22 0.2 % 1.24 [ 0.07, 21.24 ]
PRoFESS 2009 5/647 6/713 1.0 % 0.92 [ 0.28, 3.02 ]
RIGHT 2013 2/16 4/11 0.4 % 0.25 [ 0.04, 1.71 ]
SCAST 2011 66/873 67/882 11.2 % 0.99 [ 0.70, 1.42 ]
TAST 2013 1/12 1/7 0.2 % 0.55 [ 0.03, 10.37 ]
VENTURE 2013 2/187 0/186 0.2 % 5.03 [ 0.24, 105.42 ]
Subtotal (95% CI) 5572 5666 56.8 % 0.95 [ 0.78, 1.16 ]
Total events: 336 (Active), 357 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.95, df = 8 (P = 0.35); I2 =11%
Test for overall effect: Z = 0.49 (P = 0.63)
2 Combined ischaemic stroke and intracerebral haemorrhage
Bath 2000 3/16 1/21 0.3 % 4.62 [ 0.43, 49.30 ]
CHHIPS 2009 11/113 12/59 1.8 % 0.42 [ 0.17, 1.03 ]
PIL-FAST 2013 1/4 1/7 0.1 % 2.00 [ 0.09, 44.35 ]
Rashid 2003 10 mg 0/20 1/10 0.1 % 0.15 [ 0.01, 4.15 ]
Rashid 2003 5 mg 2/20 1/10 0.2 % 1.00 [ 0.08, 12.56 ]
Rashid 2003 5/10 mg 1/20 1/10 0.2 % 0.47 [ 0.03, 8.46 ]
Willmot 2006 0/12 0/6 Not estimable
Subtotal (95% CI) 205 123 2.7 % 0.59 [ 0.29, 1.22 ]
Total events: 18 (Active), 17 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.89, df = 5 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
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(. . . Continued)
Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Intracerebral haemorrhage
ENOS 2014 42/310 47/319 7.0 % 0.91 [ 0.58, 1.42 ]
INTERACT pilot 2008 21/203 25/201 3.7 % 0.81 [ 0.44, 1.50 ]
INTERACT-2 2013 166/1399 170/1430 27.0 % 1.00 [ 0.79, 1.25 ]
Koch 2008 3/21 3/21 0.5 % 1.00 [ 0.18, 5.63 ]
RIGHT 2013 2/5 1/1 0.1 % 0.24 [ 0.01, 8.62 ]
SCAST 2011 18/144 11/130 2.2 % 1.55 [ 0.70, 3.41 ]
Subtotal (95% CI) 2082 2102 40.5 % 0.98 [ 0.82, 1.18 ]
Total events: 252 (Active), 257 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.37, df = 5 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Total (95% CI) 7859 7891 100.0 % 0.95 [ 0.84, 1.07 ]
Total events: 606 (Active), 631 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.98, df = 20 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Chi2 = 1.79, df = 2 (P = 0.41), I2 =0.0%
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Analysis 1.10. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 10 Death, end of
trial by time to treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 10 Death, end of trial by time to treatment
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ultra-acute/pre-hospital
RIGHT 2013 4/25 6/16 1.5 % 0.32 [ 0.07, 1.38 ]
PIL-FAST 2013 1/4 1/7 0.3 % 2.00 [ 0.09, 44.35 ]
Subtotal (95% CI) 29 23 1.8 % 0.47 [ 0.11, 2.07 ]
Total events: 5 (Experimental), 7 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 1.11, df = 1 (P = 0.29); I2 =10%
Test for overall effect: Z = 1.00 (P = 0.32)
2 Hyper-acute
INTERACT pilot 2008 21/203 25/201 6.9 % 0.81 [ 0.44, 1.50 ]
INTERACT-2 2013 166/1399 170/1430 20.9 % 1.00 [ 0.79, 1.25 ]
ENOS 2014 11/144 26/129 5.0 % 0.33 [ 0.15, 0.69 ]
Subtotal (95% CI) 1746 1760 32.8 % 0.70 [ 0.38, 1.26 ]
Total events: 198 (Experimental), 221 (Control)
Heterogeneity: Tau2 = 0.20; Chi2 = 7.86, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 1.19 (P = 0.24)
3 Acute
CHHIPS 2009 11/113 12/59 3.7 % 0.42 [ 0.17, 1.03 ]
SCAST 2011 84/1017 78/1012 15.9 % 1.08 [ 0.78, 1.49 ]
VENTURE 2013 2/187 0/186 0.4 % 5.03 [ 0.24, 105.42 ]
Koch 2008 3/21 3/21 1.1 % 1.00 [ 0.18, 5.63 ]
CATIS 2013 68/1988 54/1987 14.0 % 1.27 [ 0.88, 1.82 ]
ENOS 2014 222/1856 237/1882 22.8 % 0.94 [ 0.78, 1.15 ]
Eveson 2007 1/18 1/22 0.4 % 1.24 [ 0.07, 21.24 ]
ACCESS 2003 5/173 12/166 2.7 % 0.38 [ 0.13, 1.11 ]
Subtotal (95% CI) 5373 5335 61.0 % 0.97 [ 0.77, 1.22 ]
Total events: 396 (Experimental), 397 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.01, df = 7 (P = 0.19); I2 =30%
Test for overall effect: Z = 0.27 (P = 0.79)
4 Subacute
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(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Willmot 2006 0/12 0/6 Not estimable
Bath 2000 3/16 1/21 0.6 % 4.62 [ 0.43, 49.30 ]
Dyker 1997 0/14 0/14 Not estimable
PRoFESS 2009 5/647 6/713 2.2 % 0.92 [ 0.28, 3.02 ]
TAST 2013 1/12 1/7 0.4 % 0.55 [ 0.03, 10.37 ]
Rashid 2003 10 mg 0/20 1/10 0.3 % 0.15 [ 0.01, 4.15 ]
Rashid 2003 5 mg 2/20 1/10 0.5 % 1.00 [ 0.08, 12.56 ]
Rashid 2003 5/10 mg 1/20 1/10 0.4 % 0.47 [ 0.03, 8.46 ]
Subtotal (95% CI) 761 791 4.4 % 0.92 [ 0.39, 2.15 ]
Total events: 12 (Experimental), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.24, df = 5 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 7909 7909 100.0 % 0.90 [ 0.75, 1.08 ]
Total events: 611 (Experimental), 636 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 23.98, df = 18 (P = 0.16); I2 =25%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 1.79, df = 3 (P = 0.62), I2 =0.0%
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Analysis 1.11. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 11 Barthel Index,
end of trial, by intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 11 Barthel Index, end of trial, by intervention
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ARA
ACCESS 2003 173 87 (22.9) 166 88.9 (19.9) 38.3 % -1.90 [ -6.46, 2.66 ]
Subtotal (95% CI) 173 166 38.3 % -1.90 [ -6.46, 2.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
2 Nitric oxide donor
ENOS 2014 2000 65.5 (38.1) 2011 63.3 (39.4) 61.7 % 2.20 [ -0.20, 4.60 ]
Subtotal (95% CI) 2000 2011 61.7 % 2.20 [ -0.20, 4.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
Total (95% CI) 2173 2177 100.0 % 0.63 [ -3.28, 4.54 ]
Heterogeneity: Tau2 = 4.95; Chi2 = 2.43, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Chi2 = 2.43, df = 1 (P = 0.12), I2 =59%
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Analysis 1.12. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 12 Barthel Index,
end of trial, by stroke type.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 12 Barthel Index, end of trial, by stroke type
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic stroke
ACCESS 2003 173 87 (27.9) 166 88.9 (19.9) 19.9 % -1.90 [ -7.04, 3.24 ]
ENOS 2014 1664 66.1 (38.1) 1678 63.7 (39.3) 65.6 % 2.40 [ -0.22, 5.02 ]
Subtotal (95% CI) 1837 1844 85.5 % 0.84 [ -3.21, 4.89 ]
Heterogeneity: Tau2 = 4.91; Chi2 = 2.13, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 0.41 (P = 0.68)
2 Intracerebral haemorrhage
ENOS 2014 310 62.3 (38.06) 319 61.4 (39.71) 14.5 % 0.90 [ -5.18, 6.98 ]
Subtotal (95% CI) 310 319 14.5 % 0.90 [ -5.18, 6.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 2147 2163 100.0 % 1.33 [ -1.04, 3.69 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 2.16, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 1.13. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 13 Barthel Index,
end of trial, by time to treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 13 Barthel Index, end of trial, by time to treatment
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ultra-acute
ENOS 2014 144 32 (22.92) 129 50 (38.76) 29.2 % -18.00 [ -25.66, -10.34 ]
Subtotal (95% CI) 144 129 29.2 % -18.00 [ -25.66, -10.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.60 (P < 0.00001)
2 Acute
ACCESS 2003 173 87 (22.9) 166 88.9 (19.9) 34.2 % -1.90 [ -6.46, 2.66 ]
ENOS 2014 1856 64.84 (38.36) 1882 63.52 (39.33) 36.6 % 1.32 [ -1.17, 3.81 ]
Subtotal (95% CI) 2029 2048 70.8 % 0.30 [ -2.64, 3.24 ]
Heterogeneity: Tau2 = 1.67; Chi2 = 1.47, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 2173 2177 100.0 % -5.43 [ -14.19, 3.33 ]
Heterogeneity: Tau2 = 53.00; Chi2 = 22.35, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Chi2 = 19.10, df = 1 (P = 0.00), I2 =95%
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Analysis 1.14. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 14 Early
neurological deterioration, by intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 14 Early neurological deterioration, by intervention
Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ACE inhibitors
CHHIPS 2009 6/57 2/29 0.8 % 1.59 [ 0.30, 8.41 ]
Subtotal (95% CI) 57 29 0.8 % 1.59 [ 0.30, 8.41 ]
Total events: 6 (Active), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Beta-blockers
CHHIPS 2009 1/56 1/30 0.3 % 0.53 [ 0.03, 8.74 ]
Subtotal (95% CI) 56 30 0.3 % 0.53 [ 0.03, 8.74 ]
Total events: 1 (Active), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
3 Nitric oxide donor
ENOS 2014 141/2000 113/2011 35.7 % 1.27 [ 0.99, 1.64 ]
RIGHT 2013 5/25 5/16 1.1 % 0.55 [ 0.13, 2.32 ]
Subtotal (95% CI) 2025 2027 36.8 % 1.14 [ 0.66, 1.98 ]
Total events: 146 (Active), 118 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 1.26, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 0.48 (P = 0.63)
4 Low BP target
ICH-ADAPT 2013 3/37 2/39 0.7 % 1.63 [ 0.26, 10.37 ]
INTERACT pilot 2008 31/203 30/201 7.9 % 1.03 [ 0.60, 1.77 ]
INTERACT-2 2013 198/1399 211/1430 53.1 % 0.95 [ 0.77, 1.17 ]
Koch 2008 2/21 1/21 0.4 % 2.11 [ 0.18, 25.17 ]
Subtotal (95% CI) 1660 1691 62.0 % 0.97 [ 0.80, 1.18 ]
Total events: 234 (Active), 244 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 3798 3777 100.0 % 1.07 [ 0.92, 1.24 ]
Total events: 387 (Active), 365 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.76, df = 7 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 0.80, df = 3 (P = 0.85), I2 =0.0%
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Analysis 1.15. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 15 Early
neurological deterioration, by stroke type.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 15 Early neurological deterioration, by stroke type
Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke
ENOS 2014 109/1644 91/1678 28.5 % 1.24 [ 0.93, 1.65 ]
RIGHT 2013 2/16 5/11 0.7 % 0.17 [ 0.03, 1.14 ]
Subtotal (95% CI) 1660 1689 29.1 % 0.58 [ 0.09, 3.82 ]
Total events: 111 (Active), 96 (Control)
Heterogeneity: Tau2 = 1.48; Chi2 = 4.08, df = 1 (P = 0.04); I2 =75%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Combined ischaemic stroke and intracerebral haemorrhage
CHHIPS 2009 7/113 3/59 1.2 % 1.23 [ 0.31, 4.95 ]
Subtotal (95% CI) 113 59 1.2 % 1.23 [ 0.31, 4.95 ]
Total events: 7 (Active), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
3 Intracerebral haemorrhage
ENOS 2014 30/310 22/319 7.1 % 1.45 [ 0.81, 2.57 ]
ICH-ADAPT 2013 3/37 2/39 0.7 % 1.63 [ 0.26, 10.37 ]
INTERACT pilot 2008 31/203 30/201 7.9 % 1.03 [ 0.60, 1.77 ]
INTERACT-2 2013 198/1399 211/1430 53.4 % 0.95 [ 0.77, 1.17 ]
Koch 2008 2/21 1/21 0.4 % 2.11 [ 0.18, 25.17 ]
RIGHT 2013 2/5 0/1 0.2 % 2.14 [ 0.06, 77.54 ]
Subtotal (95% CI) 1975 2011 69.7 % 1.01 [ 0.84, 1.22 ]
Total events: 266 (Active), 266 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 5 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Total (95% CI) 3748 3759 100.0 % 1.06 [ 0.91, 1.24 ]
Total events: 384 (Active), 365 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.50, df = 8 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 0.41, df = 2 (P = 0.81), I2 =0.0%
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Analysis 1.16. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 16 Early
neurological deterioration, by time to treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 16 Early neurological deterioration, by time to treatment
Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ultra-acute
RIGHT 2013 5/25 5/16 1.9 % 0.55 [ 0.13, 2.32 ]
Subtotal (95% CI) 25 16 1.9 % 0.55 [ 0.13, 2.32 ]
Total events: 5 (Active), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
2 Hyper-acute
INTERACT pilot 2008 31/203 30/201 11.6 % 1.03 [ 0.60, 1.77 ]
INTERACT-2 2013 198/1399 211/1430 44.0 % 0.95 [ 0.77, 1.17 ]
ENOS 2014 11/144 16/129 5.7 % 0.58 [ 0.26, 1.31 ]
Subtotal (95% CI) 1746 1760 61.2 % 0.94 [ 0.77, 1.13 ]
Total events: 240 (Active), 257 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.45, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
3 Acute
Koch 2008 2/21 1/21 0.6 % 2.11 [ 0.18, 25.17 ]
ICH-ADAPT 2013 3/37 2/39 1.1 % 1.63 [ 0.26, 10.37 ]
ENOS 2014 130/1856 97/1882 33.1 % 1.39 [ 1.06, 1.82 ]
CHHIPS 2009 7/113 3/59 2.0 % 1.23 [ 0.31, 4.95 ]
Subtotal (95% CI) 2027 2001 36.9 % 1.39 [ 1.07, 1.81 ]
Total events: 142 (Active), 103 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.013)
Total (95% CI) 3798 3777 100.0 % 1.06 [ 0.87, 1.30 ]
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(. . . Continued)
Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 387 (Active), 365 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.20, df = 7 (P = 0.32); I2 =15%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Chi2 = 6.59, df = 2 (P = 0.04), I2 =70%
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Analysis 1.17. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 17 Quality of life
(EuroQol) at end of trial, by intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 17 Quality of life (EuroQol) at end of trial, by intervention
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Nitric oxide donor
ENOS 2014 2000 0.49 (0.32) 2011 0.48 (0.33) 67.1 % 0.01 [ -0.01, 0.03 ]
RIGHT 2013 25 0.45 (0.33) 16 0.25 (0.26) 0.8 % 0.20 [ 0.02, 0.38 ]
Subtotal (95% CI) 2025 2027 67.9 % 0.01 [ -0.01, 0.03 ]
Heterogeneity: Chi2 = 4.16, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.21 (P = 0.23)
2 Low BP target
INTERACT-2 2013 1399 0.6 (0.39) 1430 0.55 (0.4) 32.1 % 0.05 [ 0.02, 0.08 ]
Subtotal (95% CI) 1399 1430 32.1 % 0.05 [ 0.02, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.37 (P = 0.00076)
Total (95% CI) 3424 3457 100.0 % 0.02 [ 0.01, 0.04 ]
Heterogeneity: Chi2 = 8.53, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 2.90 (P = 0.0037)
Test for subgroup differences: Chi2 = 4.38, df = 1 (P = 0.04), I2 =77%
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Analysis 1.18. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 18 Quality of life
(EuroQoL) at end of trial, by stroke type.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 18 Quality of life (EuroQoL) at end of trial, by stroke type
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic stroke
ENOS 2014 2000 0.5 (0.32) 2011 0.49 (0.33) 37.1 % 0.01 [ -0.01, 0.03 ]
RIGHT 2013 16 0.5 (0.35) 11 0.21 (0.23) 3.3 % 0.29 [ 0.07, 0.51 ]
Subtotal (95% CI) 2016 2022 40.4 % 0.13 [ -0.14, 0.40 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 6.24, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Intracerebral haemorrhage
ENOS 2014 310 0.45 (0.31) 319 0.46 (0.32) 25.8 % -0.01 [ -0.06, 0.04 ]
INTERACT-2 2013 1399 0.6 (0.39) 1430 0.55 (0.4) 33.8 % 0.05 [ 0.02, 0.08 ]
RIGHT 2013 5 0.25 (0.26) 1 0 (0) Not estimable
Subtotal (95% CI) 1714 1750 59.6 % 0.02 [ -0.03, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.23, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 3730 3772 100.0 % 0.03 [ -0.01, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 12.29, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.55, df = 1 (P = 0.46), I2 =0.0%
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Analysis 1.19. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 19 Quality of life
(EuroQoL) at end of trial, by time to treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 19 Quality of life (EuroQoL) at end of trial, by time to treatment
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ultra-acute
RIGHT 2013 16 0.5 (0.35) 11 0.21 (0.23) 5.3 % 0.29 [ 0.07, 0.51 ]
Subtotal (95% CI) 16 11 5.3 % 0.29 [ 0.07, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0094)
2 Hyperacute
ENOS 2014 144 0.55 (0.32) 129 0.46 (0.32) 22.1 % 0.09 [ 0.01, 0.17 ]
INTERACT-2 2013 1399 0.6 (0.39) 1430 0.55 (0.4) 35.4 % 0.05 [ 0.02, 0.08 ]
Subtotal (95% CI) 1543 1559 57.5 % 0.06 [ 0.03, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 3.97 (P = 0.000071)
3 Acute
ENOS 2014 1856 0.48 (0.32) 1882 0.48 (0.33) 37.2 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 1856 1882 37.2 % 0.0 [ -0.02, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 3415 3452 100.0 % 0.05 [ 0.00, 0.11 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 16.67, df = 3 (P = 0.00083); I2 =82%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Chi2 = 15.74, df = 2 (P = 0.00), I2 =87%
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Analysis 1.20. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 20 Length of stay,
by intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 20 Length of stay, by intervention
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ACE inhibitors
CHHIPS 2009 57 11.23 (4.46) 29 11.36 (4.42) 2.2 % -0.13 [ -2.11, 1.85 ]
Subtotal (95% CI) 57 29 2.2 % -0.13 [ -2.11, 1.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
2 Beta-blockers
CHHIPS 2009 56 11.57 (4.46) 30 11.36 (4.42) 2.2 % 0.21 [ -1.76, 2.18 ]
Subtotal (95% CI) 56 30 2.2 % 0.21 [ -1.76, 2.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
3 Nitric oxide donor
ENOS 2014 2000 20.71 (23.4) 2011 21.05 (23.78) 4.0 % -0.34 [ -1.80, 1.12 ]
RIGHT 2013 25 20.64 (27.8) 16 17.81 (20.57) 0.0 % 2.83 [ -12.01, 17.67 ]
Subtotal (95% CI) 2025 2027 4.1 % -0.31 [ -1.76, 1.14 ]
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
4 Low BP target
CATIS 2013 2038 13 (5) 2033 13 (5) 91.5 % 0.0 [ -0.31, 0.31 ]
Subtotal (95% CI) 2038 2033 91.5 % 0.0 [ -0.31, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 4176 4119 100.0 % -0.01 [ -0.30, 0.28 ]
Heterogeneity: Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Chi2 = 0.23, df = 3 (P = 0.97), I2 =0.0%
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Analysis 1.21. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 21 Length of stay,
by stroke type.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 21 Length of stay, by stroke type
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic stroke
CATIS 2013 2038 13 (5) 2033 13 (5) 91.6 % 0.0 [ -0.31, 0.31 ]
ENOS 2014 1644 20.2 (22.7) 1678 20.9 (23.7) 3.5 % -0.70 [ -2.28, 0.88 ]
Subtotal (95% CI) 3682 3711 95.0 % -0.03 [ -0.33, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
2 Combined ischaemic and Intracerebral haemorrhage
CHHIPS 2009 113 11.6 (4.5) 59 11.4 (4.4) 4.4 % 0.20 [ -1.20, 1.60 ]
Subtotal (95% CI) 113 59 4.4 % 0.20 [ -1.20, 1.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
3 Intracerebral haemorrhage
ENOS 2014 310 24.6 (27.1) 319 22 (25.1) 0.5 % 2.60 [ -1.49, 6.69 ]
Subtotal (95% CI) 310 319 0.5 % 2.60 [ -1.49, 6.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Total (95% CI) 4105 4089 100.0 % 0.00 [ -0.30, 0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.39, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 1.66, df = 2 (P = 0.44), I2 =0.0%
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Analysis 1.22. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 22 Length of stay,
by time to treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 22 Length of stay, by time to treatment
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ultra-acute
RIGHT 2013 25 20.64 (27.8) 16 17.81 (20.6) 0.0 % 2.83 [ -12.02, 17.68 ]
ENOS 2014 144 15.5 (20.4) 129 17.9 (21.3) 0.4 % -2.40 [ -7.36, 2.56 ]
Subtotal (95% CI) 169 145 0.4 % -1.88 [ -6.58, 2.83 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
2 Acute
CHHIPS 2009 113 11.6 (4.5) 59 11.4 (4.4) 4.4 % 0.20 [ -1.20, 1.60 ]
ENOS 2014 1856 21.1 (23.6) 1882 21.3 (23.9) 3.7 % -0.20 [ -1.72, 1.32 ]
CATIS 2013 2038 13 (5) 2033 13 (5) 91.5 % 0.0 [ -0.31, 0.31 ]
Subtotal (95% CI) 4007 3974 99.6 % 0.00 [ -0.29, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 4176 4119 100.0 % -0.01 [ -0.30, 0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.18, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 0.61, df = 1 (P = 0.44), I2 =0.0%
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Analysis 1.23. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 23 SBP, first after
randomisation, by intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 23 SBP, first after randomisation, by intervention
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors(po)
CHHIPS 2009 29 161.2 (18) 16 172.6 (13) 3.8 % -11.40 [ -20.54, -2.26 ]
Dyker 1997 12 150 (21) 12 173 (23) 1.4 % -23.00 [ -40.62, -5.38 ]
Eveson 2007 17 153.8 (20.2) 18 169.1 (14.5) 2.7 % -15.30 [ -27.01, -3.59 ]
Lisk 1993 3 168.3 (23.6) 2 159.17 (18.5) 0.4 % 9.13 [ -27.89, 46.15 ]
PIL-FAST 2013 6 171 (30) 8 186 (13) 0.7 % -15.00 [ -40.64, 10.64 ]
Subtotal (95% CI) 67 56 9.0 % -13.68 [ -20.03, -7.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.86, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 4.22 (P = 0.000025)
2 ACE inhibitors (s/l)
CHHIPS 2009 28 161.1 (18) 14 167.1 (18) 2.8 % -6.00 [ -17.55, 5.55 ]
Subtotal (95% CI) 28 14 2.8 % -6.00 [ -17.55, 5.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
3 ARA (po)
PRoFESS 2009 647 135.3 (17.8) 713 141.4 (17) 9.1 % -6.10 [ -7.95, -4.25 ]
SCAST 2011 1017 157.1 (19) 1012 159.8 (19.2) 9.2 % -2.70 [ -4.36, -1.04 ]
TAST 2013 12 164.5 (12.5) 7 173.9 (16.7) 2.0 % -9.40 [ -23.65, 4.85 ]
Subtotal (95% CI) 1676 1732 20.4 % -4.59 [ -7.71, -1.48 ]
Heterogeneity: Tau2 = 4.47; Chi2 = 7.67, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 2.89 (P = 0.0038)
4 A2AA(po)
Lisk 1993 2 145.5 (7.77) 2 159.17 (18.5) 0.6 % -13.67 [ -41.48, 14.14 ]
Subtotal (95% CI) 2 2 0.6 % -13.67 [ -41.48, 14.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
5 Beta-blockers (po)
CHHIPS 2009 29 161.1 (16) 15 172.6 (13) 4.0 % -11.50 [ -20.29, -2.71 ]
Subtotal (95% CI) 29 15 4.0 % -11.50 [ -20.29, -2.71 ]
Heterogeneity: not applicable
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Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 2.57 (P = 0.010)
6 Beta-blockers (iv)
CHHIPS 2009 27 153.1 (15) 14 169.5 (18) 3.0 % -16.40 [ -27.40, -5.40 ]
Subtotal (95% CI) 27 14 3.0 % -16.40 [ -27.40, -5.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.92 (P = 0.0035)
7 Calcium channel blockers (po)
Fagan 1988 120 mg 10 139 (22) 5 141 (24) 0.8 % -2.00 [ -27.07, 23.07 ]
Fagan 1988 240 mg 10 133 (17) 4 141 (24) 0.7 % -8.00 [ -33.77, 17.77 ]
Uzuner 1995 38 136.2 (21.2) 39 144.9 (29) 2.8 % -8.70 [ -20.03, 2.63 ]
Subtotal (95% CI) 58 48 4.3 % -7.62 [ -17.21, 1.96 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
8 Calcium channel blockers (iv)
Uzuner 1995 8 146.9 (19) 3 156.66 (5.7) 1.9 % -9.76 [ -24.42, 4.90 ]
Subtotal (95% CI) 8 3 1.9 % -9.76 [ -24.42, 4.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
9 Nitric oxide donor
Bath 2000 13 159.23 (29.37) 19 152.63 (22.1) 1.3 % 6.60 [ -12.21, 25.41 ]
ENOS 2014 2000 156.6 (22.6) 2011 163.7 (22.5) 9.4 % -7.10 [ -8.50, -5.70 ]
Rashid 2003 10 mg 20 139.2 (15.7) 10 151.7 (22.7) 1.7 % -12.50 [ -28.16, 3.16 ]
Rashid 2003 5 mg 20 141.1 (18.4) 10 151.1 (22.7) 1.6 % -10.00 [ -26.22, 6.22 ]
Rashid 2003 5/10 mg 20 142.5 (20.3) 10 151.1 (22.7) 1.6 % -8.60 [ -25.25, 8.05 ]
RIGHT 2013 25 157.5 (26.8) 16 177.2 (27.1) 1.5 % -19.70 [ -36.63, -2.77 ]
Willmot 2006 12 159.5 (22.94) 6 185.17 (18.82) 1.2 % -25.67 [ -45.55, -5.79 ]
Subtotal (95% CI) 2110 2082 18.2 % -9.25 [ -14.54, -3.96 ]
Heterogeneity: Tau2 = 13.55; Chi2 = 8.07, df = 6 (P = 0.23); I2 =26%
Test for overall effect: Z = 3.43 (P = 0.00061)
10 Thiazide-like diuretic (po)
Eames 2005 18 156 (26) 22 176 (34) 1.3 % -20.00 [ -38.60, -1.40 ]
Subtotal (95% CI) 18 22 1.3 % -20.00 [ -38.60, -1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
11 Low BP target
CATIS 2013 2038 144.7 (15) 2033 152.9 (15.9) 9.5 % -8.20 [ -9.15, -7.25 ]
ICH-ADAPT 2013 39 159.4 (20) 36 167.9 (25) 3.2 % -8.50 [ -18.80, 1.80 ]
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Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
INTERACT pilot 2008 203 153 (18) 201 167 (19) 7.8 % -14.00 [ -17.61, -10.39 ]
INTERACT-2 2013 1399 150 (17) 1430 164 (17) 9.4 % -14.00 [ -15.25, -12.75 ]
Koch 2008 21 113.8 (13) 21 124.1 (12.8) 4.5 % -10.30 [ -18.10, -2.50 ]
Subtotal (95% CI) 3700 3721 34.5 % -11.39 [ -15.30, -7.49 ]
Heterogeneity: Tau2 = 14.16; Chi2 = 56.26, df = 4 (P<0.00001); I2 =93%
Test for overall effect: Z = 5.72 (P < 0.00001)
Total (95% CI) 7723 7709 100.0 % -9.83 [ -12.11, -7.56 ]
Heterogeneity: Tau2 = 13.87; Chi2 = 157.60, df = 28 (P<0.00001); I2 =82%
Test for overall effect: Z = 8.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.00, df = 10 (P = 0.13), I2 =33%
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Analysis 1.24. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 24 SBP, first after
randomisation by stroke type.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 24 SBP, first after randomisation by stroke type
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic stroke
ACCESS 2003 173 165.8 (20.9) 166 168.4 (19.7) 7.0 % -2.60 [ -6.92, 1.72 ]
CATIS 2013 2038 144.7 (15) 2033 152.9 (15.9) 9.3 % -8.20 [ -9.15, -7.25 ]
Dyker 1997 12 150 (21) 12 173 (23) 1.4 % -23.00 [ -40.62, -5.38 ]
Eames 2005 18 156 (26) 19 176 (34) 1.2 % -20.00 [ -39.44, -0.56 ]
ENOS 2014 1664 155.8 (22) 1678 162.4 (22.1) 9.1 % -6.60 [ -8.10, -5.10 ]
Eveson 2007 17 153.8 (20.2) 18 169.1 (14.5) 2.7 % -15.30 [ -27.01, -3.59 ]
Fagan 1988 120 mg 10 139 (22) 5 141 (24) 0.8 % -2.00 [ -27.07, 23.07 ]
Fagan 1988 240 mg 10 133 (17) 4 141 (24) 0.7 % -8.00 [ -33.77, 17.77 ]
PRoFESS 2009 647 135.3 (17.8) 713 141.4 (17) 8.9 % -6.10 [ -7.95, -4.25 ]
TAST 2013 12 164.5 (12.5) 7 173.9 (16.7) 2.0 % -9.40 [ -23.65, 4.85 ]
Subtotal (95% CI) 4601 4655 43.0 % -6.99 [ -8.61, -5.38 ]
Heterogeneity: Tau2 = 1.86; Chi2 = 17.08, df = 9 (P = 0.05); I2 =47%
Test for overall effect: Z = 8.51 (P < 0.00001)
2 Combined ischaemic stroke and intracerebral haemorrhage
Bath 2000 13 159.23 (29.37) 19 152.63 (22.1) 1.3 % 6.60 [ -12.21, 25.41 ]
CHHIPS 2009 113 161.5 (14) 59 171.9 (11) 7.4 % -10.40 [ -14.21, -6.59 ]
PIL-FAST 2013 6 171 (30) 8 186 (13) 0.7 % -15.00 [ -40.64, 10.64 ]
Rashid 2003 10 mg 20 139.2 (15.7) 10 151.1 (22.7) 1.7 % -11.90 [ -27.56, 3.76 ]
Rashid 2003 5 mg 20 141.1 (18.4) 10 151.1 (22.7) 1.6 % -10.00 [ -26.22, 6.22 ]
Rashid 2003 5/10 mg 20 142.5 (20.3) 10 151.1 (22.7) 1.6 % -8.60 [ -25.25, 8.05 ]
RIGHT 2013 25 157.5 (26.8) 16 177.2 (27.1) 1.5 % -19.70 [ -36.63, -2.77 ]
SCAST 2011 1017 157.1 (19) 1012 159.8 (19.2) 9.0 % -2.70 [ -4.36, -1.04 ]
Uzuner 1995 38 136.2 (21.2) 39 144.9 (29) 2.8 % -8.70 [ -20.03, 2.63 ]
Uzuner 1995 8 146.9 (19) 3 156.66 (5.7) 1.9 % -9.76 [ -24.42, 4.90 ]
Subtotal (95% CI) 1280 1186 29.5 % -7.89 [ -12.43, -3.36 ]
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Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 18.94; Chi2 = 21.27, df = 9 (P = 0.01); I2 =58%
Test for overall effect: Z = 3.41 (P = 0.00065)
3 Intracerebral haemorrhage
ENOS 2014 310 162.7 (24.6) 319 170.2 (23.3) 7.5 % -7.50 [ -11.25, -3.75 ]
ICH-ADAPT 2013 39 159.4 (20) 36 167.9 (25) 3.2 % -8.50 [ -18.80, 1.80 ]
INTERACT pilot 2008 203 153 (18) 201 167 (19) 7.6 % -14.00 [ -17.61, -10.39 ]
INTERACT-2 2013 1399 150 (17) 1430 164 (17) 9.2 % -14.00 [ -15.25, -12.75 ]
Subtotal (95% CI) 1951 1986 27.5 % -11.77 [ -15.25, -8.30 ]
Heterogeneity: Tau2 = 8.08; Chi2 = 11.38, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 6.64 (P < 0.00001)
Total (95% CI) 7832 7827 100.0 % -8.77 [ -11.04, -6.50 ]
Heterogeneity: Tau2 = 14.24; Chi2 = 161.25, df = 23 (P<0.00001); I2 =86%
Test for overall effect: Z = 7.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.98, df = 2 (P = 0.05), I2 =67%
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Analysis 1.25. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 25 SBP, first after
randomisation by time to treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 25 SBP, first after randomisation by time to treatment
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ultra-acute/prehospital
PIL-FAST 2013 6 171 (30) 8 177 (20) 0.7 % -6.00 [ -33.72, 21.72 ]
RIGHT 2013 25 157.5 (26.8) 16 177.2 (27.1) 1.8 % -19.70 [ -36.63, -2.77 ]
Subtotal (95% CI) 31 24 2.5 % -15.98 [ -30.43, -1.53 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
2 Hyper-acute
INTERACT pilot 2008 203 153 (18) 201 167 (19) 9.0 % -14.00 [ -17.61, -10.39 ]
INTERACT-2 2013 1399 150 (17) 1430 164 (17) 10.9 % -14.00 [ -15.25, -12.75 ]
ENOS 2014 144 154.4 (22.3) 129 163.8 (20.4) 7.6 % -9.40 [ -14.47, -4.33 ]
Subtotal (95% CI) 1746 1760 27.5 % -13.38 [ -15.41, -11.35 ]
Heterogeneity: Tau2 = 1.28; Chi2 = 3.00, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 12.91 (P < 0.00001)
3 Acute
SCAST 2011 1017 157.1 (19) 1012 159.8 (19.2) 10.6 % -2.70 [ -4.36, -1.04 ]
CATIS 2013 2038 144.7 (15) 2033 152.9 (15.9) 11.0 % -8.20 [ -9.15, -7.25 ]
ICH-ADAPT 2013 39 159.4 (20) 36 167.9 (25) 3.8 % -8.50 [ -18.80, 1.80 ]
CHHIPS 2009 113 161.5 (14) 59 171.9 (11) 8.8 % -10.40 [ -14.21, -6.59 ]
Eveson 2007 17 153.8 (20.2) 18 169.1 (14.5) 3.2 % -15.30 [ -27.01, -3.59 ]
ENOS 2014 1856 156.8 (22.6) 1882 163.6 (22.6) 10.8 % -6.80 [ -8.25, -5.35 ]
Subtotal (95% CI) 5080 5040 48.2 % -7.23 [ -9.83, -4.63 ]
Heterogeneity: Tau2 = 6.66; Chi2 = 36.98, df = 5 (P<0.00001); I2 =86%
Test for overall effect: Z = 5.44 (P < 0.00001)
4 Subacute
Eames 2005 18 156 (26) 19 176 (34) 1.4 % -20.00 [ -39.44, -0.56 ]
Dyker 1997 12 150 (21) 12 173 (23) 1.7 % -23.00 [ -40.62, -5.38 ]
PRoFESS 2009 647 135.3 (17.8) 713 141.4 (17) 10.5 % -6.10 [ -7.95, -4.25 ]
Rashid 2003 5 mg 20 141.1 (18.4) 10 151.1 (22.7) 1.9 % -10.00 [ -26.22, 6.22 ]
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Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rashid 2003 5/10 mg 20 142.5 (20.3) 10 151.1 (22.7) 1.8 % -8.60 [ -25.25, 8.05 ]
Rashid 2003 10 mg 20 139.2 (15.7) 10 151.1 (22.7) 2.0 % -11.90 [ -27.56, 3.76 ]
TAST 2013 12 164.5 (12.5) 7 173.9 (16.7) 2.4 % -9.40 [ -23.65, 4.85 ]
Subtotal (95% CI) 749 781 21.8 % -7.26 [ -10.02, -4.50 ]
Heterogeneity: Tau2 = 1.49; Chi2 = 6.24, df = 6 (P = 0.40); I2 =4%
Test for overall effect: Z = 5.15 (P < 0.00001)
Total (95% CI) 7606 7605 100.0 % -9.67 [ -12.14, -7.20 ]
Heterogeneity: Tau2 = 14.24; Chi2 = 149.93, df = 17 (P<0.00001); I2 =89%
Test for overall effect: Z = 7.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 19.39, df = 3 (P = 0.00), I2 =85%
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Analysis 1.26. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 26 SBP, at day 1.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 26 SBP, at day 1
Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors (po)
Lisk 1993 3 166.6 (20.8) 2 174.3 (24.5) 0.4 % -7.70 [ -49.01, 33.61 ]
PIL-FAST 2013 5 143 (47) 7 159 (35) 0.3 % -16.00 [ -64.68, 32.68 ]
CHHIPS 2009 29 155 (21.2) 16 167 (21.9) 3.0 % -12.00 [ -25.22, 1.22 ]
Dyker 1997 12 158.25 (20.85) 11 175.78 (23.32) 1.8 % -17.53 [ -35.67, 0.61 ]
Eveson 2007 17 164.9 (25.8) 18 160.2 (18.2) 2.5 % 4.70 [ -10.17, 19.57 ]
Subtotal (95% CI) 66 54 7.9 % -7.90 [ -16.83, 1.03 ]
Heterogeneity: Tau2 = 8.34; Chi2 = 4.32, df = 4 (P = 0.36); I2 =7%
Test for overall effect: Z = 1.73 (P = 0.083)
2 ACE inhibitors (s/l)
CHHIPS 2009 28 161 (21.2) 14 173 (21.2) 2.9 % -12.00 [ -25.60, 1.60 ]
Subtotal (95% CI) 28 14 2.9 % -12.00 [ -25.60, 1.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
3 ARA (po)
SCAST 2011 1017 167.8 (19) 1012 167.8 (19.2) 11.2 % 0.0 [ -1.66, 1.66 ]
ACCESS 2003 173 165.8 (20.9) 166 168.4 (19.7) 8.9 % -2.60 [ -6.92, 1.72 ]
Subtotal (95% CI) 1190 1178 20.1 % -0.50 [ -2.52, 1.51 ]
Heterogeneity: Tau2 = 0.59; Chi2 = 1.21, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 0.49 (P = 0.62)
4 A2AA (po)
Lisk 1993 2 152.5 (20.5) 2 174.33 (24.52) 0.3 % -21.83 [ -66.12, 22.46 ]
Subtotal (95% CI) 2 2 0.3 % -21.83 [ -66.12, 22.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
5 Beta-blockers(po)
CHHIPS 2009 29 159 (21.5) 15 173 (21.2) 3.0 % -14.00 [ -27.28, -0.72 ]
Subtotal (95% CI) 29 15 3.0 % -14.00 [ -27.28, -0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
6 Beta-blockers (iv)
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(. . . Continued)
Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CHHIPS 2009 29 168 (20.8) 14 173 (21.2) 2.9 % -5.00 [ -18.44, 8.44 ]
Subtotal (95% CI) 29 14 2.9 % -5.00 [ -18.44, 8.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
7 Calcium channel blockers (po)
Lisk 1993 5 140.2 (13.64) 2 174.3 (24.5) 0.5 % -34.10 [ -70.10, 1.90 ]
Uzuner 1995 38 136.3 (22.2) 39 138.2 (25.7) 4.0 % -1.90 [ -12.62, 8.82 ]
Subtotal (95% CI) 43 41 4.5 % -13.23 [ -43.36, 16.91 ]
Heterogeneity: Tau2 = 334.80; Chi2 = 2.82, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.86 (P = 0.39)
8 Calcium channel blockers (iv)
Uzuner 1995 8 138.1 (19.3) 3 170 (26.5) 0.6 % -31.90 [ -64.73, 0.93 ]
Subtotal (95% CI) 8 3 0.6 % -31.90 [ -64.73, 0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
9 Nitric oxide donor
ENOS 2014 2000 156.6 (22.6) 2011 163.6 (22.5) 11.3 % -7.00 [ -8.40, -5.60 ]
RIGHT 2013 16 147.1 (10.8) 11 176.1 (22.5) 2.6 % -29.00 [ -43.31, -14.69 ]
Bath 2000 16 153.8 (23.3) 21 156.2 (20.9) 2.6 % -2.40 [ -16.90, 12.10 ]
Rashid 2003 10 mg 20 139.2 (15.7) 10 151.1 (22.7) 2.3 % -11.90 [ -27.56, 3.76 ]
Rashid 2003 5 mg 20 141.1 (18.4) 10 151.1 (22.7) 2.2 % -10.00 [ -26.22, 6.22 ]
Rashid 2003 5/10 mg 20 142.5 (20.3) 10 151.1 (22.7) 2.1 % -8.60 [ -25.25, 8.05 ]
Willmot 2006 12 159 (22.92) 6 185 (18.82) 1.5 % -26.00 [ -45.87, -6.13 ]
Subtotal (95% CI) 2104 2079 24.6 % -12.10 [ -19.06, -5.14 ]
Heterogeneity: Tau2 = 41.29; Chi2 = 13.31, df = 6 (P = 0.04); I2 =55%
Test for overall effect: Z = 3.41 (P = 0.00065)
10 Low BP target
INTERACT pilot 2008 203 146 (14.6) 201 157 (16.4) 10.2 % -11.00 [ -14.03, -7.97 ]
CATIS 2013 2038 144.7 (15) 2033 152.9 (15.9) 11.5 % -8.20 [ -9.15, -7.25 ]
INTERACT-2 2013 1399 140.9 (17) 1430 152.2 (17) 11.4 % -11.30 [ -12.55, -10.05 ]
Subtotal (95% CI) 3640 3664 33.1 % -10.04 [ -12.47, -7.61 ]
Heterogeneity: Tau2 = 3.78; Chi2 = 16.03, df = 2 (P = 0.00033); I2 =88%
Test for overall effect: Z = 8.09 (P < 0.00001)
Total (95% CI) 7139 7064 100.0 % -8.33 [ -10.97, -5.69 ]
Heterogeneity: Tau2 = 15.53; Chi2 = 150.12, df = 23 (P<0.00001); I2 =85%
Test for overall effect: Z = 6.18 (P < 0.00001)
Test for subgroup differences: Chi2 = 46.24, df = 9 (P = 0.00), I2 =81%
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Analysis 1.27. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 27 SBP, at day 7.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 27 SBP, at day 7
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors
PIL-FAST 2013 4 129 (7) 7 155 (21) 2.1 % -26.00 [ -43.00, -9.00 ]
Subtotal (95% CI) 4 7 2.1 % -26.00 [ -43.00, -9.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
2 ARA(po)
ACCESS 2003 173 148.3 (20.9) 166 153.7 (19.7) 10.4 % -5.40 [ -9.72, -1.08 ]
PRoFESS 2009 647 135.3 (17.8) 713 141.4 (17) 13.5 % -6.10 [ -7.95, -4.25 ]
SCAST 2011 1017 147 (23) 1012 152 (22) 13.4 % -5.00 [ -6.96, -3.04 ]
TAST 2013 12 145.3 (12.5) 7 164.5 (16.7) 2.8 % -19.20 [ -33.45, -4.95 ]
Subtotal (95% CI) 1849 1898 40.1 % -5.74 [ -7.44, -4.03 ]
Heterogeneity: Tau2 = 0.83; Chi2 = 4.13, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 6.59 (P < 0.00001)
3 Thiazide-like diuretic (po)
Eames 2005 18 158 (24) 19 173 (35) 1.7 % -15.00 [ -34.25, 4.25 ]
Subtotal (95% CI) 18 19 1.7 % -15.00 [ -34.25, 4.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
4 Nitric oxide donor
ENOS 2014 2000 150.2 (24.1) 2011 151.3 (23.7) 13.8 % -1.10 [ -2.58, 0.38 ]
RIGHT 2013 25 141.6 (25.3) 16 148.4 (21.9) 2.7 % -6.80 [ -21.41, 7.81 ]
Subtotal (95% CI) 2025 2027 16.5 % -1.16 [ -2.63, 0.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
5 Low BP target
CATIS 2013 2038 137.3 (11.8) 2033 146.5 (13.6) 14.3 % -9.20 [ -9.98, -8.42 ]
INTERACT pilot 2008 203 133.2 (18) 201 143.3 (19) 11.4 % -10.10 [ -13.71, -6.49 ]
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Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
INTERACT-2 2013 1399 137.5 (17) 1430 141.53 (17) 14.0 % -4.03 [ -5.28, -2.78 ]
Subtotal (95% CI) 3640 3664 39.7 % -7.62 [ -11.69, -3.56 ]
Heterogeneity: Tau2 = 11.73; Chi2 = 48.63, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 3.68 (P = 0.00024)
Total (95% CI) 7536 7615 100.0 % -6.74 [ -9.39, -4.10 ]
Heterogeneity: Tau2 = 12.61; Chi2 = 127.17, df = 10 (P<0.00001); I2 =92%
Test for overall effect: Z = 4.99 (P < 0.00001)
Test for subgroup differences: Chi2 = 28.38, df = 4 (P = 0.00), I2 =86%
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Analysis 1.28. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 28 SBP, at end of
treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 28 SBP, at end of treatment
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors (po)
CHHIPS 2009 29 145 (16) 16 155 (17) 2.7 % -10.00 [ -20.16, 0.16 ]
Dyker 1997 14 152.4 (17) 14 170.5 (21) 1.7 % -18.10 [ -32.25, -3.95 ]
Eveson 2007 18 136 (13) 21 156 (14) 3.4 % -20.00 [ -28.48, -11.52 ]
PIL-FAST 2013 4 129 (7) 7 155 (21) 1.2 % -26.00 [ -43.00, -9.00 ]
Subtotal (95% CI) 65 58 9.1 % -17.37 [ -23.42, -11.31 ]
Heterogeneity: Tau2 = 4.62; Chi2 = 3.39, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 5.62 (P < 0.00001)
2 ACE inhibitors (s/l)
CHHIPS 2009 28 157.1 (16) 14 158.6 (17) 2.5 % -1.50 [ -12.20, 9.20 ]
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Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 28 14 2.5 % -1.50 [ -12.20, 9.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
3 ARA (po)
ACCESS 2003 173 150.5 (20.9) 166 157 (19.7) 6.0 % -6.50 [ -10.82, -2.18 ]
ACCOST 2006 19 142.6 (3.5) 19 154.1 (5.3) 7.1 % -11.50 [ -14.36, -8.64 ]
PRoFESS 2009 647 134.5 (19.9) 713 140.3 (19) 7.6 % -5.80 [ -7.87, -3.73 ]
SCAST 2011 1017 147 (23) 1012 152 (22) 7.7 % -5.00 [ -6.96, -3.04 ]
TAST 2013 12 142.9 (12.5) 7 157.5 (16.7) 1.7 % -14.60 [ -28.85, -0.35 ]
Subtotal (95% CI) 1868 1917 30.0 % -7.37 [ -10.19, -4.56 ]
Heterogeneity: Tau2 = 6.50; Chi2 = 15.65, df = 4 (P = 0.004); I2 =74%
Test for overall effect: Z = 5.14 (P < 0.00001)
4 A2AA (po)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Beta-blockers (po)
CHHIPS 2009 29 153.3 (16) 15 156.5 (16) 2.8 % -3.20 [ -13.17, 6.77 ]
Subtotal (95% CI) 29 15 2.8 % -3.20 [ -13.17, 6.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
6 Beta-blockers (iv)
CHHIPS 2009 29 145 (16) 14 160 (16) 2.7 % -15.00 [ -25.21, -4.79 ]
Subtotal (95% CI) 29 14 2.7 % -15.00 [ -25.21, -4.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0040)
7 Calcium channel blockers (po)
Uzuner 1995 38 128.2 (16.7) 39 136 (24.4) 3.1 % -7.80 [ -17.12, 1.52 ]
Subtotal (95% CI) 38 39 3.1 % -7.80 [ -17.12, 1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
8 Calcium channel blockers (iv)
Uzuner 1995 8 147.5 (21.9) 3 156.7 (5.8) 1.3 % -9.20 [ -25.73, 7.33 ]
Subtotal (95% CI) 8 3 1.3 % -9.20 [ -25.73, 7.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
9 Nitric oxide donor
ENOS 2014 2000 150.2 (24.1) 2011 151.3 (23.7) 7.9 % -1.10 [ -2.58, 0.38 ]
Rashid 2003 10 mg 20 101.5 (13.6) 10 100.1 (15.7) 2.3 % 1.40 [ -10.01, 12.81 ]
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Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rashid 2003 5 mg 20 101.7 (12.4) 10 100.1 (15.7) 2.4 % 1.60 [ -9.55, 12.75 ]
Rashid 2003 5/10 mg 20 96.8 (10.1) 10 100.1 (15.7) 2.5 % -3.30 [ -13.99, 7.39 ]
Subtotal (95% CI) 2060 2041 15.2 % -1.05 [ -2.50, 0.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
10 Thiazide-like diuretic (po)
Eames 2005 18 167 (26) 19 164 (19) 1.6 % 3.00 [ -11.74, 17.74 ]
Subtotal (95% CI) 18 19 1.6 % 3.00 [ -11.74, 17.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
11 Low BP target
CATIS 2013 2038 135.2 (10.4) 2033 143.7 (14) 8.1 % -8.50 [ -9.26, -7.74 ]
ICH-ADAPT 2013 39 140 (19) 36 162 (12) 4.1 % -22.00 [ -29.14, -14.86 ]
INTERACT pilot 2008 203 133.2 (18) 201 143.3 (19) 6.6 % -10.10 [ -13.71, -6.49 ]
INTERACT-2 2013 1399 137.5 (17) 1430 141.53 (17) 8.0 % -4.03 [ -5.28, -2.78 ]
Koch 2008 21 101.1 (11.5) 21 113.9 (6.8) 5.0 % -12.80 [ -18.51, -7.09 ]
Subtotal (95% CI) 3700 3721 31.8 % -10.06 [ -13.58, -6.55 ]
Heterogeneity: Tau2 = 12.27; Chi2 = 57.26, df = 4 (P<0.00001); I2 =93%
Test for overall effect: Z = 5.61 (P < 0.00001)
Total (95% CI) 7843 7841 100.0 % -8.02 [ -10.07, -5.97 ]
Heterogeneity: Tau2 = 13.33; Chi2 = 162.68, df = 23 (P<0.00001); I2 =86%
Test for overall effect: Z = 7.66 (P < 0.00001)
Test for subgroup differences: Chi2 = 58.27, df = 9 (P = 0.00), I2 =85%
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Analysis 1.29. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 29 DBP, first after
randomisation by intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 29 DBP, first after randomisation by intervention
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors(po)
CHHIPS 2009 29 86.8 (12) 16 92.2 (11) 2.6 % -5.40 [ -12.34, 1.54 ]
Dyker 1997 12 79 (14) 12 91 (13) 1.2 % -12.00 [ -22.81, -1.19 ]
Eveson 2007 17 92.6 (16.5) 18 88.7 (13.4) 1.4 % 3.90 [ -6.09, 13.89 ]
Lisk 1993 3 93 (10.8) 2 94.16 (9.17) 0.5 % -1.16 [ -18.79, 16.47 ]
PIL-FAST 2013 6 91 (23) 8 97 (16) 0.3 % -6.00 [ -27.49, 15.49 ]
Subtotal (95% CI) 67 56 6.0 % -4.23 [ -9.68, 1.21 ]
Heterogeneity: Tau2 = 6.57; Chi2 = 4.78, df = 4 (P = 0.31); I2 =16%
Test for overall effect: Z = 1.52 (P = 0.13)
2 ACE inhibitors (s/l)
CHHIPS 2009 28 94.9 (12) 14 92.7 (12) 2.2 % 2.20 [ -5.50, 9.90 ]
Subtotal (95% CI) 28 14 2.2 % 2.20 [ -5.50, 9.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
3 ARA (po)
PRoFESS 2009 647 78.4 (10.8) 713 81.6 (11) 15.8 % -3.20 [ -4.36, -2.04 ]
SCAST 2011 1017 85.2 (13.9) 1012 86.6 (14.2) 15.5 % -1.40 [ -2.62, -0.18 ]
TAST 2013 12 81.1 (16.8) 7 92.2 (12.4) 0.8 % -11.10 [ -24.32, 2.12 ]
Subtotal (95% CI) 1676 1732 32.1 % -2.48 [ -4.35, -0.61 ]
Heterogeneity: Tau2 = 1.48; Chi2 = 6.06, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 2.60 (P = 0.0093)
4 A2AA
Lisk 1993 2 92 (2.8) 2 94.1 (9.2) 0.8 % -2.10 [ -15.43, 11.23 ]
Subtotal (95% CI) 2 2 0.8 % -2.10 [ -15.43, 11.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
5 Beta-Blockers (po)
CHHIPS 2009 28 86.8 (14) 15 92.2 (11) 2.3 % -5.40 [ -13.01, 2.21 ]
Subtotal (95% CI) 28 15 2.3 % -5.40 [ -13.01, 2.21 ]
Heterogeneity: not applicable
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Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 1.39 (P = 0.16)
6 Beta-Blockers (iv)
CHHIPS 2009 27 75.2 (14) 14 92.7 (11) 2.1 % -17.50 [ -25.32, -9.68 ]
Subtotal (95% CI) 27 14 2.1 % -17.50 [ -25.32, -9.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.39 (P = 0.000011)
7 Calcium channel blockers (po)
Uzuner 1995 38 80 (11.2) 39 83.3 (15.3) 3.4 % -3.30 [ -9.28, 2.68 ]
Subtotal (95% CI) 38 39 3.4 % -3.30 [ -9.28, 2.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
8 Calcium channel blockers (iv)
Uzuner 1995 8 83.8 (9.2) 3 96.7 (15.3) 0.4 % -12.90 [ -31.35, 5.55 ]
Subtotal (95% CI) 8 3 0.4 % -12.90 [ -31.35, 5.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
9 Nitric oxide donor
Bath 2000 12 91.42 (17.98) 19 88.42 (17.49) 0.9 % 3.00 [ -9.86, 15.86 ]
ENOS 2014 2000 84.3 (14.1) 2011 87.8 (14.5) 16.8 % -3.50 [ -4.39, -2.61 ]
Rashid 2003 10 mg 20 81.7 (11.7) 10 84.4 (11.7) 1.7 % -2.70 [ -11.58, 6.18 ]
Rashid 2003 5 mg 20 82 (13.7) 10 84.4 (11.7) 1.5 % -2.40 [ -11.81, 7.01 ]
Rashid 2003 5/10 mg 20 82.9 (12.6) 10 84.4 (11.7) 1.6 % -1.50 [ -10.61, 7.61 ]
RIGHT 2013 25 85 (16) 16 82 (16) 1.4 % 3.00 [ -7.04, 13.04 ]
Subtotal (95% CI) 2097 2076 23.8 % -3.39 [ -4.25, -2.52 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.79, df = 5 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 7.65 (P < 0.00001)
10 Low BP target
CATIS 2013 2038 85.9 (8.9) 2033 89.6 (9.6) 17.7 % -3.70 [ -4.27, -3.13 ]
INTERACT pilot 2008 203 81.8 (14) 201 91.3 (15) 9.2 % -9.50 [ -12.33, -6.67 ]
Subtotal (95% CI) 2241 2234 26.9 % -6.43 [ -12.10, -0.75 ]
Heterogeneity: Tau2 = 15.74; Chi2 = 15.51, df = 1 (P = 0.00008); I2 =94%
Test for overall effect: Z = 2.22 (P = 0.026)
Total (95% CI) 6212 6185 100.0 % -3.86 [ -5.07, -2.64 ]
Heterogeneity: Tau2 = 2.10; Chi2 = 54.05, df = 21 (P = 0.00010); I2 =61%
Test for overall effect: Z = 6.20 (P < 0.00001)
Test for subgroup differences: Chi2 = 17.97, df = 9 (P = 0.04), I2 =50%
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Analysis 1.30. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 30 DBP, first after
randomisation by stroke type.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 30 DBP, first after randomisation by stroke type
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic stroke
CATIS 2013 2038 85.9 (8.9) 2033 89.6 (9.6) 19.0 % -3.70 [ -4.27, -3.13 ]
Dyker 1997 12 79 (14) 12 91 (13) 0.8 % -12.00 [ -22.81, -1.19 ]
ENOS 2014 1664 83.7 (13.7) 1678 86.9 (14.2) 17.0 % -3.20 [ -4.15, -2.25 ]
Eveson 2007 17 92.6 (16.5) 18 88.7 (13.4) 0.9 % 3.90 [ -6.09, 13.89 ]
Lisk 1993 3 93 (10.8) 2 94.16 (9.17) 0.3 % -1.16 [ -18.79, 16.47 ]
Lisk 1993 2 92 (2.8) 2 94.2 (9.2) 0.5 % -2.20 [ -15.53, 11.13 ]
TAST 2013 12 81.1 (16.8) 7 92.2 (12.4) 0.5 % -11.10 [ -24.32, 2.12 ]
Subtotal (95% CI) 3748 3752 39.0 % -3.53 [ -4.20, -2.87 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 6.63, df = 6 (P = 0.36); I2 =10%
Test for overall effect: Z = 10.41 (P < 0.00001)
2 Combined ischaemic stroke and Intracerebral haemorrhage
Bath 2000 12 91.42 (17.98) 19 88.42 (17.49) 0.5 % 3.00 [ -9.86, 15.86 ]
CHHIPS 2009 56 83.8 (12) 59 89.8 (11) 4.2 % -6.00 [ -10.21, -1.79 ]
ENOS 2014 2000 84.1 (13) 2011 87.8 (13.3) 17.8 % -3.70 [ -4.51, -2.89 ]
PIL-FAST 2013 6 91 (23) 8 97 (16) 0.2 % -6.00 [ -27.49, 15.49 ]
Rashid 2003 10 mg 20 81.7 (11.7) 10 84.4 (11.7) 1.1 % -2.70 [ -11.58, 6.18 ]
Rashid 2003 5 mg 20 82 (13.7) 10 84.4 (11.7) 1.0 % -2.40 [ -11.81, 7.01 ]
Rashid 2003 5/10 mg 20 82.9 (12.6) 10 84.4 (11.7) 1.1 % -1.50 [ -10.61, 7.61 ]
RIGHT 2013 25 85 (16) 16 82 (16) 0.9 % 3.00 [ -7.04, 13.04 ]
SCAST 2011 1017 85.2 (13.9) 1012 86.6 (14.2) 15.3 % -1.40 [ -2.62, -0.18 ]
Uzuner 1995 38 80 (11.2) 39 83.3 (15.3) 2.3 % -3.30 [ -9.28, 2.68 ]
Uzuner 1995 8 83.8 (9.2) 3 96.7 (15.3) 0.3 % -12.90 [ -31.35, 5.55 ]
Subtotal (95% CI) 3222 3197 44.6 % -2.85 [ -4.26, -1.44 ]
Heterogeneity: Tau2 = 1.11; Chi2 = 14.88, df = 10 (P = 0.14); I2 =33%
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Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 3.95 (P = 0.000078)
3 Intracerebral haemorrhage
ENOS 2014 310 88.1 (15.2) 319 92.3 (15.6) 9.0 % -4.20 [ -6.61, -1.79 ]
INTERACT pilot 2008 203 81.8 (14) 201 91.3 (15) 7.4 % -9.50 [ -12.33, -6.67 ]
Subtotal (95% CI) 513 520 16.3 % -6.80 [ -11.99, -1.60 ]
Heterogeneity: Tau2 = 12.25; Chi2 = 7.82, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 2.56 (P = 0.010)
Total (95% CI) 7483 7469 100.0 % -3.73 [ -4.69, -2.76 ]
Heterogeneity: Tau2 = 1.18; Chi2 = 41.13, df = 19 (P = 0.002); I2 =54%
Test for overall effect: Z = 7.59 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.36, df = 2 (P = 0.31), I2 =15%
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Analysis 1.31. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 31 DBP, first after
randomisation by time to treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 31 DBP, first after randomisation by time to treatment
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ultra-acute/prehospital
PIL-FAST 2013 6 91 (23) 8 97 (16) 0.3 % -6.00 [ -27.49, 15.49 ]
RIGHT 2013 25 85 (16) 16 82 (16) 1.5 % 3.00 [ -7.04, 13.04 ]
Subtotal (95% CI) 31 24 1.8 % 1.39 [ -7.71, 10.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
2 Hyper-acute
INTERACT pilot 2008 203 81.8 (14) 201 91.3 (15) 10.4 % -9.50 [ -12.33, -6.67 ]
ENOS 2014 144 84.5 (15) 129 87.8 (14) 8.3 % -3.30 [ -6.74, 0.14 ]
Subtotal (95% CI) 347 330 18.7 % -6.48 [ -12.55, -0.41 ]
Heterogeneity: Tau2 = 16.64; Chi2 = 7.44, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 2.09 (P = 0.037)
3 Acute
SCAST 2011 1017 85.2 (13.9) 1012 86.6 (14.2) 18.1 % -1.40 [ -2.62, -0.18 ]
CHHIPS 2009 56 83.8 (12) 59 89.8 (11) 6.4 % -6.00 [ -10.21, -1.79 ]
Eveson 2007 17 92.6 (16.5) 18 88.7 (13.4) 1.5 % 3.90 [ -6.09, 13.89 ]
CATIS 2013 2038 85.9 (8.9) 2033 89.6 (9.6) 20.9 % -3.70 [ -4.27, -3.13 ]
ENOS 2014 1856 84.3 (14) 1882 87.8 (14.6) 19.6 % -3.50 [ -4.42, -2.58 ]
Uzuner 1995 38 80 (11.2) 39 83.3 (15.3) 3.7 % -3.30 [ -9.28, 2.68 ]
Uzuner 1995 8 83.8 (9.2) 3 96.7 (15.3) 0.5 % -12.90 [ -31.35, 5.55 ]
Subtotal (95% CI) 5030 5046 70.6 % -3.11 [ -4.26, -1.97 ]
Heterogeneity: Tau2 = 0.93; Chi2 = 15.90, df = 6 (P = 0.01); I2 =62%
Test for overall effect: Z = 5.35 (P < 0.00001)
4 Subacute
Dyker 1997 12 79 (14) 12 91 (13) 1.3 % -12.00 [ -22.81, -1.19 ]
Rashid 2003 5 mg 20 82 (13.7) 10 84.4 (11.7) 1.7 % -2.40 [ -11.81, 7.01 ]
Rashid 2003 5/10 mg 20 82.9 (12.6) 10 84.4 (11.7) 1.8 % -1.50 [ -10.61, 7.61 ]
Rashid 2003 10 mg 20 81.7 (11.7) 10 84.4 (11.7) 1.8 % -2.70 [ -11.58, 6.18 ]
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Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TAST 2013 12 81.1 (16.8) 7 92.2 (12.4) 0.9 % -11.10 [ -24.32, 2.12 ]
Bath 2000 12 91.42 (17.98) 19 88.42 (17.49) 0.9 % 3.00 [ -9.86, 15.86 ]
Lisk 1993 3 93 (10.8) 2 94.16 (9.17) 0.5 % -1.16 [ -18.79, 16.47 ]
Subtotal (95% CI) 99 70 8.8 % -3.88 [ -7.98, 0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.93, df = 6 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
Total (95% CI) 5507 5470 100.0 % -3.80 [ -5.06, -2.54 ]
Heterogeneity: Tau2 = 1.90; Chi2 = 40.17, df = 17 (P = 0.001); I2 =58%
Test for overall effect: Z = 5.91 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.23, df = 3 (P = 0.53), I2 =0.0%
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Analysis 1.32. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 32 DBP, at day 1.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 32 DBP, at day 1
Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors (po)
Lisk 1993 3 85 (5) 2 96.83 (6.34) 1.1 % -11.83 [ -22.28, -1.38 ]
PIL-FAST 2013 5 77 (20) 7 81 (19) 0.3 % -4.00 [ -26.48, 18.48 ]
CHHIPS 2009 28 77 (12) 16 78 (12) 2.2 % -1.00 [ -8.37, 6.37 ]
Eveson 2007 17 87.6 (15.2) 18 86.7 (12.5) 1.4 % 0.90 [ -8.35, 10.15 ]
Subtotal (95% CI) 53 43 5.0 % -3.24 [ -8.95, 2.47 ]
Heterogeneity: Tau2 = 6.76; Chi2 = 3.72, df = 3 (P = 0.29); I2 =19%
Test for overall effect: Z = 1.11 (P = 0.27)
2 ACE inhibitors (s/l)
CHHIPS 2009 28 77 (12) 14 79 (12) 2.0 % -2.00 [ -9.70, 5.70 ]
Subtotal (95% CI) 28 14 2.0 % -2.00 [ -9.70, 5.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
3 ARA (po)
SCAST 2011 1017 90.8 (19) 1012 90.8 (19.2) 15.6 % 0.0 [ -1.66, 1.66 ]
ACCESS 2003 173 87.2 (14.9) 166 89.8 (13) 9.1 % -2.60 [ -5.57, 0.37 ]
Subtotal (95% CI) 1190 1178 24.7 % -1.00 [ -3.47, 1.48 ]
Heterogeneity: Tau2 = 1.87; Chi2 = 2.24, df = 1 (P = 0.13); I2 =55%
Test for overall effect: Z = 0.79 (P = 0.43)
4 A2AA (po)
Lisk 1993 2 97 (18.38) 2 96.83 (6.33) 0.2 % 0.17 [ -26.77, 27.11 ]
Subtotal (95% CI) 2 2 0.2 % 0.17 [ -26.77, 27.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
5 Beta-blockers (po)
CHHIPS 2009 28 77 (14) 15 78 (12) 1.9 % -1.00 [ -8.99, 6.99 ]
Subtotal (95% CI) 28 15 1.9 % -1.00 [ -8.99, 6.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
6 Beta-blockers (iv)
CHHIPS 2009 27 74 (14) 14 79 (12) 1.8 % -5.00 [ -13.21, 3.21 ]
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Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 27 14 1.8 % -5.00 [ -13.21, 3.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
7 Calcium channel blockers (po)
Lisk 1993 5 84.8 (9.12) 2 96.83 (6.33) 0.9 % -12.03 [ -23.90, -0.16 ]
Uzuner 1995 38 80 (11.2) 39 83.3 (15.3) 3.2 % -3.30 [ -9.28, 2.68 ]
Subtotal (95% CI) 43 41 4.1 % -6.10 [ -14.08, 1.89 ]
Heterogeneity: Tau2 = 15.12; Chi2 = 1.66, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 1.50 (P = 0.13)
8 Calcium channel blockers (iv)
Uzuner 1995 8 83.8 (9.2) 3 96.7 (15.3) 0.4 % -12.90 [ -31.35, 5.55 ]
Subtotal (95% CI) 8 3 0.4 % -12.90 [ -31.35, 5.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
9 Nitric oxide donor
ENOS 2014 2000 84.31 (14.08) 2011 87.78 (14.54) 20.5 % -3.47 [ -4.36, -2.58 ]
RIGHT 2013 25 85.8 (15) 16 82.3 (13.4) 1.6 % 3.50 [ -5.31, 12.31 ]
Bath 2000 16 90.5 (14.37) 21 86.71 (16.37) 1.3 % 3.79 [ -6.14, 13.72 ]
Rashid 2003 10 mg 20 81.7 (11.7) 10 84.4 (11.7) 1.6 % -2.70 [ -11.58, 6.18 ]
Rashid 2003 5 mg 20 82 (13.7) 10 84.4 (11.7) 1.4 % -2.40 [ -11.81, 7.01 ]
Rashid 2003 5/10 mg 20 82.9 (12.6) 10 84.4 (11.7) 1.5 % -1.50 [ -10.61, 7.61 ]
Willmot 2006 12 89 (11.07) 6 91 (16.92) 0.6 % -2.00 [ -16.92, 12.92 ]
Subtotal (95% CI) 2113 2084 28.3 % -3.31 [ -4.17, -2.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.62, df = 6 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 7.50 (P < 0.00001)
10 Low BP target
CATIS 2013 2038 85.9 (8.9) 2033 89.6 (9.6) 22.1 % -3.70 [ -4.27, -3.13 ]
INTERACT pilot 2008 203 80.3 (14) 201 87.8 (15) 9.6 % -7.50 [ -10.33, -4.67 ]
Subtotal (95% CI) 2241 2234 31.7 % -5.34 [ -9.02, -1.65 ]
Heterogeneity: Tau2 = 6.14; Chi2 = 6.66, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 2.84 (P = 0.0046)
Total (95% CI) 5733 5628 100.0 % -3.05 [ -4.20, -1.91 ]
Heterogeneity: Tau2 = 1.46; Chi2 = 37.62, df = 21 (P = 0.01); I2 =44%
Test for overall effect: Z = 5.23 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.59, df = 9 (P = 0.68), I2 =0.0%
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Analysis 1.33. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 33 DBP, at day 7.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 33 DBP, at day 7
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors
PIL-FAST 2013 4 73 (3) 7 91 (20) 0.5 % -18.00 [ -33.10, -2.90 ]
Subtotal (95% CI) 4 7 0.5 % -18.00 [ -33.10, -2.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.020)
2 ARA(po)
ACCESS 2003 173 75.8 (20.9) 166 75.8 (19.7) 4.6 % 0.0 [ -4.32, 4.32 ]
PRoFESS 2009 647 78.4 (10.8) 713 81.6 (11) 15.7 % -3.20 [ -4.36, -2.04 ]
SCAST 2011 1017 82 (14) 1012 84 (14) 15.4 % -2.00 [ -3.22, -0.78 ]
TAST 2013 12 78.2 (16.8) 7 92.2 (12.4) 0.6 % -14.00 [ -27.22, -0.78 ]
VENTURE 2013 203 84.7 (2.5) 202 87.1 (2.7) 18.5 % -2.40 [ -2.91, -1.89 ]
Subtotal (95% CI) 2052 2100 54.9 % -2.47 [ -3.24, -1.70 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 6.34, df = 4 (P = 0.18); I2 =37%
Test for overall effect: Z = 6.31 (P < 0.00001)
3 Nitric oxide donor
ENOS 2014 2000 82.9 (14.7) 2011 84 (14.4) 17.0 % -1.10 [ -2.00, -0.20 ]
Subtotal (95% CI) 2000 2011 17.0 % -1.10 [ -2.00, -0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
4 Thiazide-like diuretic (po)
Eames 2005 18 78 (15) 19 83 (19) 0.9 % -5.00 [ -16.00, 6.00 ]
Subtotal (95% CI) 18 19 0.9 % -5.00 [ -16.00, 6.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
5 Low BP target
CATIS 2013 2038 82.4 (7.2) 2033 86.4 (8.1) 18.6 % -4.00 [ -4.47, -3.53 ]
INTERACT pilot 2008 203 77.2 (14) 201 83.2 (15) 8.2 % -6.00 [ -8.83, -3.17 ]
Subtotal (95% CI) 2241 2234 26.8 % -4.49 [ -6.18, -2.80 ]
Heterogeneity: Tau2 = 0.93; Chi2 = 1.87, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 5.21 (P < 0.00001)
Total (95% CI) 6315 6371 100.0 % -2.90 [ -3.96, -1.83 ]
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Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 1.53; Chi2 = 55.21, df = 9 (P<0.00001); I2 =84%
Test for overall effect: Z = 5.33 (P < 0.00001)
Test for subgroup differences: Chi2 = 17.75, df = 4 (P = 0.00), I2 =77%
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Analysis 1.34. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 34 DBP, at end of
treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 34 DBP, at end of treatment
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors (po)
CHHIPS 2009 29 86.8 (12) 16 90.8 (11) 2.4 % -4.00 [ -10.94, 2.94 ]
Dyker 1997 14 83 (9) 14 83 (14) 1.6 % 0.0 [ -8.72, 8.72 ]
Eveson 2007 18 78 (6) 21 86 (9) 4.2 % -8.00 [ -12.74, -3.26 ]
PIL-FAST 2013 4 73 (3) 7 91 (20) 0.6 % -18.00 [ -33.10, -2.90 ]
Subtotal (95% CI) 65 58 8.8 % -6.06 [ -11.18, -0.95 ]
Heterogeneity: Tau2 = 11.28; Chi2 = 5.23, df = 3 (P = 0.16); I2 =43%
Test for overall effect: Z = 2.32 (P = 0.020)
2 ARA (po)
ACCESS 2003 173 77.4 (14.9) 166 77.4 (13) 7.0 % 0.0 [ -2.97, 2.97 ]
ACCOST 2006 19 82.3 (3.5) 19 92.4 (3.6) 8.5 % -10.10 [ -12.36, -7.84 ]
PRoFESS 2009 647 79.2 (11.1) 713 81.5 (11.2) 10.9 % -2.30 [ -3.49, -1.11 ]
SCAST 2011 1012 82 (14) 1017 84 (14) 10.8 % -2.00 [ -3.22, -0.78 ]
TAST 2013 12 79.9 (16.8) 7 97.5 (12.4) 0.8 % -17.60 [ -30.82, -4.38 ]
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Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
VENTURE 2013 203 84.7 (2.5) 202 87.1 (2.7) 11.9 % -2.40 [ -2.91, -1.89 ]
Subtotal (95% CI) 2066 2124 49.9 % -3.61 [ -5.61, -1.61 ]
Heterogeneity: Tau2 = 4.53; Chi2 = 52.04, df = 5 (P<0.00001); I2 =90%
Test for overall effect: Z = 3.54 (P = 0.00040)
3 ACE inhibitors (s/l)
CHHIPS 2009 28 82.4 (12) 14 82.4 (12) 2.0 % 0.0 [ -7.70, 7.70 ]
Subtotal (95% CI) 28 14 2.0 % 0.0 [ -7.70, 7.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Beta-blockers (po)
CHHIPS 2009 28 87.9 (14) 15 87 (13) 1.8 % 0.90 [ -7.48, 9.28 ]
Subtotal (95% CI) 28 15 1.8 % 0.90 [ -7.48, 9.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
5 Beta-Blockers (iv)
CHHIPS 2009 27 76.3 (14) 14 92.7 (11) 2.0 % -16.40 [ -24.22, -8.58 ]
Subtotal (95% CI) 27 14 2.0 % -16.40 [ -24.22, -8.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
6 Calcium channel blockers (po)
Uzuner 1995 38 74.3 (10.3) 39 83.7 (16.4) 2.9 % -9.40 [ -15.50, -3.30 ]
Subtotal (95% CI) 38 39 2.9 % -9.40 [ -15.50, -3.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
7 Calcium channel blockers (iv)
Uzuner 1995 8 83.8 (9.2) 3 86.7 (15.3) 0.4 % -2.90 [ -21.35, 15.55 ]
Subtotal (95% CI) 8 3 0.4 % -2.90 [ -21.35, 15.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
8 Nitric oxide donor
ENOS 2014 2000 82.9 (14.7) 2011 84 (14.4) 11.4 % -1.10 [ -2.00, -0.20 ]
Subtotal (95% CI) 2000 2011 11.4 % -1.10 [ -2.00, -0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
9 Thiazide-like diuretic (po)
Eames 2005 18 90 (14) 19 94 (14) 1.5 % -4.00 [ -13.03, 5.03 ]
Subtotal (95% CI) 18 19 1.5 % -4.00 [ -13.03, 5.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
10 Low BP target
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Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CATIS 2013 2038 81.4 (7.4) 2033 85.3 (8.3) 12.0 % -3.90 [ -4.38, -3.42 ]
INTERACT pilot 2008 203 77.4 (14) 201 83.1 (15) 7.3 % -5.70 [ -8.53, -2.87 ]
Subtotal (95% CI) 2241 2234 19.2 % -4.24 [ -5.62, -2.86 ]
Heterogeneity: Tau2 = 0.55; Chi2 = 1.51, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 6.03 (P < 0.00001)
Total (95% CI) 6519 6531 100.0 % -3.95 [ -5.15, -2.75 ]
Heterogeneity: Tau2 = 3.08; Chi2 = 115.40, df = 18 (P<0.00001); I2 =84%
Test for overall effect: Z = 6.46 (P < 0.00001)
Test for subgroup differences: Chi2 = 36.65, df = 9 (P = 0.00), I2 =75%
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Analysis 1.35. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 35 HR at baseline.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 35 HR at baseline
Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors (po)
Lisk 1993 1 63 (0) 1 79.5 (22.64) Not estimable
Dyker 1997 12 69.75 (8.71) 12 68.73 (8.82) 1.7 % 1.02 [ -5.99, 8.03 ]
Eveson 2007 17 73.1 (10) 18 74.2 (16.5) 1.0 % -1.10 [ -10.08, 7.88 ]
Subtotal (95% CI) 30 31 2.7 % 0.22 [ -5.31, 5.75 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
2 ARA(po)
PRoFESS 2009 647 72.8 (11.9) 713 73.1 (11.4) 35.5 % -0.30 [ -1.54, 0.94 ]
TAST 2013 12 69.6 (15.8) 7 74.6 (14.6) 0.4 % -5.00 [ -19.03, 9.03 ]
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Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 659 720 35.9 % -0.34 [ -1.57, 0.90 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
3 A2AA (po)
Lisk 1993 1 76 (0) 1 79.5 (22.6) Not estimable
Subtotal (95% CI) 1 1 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcium channel blockers (po)
Lisk 1993 1 71 (0) 1 79.5 (22.64) Not estimable
Uzuner 1995 38 86.6 (10.67) 39 90.2 (15.27) 2.4 % -3.60 [ -9.47, 2.27 ]
Subtotal (95% CI) 39 40 2.4 % -3.60 [ -9.47, 2.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
5 Nitric oxide donor
RIGHT 2013 25 85.6 (18.6) 16 78.1 (16.4) 0.7 % 7.50 [ -3.35, 18.35 ]
ENOS 2014 2000 77.69 (14.79) 2011 77.34 (14.64) 50.4 % 0.35 [ -0.56, 1.26 ]
Bath 2000 16 83.63 (17.04) 21 71.19 (12.32) 0.9 % 12.44 [ 2.57, 22.31 ]
Rashid 2003 10 mg 20 75.05 (9.64) 10 77.83 (14.01) 0.9 % -2.78 [ -12.44, 6.88 ]
Rashid 2003 5 mg 20 81.55 (16.62) 10 77.83 (14.01) 0.7 % 3.72 [ -7.61, 15.05 ]
Rashid 2003 5/10 mg 20 77.3 (19.55) 10 77.83 (14.01) 0.6 % -0.53 [ -12.73, 11.67 ]
Willmot 2006 12 69.42 (13.87) 6 65.83 (15.12) 0.4 % 3.59 [ -10.83, 18.01 ]
Subtotal (95% CI) 2113 2084 54.5 % 2.26 [ -1.26, 5.77 ]
Heterogeneity: Tau2 = 6.22; Chi2 = 8.28, df = 6 (P = 0.22); I2 =28%
Test for overall effect: Z = 1.26 (P = 0.21)
6 Thiazide-like diuretic (po)
Eames 2005 18 68 (11) 19 72 (9) 2.0 % -4.00 [ -10.50, 2.50 ]
Subtotal (95% CI) 18 19 2.0 % -4.00 [ -10.50, 2.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
7 Calcium channel blockers (iv)
Uzuner 1995 8 97.3 (7.6) 3 92 (7) 0.9 % 5.30 [ -4.21, 14.81 ]
Subtotal (95% CI) 8 3 0.9 % 5.30 [ -4.21, 14.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
8 Low BP target
ICH-ADAPT 2013 39 76 (15) 36 79 (18) 1.5 % -3.00 [ -10.53, 4.53 ]
Subtotal (95% CI) 39 36 1.5 % -3.00 [ -10.53, 4.53 ]
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(. . . Continued)
Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 2907 2934 100.0 % 0.07 [ -0.86, 0.99 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 14.94, df = 14 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 6.35, df = 6 (P = 0.39), I2 =6%
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Analysis 1.36. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 36 HR, first after
randomisation.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 36 HR, first after randomisation
Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors (po)
Lisk 1993 2 94 (36.76) 2 74.4 (21.3) 0.4 % 19.60 [ -39.28, 78.48 ]
Eveson 2007 17 74 (10.8) 18 75.1 (17.1) 11.7 % -1.10 [ -10.52, 8.32 ]
Subtotal (95% CI) 19 20 12.1 % -0.58 [ -9.89, 8.72 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
2 ARA(po)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers (po)
Lisk 1993 3 98.66 (28.72) 2 74.4 (21.3) 0.8 % 24.26 [ -19.64, 68.16 ]
Uzuner 1995 38 83.8 (11.5) 39 88.6 (17) 18.5 % -4.80 [ -11.27, 1.67 ]
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Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 41 41 19.2 % 1.28 [ -21.89, 24.46 ]
Heterogeneity: Tau2 = 165.90; Chi2 = 1.65, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 0.11 (P = 0.91)
4 A2AA (po)
Lisk 1993 1 0 (0) 2 74.4 (21.31) Not estimable
Subtotal (95% CI) 1 2 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donor
ENOS 2014 2000 79 (15.1) 2011 77.3 (14.9) 37.3 % 1.70 [ 0.77, 2.63 ]
Bath 2000 13 79.1 (15.2) 19 69.5 (12.7) 10.7 % 9.60 [ -0.44, 19.64 ]
Willmot 2006 12 72.83 (11.1) 6 65.5 (12.16) 8.6 % 7.33 [ -4.25, 18.91 ]
Subtotal (95% CI) 2025 2036 56.7 % 3.95 [ -1.03, 8.93 ]
Heterogeneity: Tau2 = 9.38; Chi2 = 3.24, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 1.56 (P = 0.12)
6 Calcium channel blockers (iv)
Uzuner 1995 8 98 (11.7) 3 88 (4) 11.9 % 10.00 [ 0.71, 19.29 ]
Subtotal (95% CI) 8 3 11.9 % 10.00 [ 0.71, 19.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 2094 2102 100.0 % 2.74 [ -1.13, 6.61 ]
Heterogeneity: Tau2 = 10.23; Chi2 = 11.94, df = 7 (P = 0.10); I2 =41%
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Chi2 = 2.58, df = 3 (P = 0.46), I2 =0.0%
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Analysis 1.37. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 37 HR, at day 1.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 37 HR, at day 1
Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors (po)
Lisk 1993 2 82.5 (24.74) 2 84 (28.15) 0.4 % -1.50 [ -53.44, 50.44 ]
Eveson 2007 17 71.2 (134.9) 18 68.8 (17.2) 0.3 % 2.40 [ -62.22, 67.02 ]
Subtotal (95% CI) 19 20 0.7 % 0.03 [ -40.45, 40.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
2 Calcium channel blockers (po)
Lisk 1993 4 85.25 (28.99) 2 84 (28.15) 0.5 % 1.25 [ -47.01, 49.51 ]
Uzuner 1995 38 81.5 (10.4) 39 84.1 (12.7) 14.2 % -2.60 [ -7.78, 2.58 ]
Subtotal (95% CI) 42 41 14.7 % -2.56 [ -7.71, 2.59 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
3 A2AA (po)
Lisk 1993 1 0 (0) 2 84 (28.15) Not estimable
Subtotal (95% CI) 1 2 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donor
RIGHT 2013 25 79.6 (20.7) 16 74.3 (15.9) 6.4 % 5.30 [ -5.95, 16.55 ]
ENOS 2014 2000 78.9 (15.1) 2011 77.27 (14.9) 20.9 % 1.63 [ 0.70, 2.56 ]
Bath 2000 16 82.7 (12.1) 21 70.1 (12) 10.0 % 12.60 [ 4.76, 20.44 ]
Rashid 2003 10 mg 20 78.8 (10.5) 10 75.5 (7.71) 11.8 % 3.30 [ -3.33, 9.93 ]
Rashid 2003 5 mg 20 80.6 (11.9) 10 75.5 (7.71) 11.1 % 5.10 [ -1.97, 12.17 ]
Rashid 2003 5/10 mg 20 80.8 (11.7) 10 75.5 (7.71) 11.2 % 5.30 [ -1.71, 12.31 ]
Willmot 2006 12 73 (11.12) 6 66 (12.16) 6.2 % 7.00 [ -4.59, 18.59 ]
Subtotal (95% CI) 2113 2084 77.5 % 4.53 [ 1.46, 7.60 ]
Heterogeneity: Tau2 = 6.35; Chi2 = 10.41, df = 6 (P = 0.11); I2 =42%
Test for overall effect: Z = 2.89 (P = 0.0039)
5 Calcium channel blockers (iv)
Uzuner 1995 8 81.8 (6.6) 3 98.7 (8.3) 7.1 % -16.90 [ -27.35, -6.45 ]
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Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 8 3 7.1 % -16.90 [ -27.35, -6.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.17 (P = 0.0015)
Total (95% CI) 2183 2150 100.0 % 2.35 [ -1.06, 5.76 ]
Heterogeneity: Tau2 = 14.28; Chi2 = 25.61, df = 11 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 18.04, df = 3 (P = 0.00), I2 =83%
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Analysis 1.38. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 38 HR, at day 7.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 38 HR, at day 7
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Thiazide-like diuretic (po)
Eames 2005 18 70 (10) 19 70 (9) 1.4 % 0.0 [ -6.14, 6.14 ]
Subtotal (95% CI) 18 19 1.4 % 0.0 [ -6.14, 6.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 ARA(po)
PRoFESS 2009 647 74.3 (11.1) 713 74.2 (10.8) 37.7 % 0.10 [ -1.07, 1.27 ]
Subtotal (95% CI) 647 713 37.7 % 0.10 [ -1.07, 1.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
3 Nitric oxide donor
ENOS 2014 2000 77.8 (14.9) 2011 77.1 (14.9) 60.3 % 0.70 [ -0.22, 1.62 ]
RIGHT 2013 25 79.4 (17.7) 16 77 (12.2) 0.6 % 2.40 [ -6.76, 11.56 ]
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Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 2025 2027 60.9 % 0.72 [ -0.20, 1.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 2690 2759 100.0 % 0.47 [ -0.24, 1.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Chi2 = 0.69, df = 2 (P = 0.71), I2 =0.0%
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Analysis 1.39. Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 39 HR, at end of
treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 1 Blood pressure lowering therapy in acute stroke
Outcome: 39 HR, at end of treatment
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ACE inhibitors
Eveson 2007 17 71.2 (134.9) 18 68.8 (17.2) 0.0 % 2.40 [ -62.22, 67.02 ]
Subtotal (95% CI) 17 18 0.0 % 2.40 [ -62.22, 67.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
2 Thiazide- like diuretic
Eames 2005 18 70 (10) 19 70 (9) 2.2 % 0.0 [ -6.14, 6.14 ]
Subtotal (95% CI) 18 19 2.2 % 0.0 [ -6.14, 6.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Nitric oxide donor
ENOS 2014 2000 77.8 (14.9) 2011 77.1 (14.9) 96.8 % 0.70 [ -0.22, 1.62 ]
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Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
RIGHT 2013 25 79.4 (17.7) 16 77 (12.2) 1.0 % 2.40 [ -6.76, 11.56 ]
Subtotal (95% CI) 2025 2027 97.8 % 0.72 [ -0.20, 1.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 2060 2064 100.0 % 0.70 [ -0.21, 1.61 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 0.05, df = 2 (P = 0.97), I2 =0.0%
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Analysis 2.1. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 1 Death or dependency, end of trial by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 1 Death or dependency, end of trial by C/S
Study or subgroup Favours Continue Favours Stop Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
COSSACS 2010 145/379 138/384 27.1 % 1.10 [ 0.82, 1.48 ]
ENOS 2014 689/1053 672/1044 72.9 % 1.05 [ 0.88, 1.25 ]
Total (95% CI) 1432 1428 100.0 % 1.06 [ 0.91, 1.24 ]
Total events: 834 (Favours Continue), 810 (Favours Stop)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 2 Death or dependency, end of trial by stroke type C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 2 Death or dependency, end of trial by stroke type C/S
Study or subgroup Continue Stop Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke
ENOS 2014 600/928 573/904 64.9 % 1.06 [ 0.87, 1.28 ]
Subtotal (95% CI) 928 904 64.9 % 1.06 [ 0.87, 1.28 ]
Total events: 600 (Continue), 573 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Combined ischaemic stroke and intracerebral haemorrhage
COSSACS 2010 145/379 138/384 27.4 % 1.10 [ 0.82, 1.48 ]
Subtotal (95% CI) 379 384 27.4 % 1.10 [ 0.82, 1.48 ]
Total events: 145 (Continue), 138 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
3 Intracerebral haemorrhage
ENOS 2014 84/119 91/127 7.8 % 0.95 [ 0.55, 1.65 ]
Subtotal (95% CI) 119 127 7.8 % 0.95 [ 0.55, 1.65 ]
Total events: 84 (Continue), 91 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.85)
Total (95% CI) 1426 1415 100.0 % 1.06 [ 0.91, 1.24 ]
Total events: 829 (Continue), 802 (Stop)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Chi2 = 0.23, df = 2 (P = 0.89), I2 =0.0%
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Analysis 2.3. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 3 Death or dependency, end of trial by time to treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 3 Death or dependency, end of trial by time to treatment
Study or subgroup Continue Stop Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ultra-acute
ENOS 2014 42/68 41/75 5.3 % 1.34 [ 0.69, 2.61 ]
Subtotal (95% CI) 68 75 5.3 % 1.34 [ 0.69, 2.61 ]
Total events: 42 (Continue), 41 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
2 Acute
COSSACS 2010 145/379 138/384 27.2 % 1.10 [ 0.82, 1.48 ]
ENOS 2014 647/985 631/969 67.5 % 1.03 [ 0.85, 1.24 ]
Subtotal (95% CI) 1364 1353 94.7 % 1.05 [ 0.89, 1.23 ]
Total events: 792 (Continue), 769 (Stop)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 1432 1428 100.0 % 1.06 [ 0.91, 1.24 ]
Total events: 834 (Continue), 810 (Stop)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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Analysis 2.4. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 4 Death early, by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 4 Death early, by C/S
Study or subgroup Continue Stop Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
COSSACS 2010 4/379 7/384 23.1 % 0.57 [ 0.17, 1.98 ]
ENOS 2014 34/1053 27/1044 76.9 % 1.26 [ 0.75, 2.10 ]
Total (95% CI) 1432 1428 100.0 % 1.05 [ 0.55, 2.00 ]
Total events: 38 (Continue), 34 (Stop)
Heterogeneity: Tau2 = 0.07; Chi2 = 1.31, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 5 Death early, by stroke type C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 5 Death early, by stroke type C/S
Study or subgroup Continue Stop Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke
ENOS 2014 32/928 23/904 68.1 % 1.37 [ 0.79, 2.36 ]
Subtotal (95% CI) 928 904 68.1 % 1.37 [ 0.79, 2.36 ]
Total events: 32 (Continue), 23 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
2 Combined ischaemic stroke and intracerebral haemorrhage
COSSACS 2010 4/379 7/384 20.5 % 0.57 [ 0.17, 1.98 ]
Subtotal (95% CI) 379 384 20.5 % 0.57 [ 0.17, 1.98 ]
Total events: 4 (Continue), 7 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
3 Intracerebral haemorrhage
ENOS 2014 2/119 4/127 11.4 % 0.53 [ 0.09, 2.92 ]
Subtotal (95% CI) 119 127 11.4 % 0.53 [ 0.09, 2.92 ]
Total events: 2 (Continue), 4 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Total (95% CI) 1426 1415 100.0 % 1.03 [ 0.56, 1.87 ]
Total events: 38 (Continue), 34 (Stop)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.39, df = 2 (P = 0.30); I2 =16%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 2.39, df = 2 (P = 0.30), I2 =16%
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Analysis 2.6. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 6 Death early, by time to treatment C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 6 Death early, by time to treatment C/S
Study or subgroup Continue Stop Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ultra-acute
ENOS 2014 2/68 0/75 3.6 % 5.68 [ 0.27, 120.37 ]
Subtotal (95% CI) 68 75 3.6 % 5.68 [ 0.27, 120.37 ]
Total events: 2 (Continue), 0 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
2 Acute
COSSACS 2010 4/379 7/384 20.0 % 0.57 [ 0.17, 1.98 ]
ENOS 2014 32/985 27/969 76.4 % 1.17 [ 0.70, 1.97 ]
Subtotal (95% CI) 1364 1353 96.4 % 1.03 [ 0.61, 1.76 ]
Total events: 36 (Continue), 34 (Stop)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.08, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 0.12 (P = 0.91)
Total (95% CI) 1432 1428 100.0 % 1.08 [ 0.60, 1.93 ]
Total events: 38 (Continue), 34 (Stop)
Heterogeneity: Tau2 = 0.05; Chi2 = 2.23, df = 2 (P = 0.33); I2 =10%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 1.16, df = 1 (P = 0.28), I2 =14%
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Analysis 2.7. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 7 Death, end of trial by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 7 Death, end of trial by C/S
Study or subgroup Continue Stop Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
COSSACS 2010 32/379 30/384 17.7 % 1.09 [ 0.65, 1.83 ]
ENOS 2014 167/1053 146/1044 82.3 % 1.16 [ 0.91, 1.47 ]
Total (95% CI) 1432 1428 100.0 % 1.15 [ 0.92, 1.43 ]
Total events: 199 (Continue), 176 (Stop)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 8 Death end of trial, by stroke type C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 8 Death end of trial, by stroke type C/S
Study or subgroup Continue Stop Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke
ENOS 2014 147/928 119/904 71.3 % 1.24 [ 0.96, 1.61 ]
Subtotal (95% CI) 928 904 71.3 % 1.24 [ 0.96, 1.61 ]
Total events: 147 (Continue), 119 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
2 Combined ischaemic stroke and intracerebral haemorrhage
COSSACS 2010 32/379 29/384 17.7 % 1.13 [ 0.67, 1.91 ]
Subtotal (95% CI) 379 384 17.7 % 1.13 [ 0.67, 1.91 ]
Total events: 32 (Continue), 29 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
3 Intracerebral haemorrhage
ENOS 2014 19/117 23/127 10.9 % 0.88 [ 0.45, 1.71 ]
Subtotal (95% CI) 117 127 10.9 % 0.88 [ 0.45, 1.71 ]
Total events: 19 (Continue), 23 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 1424 1415 100.0 % 1.18 [ 0.94, 1.47 ]
Total events: 198 (Continue), 171 (Stop)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Chi2 = 0.93, df = 2 (P = 0.63), I2 =0.0%
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Analysis 2.9. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 9 Death, end of trial by time to treatment C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 9 Death, end of trial by time to treatment C/S
Study or subgroup Continue Stop Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ultra-acute
ENOS 2014 11/68 7/75 4.7 % 1.87 [ 0.68, 5.15 ]
Subtotal (95% CI) 68 75 4.7 % 1.87 [ 0.68, 5.15 ]
Total events: 11 (Continue), 7 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
2 Acute
COSSACS 2010 32/379 30/384 17.7 % 1.09 [ 0.65, 1.83 ]
ENOS 2014 156/985 139/969 77.6 % 1.12 [ 0.88, 1.44 ]
Subtotal (95% CI) 1364 1353 95.3 % 1.12 [ 0.89, 1.40 ]
Total events: 188 (Continue), 169 (Stop)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI) 1432 1428 100.0 % 1.14 [ 0.92, 1.42 ]
Total events: 199 (Continue), 176 (Stop)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 0.96, df = 1 (P = 0.33), I2 =0.0%
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Analysis 2.10. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 10 Barthel Index, end of trial, by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 10 Barthel Index, end of trial, by C/S
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
COSSACS 2010 379 77.9 (29.4) 384 80.2 (28) 41.5 % -2.30 [ -6.37, 1.77 ]
ENOS 2014 1053 58.1 (40.8) 1044 61.9 (39.4) 58.5 % -3.80 [ -7.23, -0.37 ]
Total (95% CI) 1432 1428 100.0 % -3.18 [ -5.80, -0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 11 Early neurological deterioration, by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 11 Early neurological deterioration, by C/S
Study or subgroup Continue Stop Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ENOS 2014 72/1053 57/1044 100.0 % 1.27 [ 0.89, 1.82 ]
Total (95% CI) 1053 1044 100.0 % 1.27 [ 0.89, 1.82 ]
Total events: 72 (Continue), 57 (Stop)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours Continue Favours stop
143Interventions for deliberately altering blood pressure in acute stroke (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.12. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 12 Quality of life (EuroQol) at end of trial, by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 12 Quality of life (EuroQol) at end of trial, by C/S
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
COSSACS 2010 379 0.68 (0.26) 384 0.71 (0.25) 37.8 % -0.03 [ -0.07, 0.01 ]
ENOS 2014 1053 0.44 (0.33) 1044 0.47 (0.33) 62.2 % -0.03 [ -0.06, 0.00 ]
Total (95% CI) 1432 1428 100.0 % -0.03 [ -0.05, -0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0083)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 13 Length of stay, by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 13 Length of stay, by C/S
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ENOS 2014 1053 22.47 (24.53) 1044 21.27 (23.9) 100.0 % 1.20 [ -0.87, 3.27 ]
Total (95% CI) 1053 1044 100.0 % 1.20 [ -0.87, 3.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 14 SBP, first after randomisation, by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 14 SBP, first after randomisation, by C/S
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
COSSACS 2010 379 141.8 (20.3) 384 145.4 (22.4) 29.3 % -3.60 [ -6.63, -0.57 ]
ENOS 2014 1053 158.4 (22.7) 1044 161.3 (22.9) 70.7 % -2.90 [ -4.85, -0.95 ]
Total (95% CI) 1432 1428 100.0 % -3.11 [ -4.75, -1.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 15 SBP, at day 1 by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 15 SBP, at day 1 by C/S
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
COSSACS 2010 379 141.8 (20.3) 384 145.4 (22.4) 29.3 % -3.60 [ -6.63, -0.57 ]
ENOS 2014 1053 158.4 (22.7) 1044 161.3 (22.9) 70.7 % -2.90 [ -4.85, -0.95 ]
Total (95% CI) 1432 1428 100.0 % -3.11 [ -4.75, -1.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 16 SBP, at end of treatment by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 16 SBP, at end of treatment by C/S
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
COSSACS 2010 379 140 (22) 384 153.5 (23.8) 44.9 % -13.50 [ -16.75, -10.25 ]
ENOS 2014 1053 145.6 (24.5) 1044 155.1 (23.9) 55.1 % -9.50 [ -11.57, -7.43 ]
Total (95% CI) 1432 1428 100.0 % -11.30 [ -15.20, -7.40 ]
Heterogeneity: Tau2 = 6.07; Chi2 = 4.14, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 5.68 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.17. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 17 DBP, at baseline by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 17 DBP, at baseline by C/S
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
COSSACS 2010 379 79.9 (12.9) 384 81.4 (13.6) 26.1 % -1.50 [ -3.38, 0.38 ]
ENOS 2014 1053 88.1 (13.1) 1044 88.5 (13) 73.9 % -0.40 [ -1.52, 0.72 ]
Total (95% CI) 1432 1428 100.0 % -0.69 [ -1.65, 0.27 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 18 DBP at day 1, by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 18 DBP at day 1, by C/S
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
COSSACS 2010 379 77 (12.4) 384 79 (14.6) 30.2 % -2.00 [ -3.92, -0.08 ]
ENOS 2014 1053 84.7 (14.2) 1044 85.5 (14.4) 69.8 % -0.80 [ -2.02, 0.42 ]
Total (95% CI) 1432 1428 100.0 % -1.16 [ -2.24, -0.08 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 1.07, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 19 DBP, at end of treatment by C/S.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 19 DBP, at end of treatment by C/S
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
COSSACS 2010 379 76.1 (13.7) 384 84.1 (13.8) 46.5 % -8.00 [ -9.95, -6.05 ]
ENOS 2014 1053 80 (14.7) 1044 85.1 (14.3) 53.5 % -5.10 [ -6.34, -3.86 ]
Total (95% CI) 1432 1428 100.0 % -6.45 [ -9.28, -3.61 ]
Heterogeneity: Tau2 = 3.51; Chi2 = 6.04, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 4.46 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 20 HR, at day 1.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 20 HR, at day 1
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
ENOS 2014 1053 77.4 (15.5) 1044 76.8 (14.9) 100.0 % 0.60 [ -0.70, 1.90 ]
Total (95% CI) 1053 1044 100.0 % 0.60 [ -0.70, 1.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 2.21. Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S),
Outcome 21 HR, at end of treatment.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S)
Outcome: 21 HR, at end of treatment
Study or subgroup Continue Stop
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
ENOS 2014 1053 76.3 (15.9) 1044 79.5 (14.8) 100.0 % -3.20 [ -4.51, -1.89 ]
Total (95% CI) 1053 1044 100.0 % -3.20 [ -4.51, -1.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.77 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Continue Favours stop
Analysis 3.1. Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 1 Death early, by
intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 3 Blood pressure elevation therapy in acute stroke
Outcome: 1 Death early, by intervention
Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Phenylephrine (iv)
Hillis 2003 0/9 0/6 Not estimable
Total (95% CI) 9 6 Not estimable
Total events: 0 (Active), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 3.2. Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 2 Death early, by
stroke type.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 3 Blood pressure elevation therapy in acute stroke
Outcome: 2 Death early, by stroke type
Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke
Hillis 2003 0/9 0/6 Not estimable
Total (95% CI) 9 6 Not estimable
Total events: 0 (Active), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 3.3. Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 3 Death end of trial,
by intervention.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 3 Blood pressure elevation therapy in acute stroke
Outcome: 3 Death end of trial, by intervention
Study or subgroup Active Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Phenylephrine (iv)
Hillis 2003 0/9 0/6 Not estimable
Total (95% CI) 9 6 Not estimable
Total events: 0 (Active), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 3.4. Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 4 SBP, at baseline.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 3 Blood pressure elevation therapy in acute stroke
Outcome: 4 SBP, at baseline
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Phenylephrine (iv)
Hillis 2003 9 138.7 (28.1) 6 166.2 (18) 100.0 % -27.50 [ -50.83, -4.17 ]
Total (95% CI) 9 6 100.0 % -27.50 [ -50.83, -4.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 5 SBP, first after
randomisation.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 3 Blood pressure elevation therapy in acute stroke
Outcome: 5 SBP, first after randomisation
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hillis 2003 9 185.4 (15.3) 6 164.8 (40.5) 100.0 % 20.60 [ -13.31, 54.51 ]
Total (95% CI) 9 6 100.0 % 20.60 [ -13.31, 54.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 6 SBP, at day 1.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 3 Blood pressure elevation therapy in acute stroke
Outcome: 6 SBP, at day 1
Study or subgroup Active control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hillis 2003 9 185.4 (15.3) 6 164.8 (40.5) 100.0 % 20.60 [ -13.31, 54.51 ]
Total (95% CI) 9 6 100.0 % 20.60 [ -13.31, 54.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours BP elevation
153Interventions for deliberately altering blood pressure in acute stroke (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.7. Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 7 DBP, at baseline.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 3 Blood pressure elevation therapy in acute stroke
Outcome: 7 DBP, at baseline
Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hillis 2003 9 68.5 (9.6) 6 76.8 (11.03) 100.0 % -8.30 [ -19.13, 2.53 ]
Total (95% CI) 9 6 100.0 % -8.30 [ -19.13, 2.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 8 DBP, first after
randomisation.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 3 Blood pressure elevation therapy in acute stroke
Outcome: 8 DBP, first after randomisation
Study or subgroup Active Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hillis 2003 9 81.9 (10.2) 6 81.4 (17.3) 100.0 % 0.50 [ -14.86, 15.86 ]
Total (95% CI) 9 6 100.0 % 0.50 [ -14.86, 15.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours BP elevation Favours control
154Interventions for deliberately altering blood pressure in acute stroke (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.9. Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 9 DBP, at day 1.
Review: Interventions for deliberately altering blood pressure in acute stroke
Comparison: 3 Blood pressure elevation therapy in acute stroke
Outcome: 9 DBP, at day 1
Study or subgroup Active group Control group
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hillis 2003 9 81.9 (10.2) 6 81.4 (17.3) 100.0 % 0.50 [ -14.86, 15.86 ]
Total (95% CI) 9 6 100.0 % 0.50 [ -14.86, 15.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Blood pressure changes after first dose
Type Trials Participants SBP 95% CI I2 % DBP 95% CI I2%
Type of in-
tervention
ACE-I, oral 5 123 -13.7 -20.0 to -7.3 0 -4.2 -9.7 to 1.2 16
ACE-I, sub-
lingual
1 42 -6.0 -17.6 to 5.6 - +2.2 -5.5 to 9.9 -
ARA 3 3408 -4.6 -8 to -1 74 -2.5 -4.3 to -0.6 67
α-2 adreno-
ceptor ago-
nist
1 4 -13.7 -41.5 to 14.1 - -2.1 -15.4 to 11.2 -
ß-recep-
tor antago-
nist, oral
1 44 -11.5 -20.3 to -2.7 - -5.4 -13 to 2.2 -
ß-
receptor an-
tagonist, iv
1 41 -16.4 -27.4 to -5.4 - -17.5 -25.3 to -9.7 -
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Table 1. Blood pressure changes after first dose (Continued)
Cal-
cium chan-
nel blocker,
oral
3 106 -7.6 -17.2 to 1.9 0 -3.3 -9.3 to 2.7 -
Cal-
cium chan-
nel blocker,
iv
1 11 -9.7 -24.4 to 4.9 - -12.9 -31.4 to 5.6 -
Nitric oxide
donor
5 4192 -9.3 -14.5 to -4 26 -3.6 -4.4 to -2.8 0
Diuretic,
thiazide-like
1 40 -20.0 -38.6 to -1.4 - - - -
Low BP tar-
get
5 7421 -11.4 -15.3 to -7.5 93 -6.9 -15.7 to 1.9 94
Overall 27 15432 -11.2 -13.7, -8.7 86 -3.9 -5.4 to -2.6 61
ACE-I: angiotensin converting enzyme inhibitors
ARA: angiotensin receptor antagonist
BP: blood pressure
DBP: diastolic blood pressure
SBP: systolic blood pressure
iv: intravenous
Table 2. Blood pressure changes by type of intervention
SBP First Day 1 Day 7
Type of intervention
ACE-I, oral -21.0 -7.9 -26
ACE-I, sublingual -6.0 -12 -
Angiotensin receptor antago-
nist
-4.6 -0.5 -6
Alpha-2 adrenoceptor agonist -13.7 -21.8 -
Beta-receptor antagonist, oral -11.5 -14 -
Beta-receptor antagonist, iv -16.4 -5 -
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Table 2. Blood pressure changes by type of intervention (Continued)
Calcium channel blocker, oral -7.6 -13.2 -
Calcium channel blocker, iv -9.8 -31.9 -
Nitric oxide donor -9.3 -7 -1
Diuretic, thiazide-like -20.0 - -15
Low BP target -11.4 -10 -8
Overall -11.2 -7.7 -7
ACE-I: angiotensin converting enzyme inhibitors
BP: blood pressure
SBP: systolic blood pressure
iv: intravenous
Table 3. Heart rate changes at day 1
Type of intervention Trials Participants Day 1 95% CI
ACE (oral) 2 39 0.03 -40.4 to 40.5
Alpha-2 adrenoceptor
agonist
1 3 - -
Calcium channel
blocker, oral
2 83 -2.6 -7.7 to 2.6
Calcium channel
blocker, iv
1 11 -16.9 -27.4 to -6.5
Nitric oxide donor 5 4197 4.5 1.5 to 7.6
ACE: angiotensin converting enzyme
iv: intravenous
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. blood pressure.tw.
2. hypertension.tw
3. acute/
4. stroke.tw.
5. or/1-4
6. and/1-4
7. 1-4.kf.
8.1-4.ti.
9. trials
10. 1-4 and 9
11. 1-4 and 9.ti.
12. ischaemic stroke.tw/ti.
13. haemorrhagic stroke.tw/ti.
14. intracerebral haemorrhage.tw./ti.
15. blood pressure lowering/
16. blood pressure increase/
17. 1-4 or 12
18. 1-4 or 13
19. 1-4 or 14
20. 1-4 and 15
21.1-4 and 16
22. cerebr
23. 1-4 or 22
24. vasoactive/
25. 12-16 or 24
26. nitrate.tw.
27. glyceryl trinitrate/GTN.tw
28. nitric Oxide Donors.tw.
29. 1-4 and/or 26-28
30. 9, 12-13, 16 and/or 26-28
31. thiazide.tw.
32. bendrofluazide.tw.
33. bendroflumethiazide.tw.
34. hydrochrlothiazide/HCT.tw.
35. 31-34 and/or 1-4
36. 31-34 and/or 12-15
37. beta blockers.tw
38. atenolol.tw.
39. propanalol.tw.
40. 37-39 and/or 1-4
41. 37-39 and or 12-15
42. calcium channel blockers.tw.
43. nimodipine.tw.
44. nicardipine.tw.
45. amilodipine.tw.
46. felodipine.tw.
47. isradipine.tw.
48. nifedipine.tw.
49. nisolodipine.tw.
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50. 42-49 and or 1-4
51. 42-49 and or 12-15
52. angiotensin-converting enzyme inhibitors/ACE inhibitors.tw
53. captopril.tw.
54. enalapril.tw.
55. lisinopril.tw.
56. perindopril.tw.
57. ramipril.tw.
58. 52-57 and or 1-4
59. 52-57 and or 12-15
60. angiotensin receptor blockers/antagonists.tw.
61. candesartan.tw
62. losartan.tw.
63. telmisartan.tw
64. valsartan.tw.
65. clonidine.tw.
65. 60-65 and or 1-4
66. 60-65 and or 12-15
67. vasoconstrictors.tw.
68. dopamine.tw.
69. dobutamine.tw.
70. noradrenaline.tw.
71. phenylephrine.tw.
72. 67-71 and or 3, 4, 9, 16
73. cerebral blood flow
74. autoregulation
75. stroke outcome
76. 73-75 and or 1-4
77. 73-75 and or 12-16
Appendix 2. EMBASE search strategy
1. blood pressure.tw.
2. hypertension.tw
3. acute/
4. stroke.tw.
5. or/1-4
6. and/1-4
7. 1-4.kf.
8.1-4.ti.
9. trials
10. 1-4 and 9
11. 1-4 and 9.ti.
12. ischaemic stroke.tw/ti.
13. haemorrhagic stroke.tw/ti.
14. intracerebral haemorrhage.tw./ti.
15. blood pressure lowering/
16. blood pressure increase/
17. 1-4 or 12
18. 1-4 or 13
19. 1-4 or 14
20. 1-4 and 15
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21.1-4 and 16
22. cerebr
23. 1-4 or 22
24. vasoactive/
25. 12-16 or 24
26. nitrate.tw.
27. glyceryl trinitrate/GTN.tw
28. nitric Oxide Donors.tw.
29. 1-4 and/or 26-28
30. 9, 12-13, 16 and/or 26-28
31. thiazide.tw.
32. bendrofluazide.tw.
33. bendroflumethiazide.tw.
34. hydrochrlothiazide/HCT.tw.
35. 31-34 and/or 1-4
36. 31-34 and/or 12-15
37. beta blockers.tw
38. atenolol.tw.
39. propanalol.tw.
40. 37-39 and/or 1-4
41. 37-39 and or 12-15
42. calcium channel blockers.tw.
43. nimodipine.tw.
44. nicardipine.tw.
45. amilodipine.tw.
46. felodipine.tw.
47. isradipine.tw.
48. nifedipine.tw.
49. nisolodipine.tw.
50. 42-49 and or 1-4
51. 42-49 and or 12-15
52. angiotensin-converting enzyme inhibitors/ACE inhibitors.tw
53. captopril.tw.
54. enalapril.tw.
55. lisinopril.tw.
56. perindopril.tw.
57. ramipril.tw.
58. 52-57 and or 1-4
59. 52-57 and or 12-15
60. angiotensin receptor blockers/antagonists.tw.
61. candesartan.tw
62. losartan.tw.
63. telmisartan.tw
64. valsartan.tw.
65. clonidine.tw.
65. 60-65 and or 1-4
66. 60-65 and or 12-15
67. vasoconstrictors.tw.
68. dopamine.tw.
69. dobutamine.tw.
70. noradrenaline.tw.
71. phenylephrine.tw.
72. 67-71 and or 3, 4, 9, 16
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73. cerebral blood flow
74. autoregulation
75. stroke outcome
76. 73-75 and or 1-4
77. 73-75 and or 12-16
Appendix 3. Science Citation Index search strategy
1. blood pressure.TI.
2. hypertension.TI
3. acute/
4. stroke.TS.
5. OR/1-4
6. AND/1-4
7. 1-4.TI.
8.1-4.TI.
9. trials
10. 1-4 AND 9
11. 1-4 AND 9.ti.
12. ischaemic stroke.TI/TS.
13. haemorrhagic stroke.TI/TS.
14. intracerebral haemorrhage.TI./TS.
15. blood pressure lowering/
16. blood pressure increase/
17. 1-4 OR 12
18. 1-4 OR 13
19. 1-4 OR 14
20. 1-4 AND 15
21.1-4 AND 16
22. cerebr
23. 1-4 OR 22
24. vasoactive/
25. 12-16 OR 24
26. nitrate.TI./TS
27. glyceryl trinitrate/GTN.TI/TS
28. nitric Oxide Donors.TI./TS
29. 1-4 AND/OR 26-28
30. 9, 12-13, 16 AND/OR 26-28
31. thiazide.TI.
32. bendrofluazide.TI.
33. bendroflumethiazide.TI.
34. hydrochrlothiazide/HCT.TI.
35. 31-34 AND/OR 1-4
36. 31-34 AND/OR 12-15
37. beta blockers.TI
38. atenolol.TI.
39. propanalol.TI.
40. 37-39 AND/OR 1-4
41. 37-39 AND/OR 12-15
42. calcium channel blockers.TI.
43. nimodipine.TI.
44. nicardipine.TI.
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45. amilodipine.TI.
46. felodipine.TI.
47. isradipine.TI.
48. nifedipine.TI.
49. nisolodipine.TI.
50. 42-49 AND/OR 1-4
51. 42-49 AND/OR 12-15
52. angiotensin-converting enzyme inhibitors/ACE inhibitors.TI
53. captopril.TI.
54. enalapril.TI.
55. lisinopril.TI.
56. perindopril.TI.
57. ramipril.TI.
58. 52-57 AND/ OR 1-4
59. 52-57 AND/OR 12-15
60. angiotensin receptor blockers/antagonists.TI.
61. candesartan.TI.
62. losartan.TI.
63. telmisartan.TI.
64. valsartan.TI.
65. clonidine.TI.
65. 60-65 AND/OR 1-4
66. 60-65 AND/OR 12-15
67. vasoconstrictors.TI.
68. dopamine.TI.
69. dobutamine.TI.
70. noradrenaline.TI.
71. phenylephrine.TI.
72. 67-71 AND/OR 3, 4, 9, 16
73. cerebral blood flow
74. autoregulation
75. stroke outcome
76. 73-75 AND/OR 1-4
77. 73-75 AND/OR 12-16
F E E D B A C K
’BEST’ Trial
Summary
The ’Beta-blockade in acute stroke trial (BEST)’ done inNottingham in the 1980s (which compared atenolol, propranolol and placebo)
is not included in this review. Although lowering blood pressure was not the major aim of the trial, lower blood pressures did occur in
the intervention group. Should the study not be included in the review, or be explicitly excluded?
Reference: Barer DH, Cruickshank JM, Ebrahim SB,Mitchell JR. Low dose beta blockade in acute stroke (“BEST” trial): an evaluation.
Br Med J 1988;296:737-741.
Reply
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The BEST trial was not included since the trial’s primary aim was not about altering blood pressure, but rather assessing the effect
of beta blockers in acute stroke. However, BEST is included in our related review published in the Cochrane Database of Systematic
Reviews: Vasoactive drugs for acute stroke. We have drawn this distinction since there are methodological differences between studies
which aim to alter blood pressure, and those which may, or not, have measured blood pressure as part of their protocol.
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Last assessed as up-to-date: 8 July 2014.
Date Event Description
8 July 2014 New search has been performed The searches have been updated to May 2014. We have
added 14 new trials (including 15,858 participants). This
brings the total number of included studies to 26, involv-
ing 17,011 participants. We have added new subgroup
analyses
8 July 2014 New citation required but conclusions have not changed Change in authorship. Whilst substantially more informa-
tion is now available compared with the previous version,
the core questions remain unanswered so the basic conclu-
sion that more data are needed remains unchanged
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Date Event Description
24 October 2008 New search has been performed Contact details updated.
1 April 2008 New search has been performed Review was updated:
(1) Addition of seven completed trials (ACCESS 2003; Hillis 2003; Rashid
2003; Eames 2005; Willmot 2006; Eveson 2007; INTERACT pilot 2008)
involving 943 patients;
(2) Addition of nine ongoing or planned trials (COSSACS 2002; CHIPPS
2005; SCAST2005; ACCOST2006; ATACH2006; TAST2006; Geeganage
2007; Intracerebral haemorrhage ADAPT-E 2007; INTERACT2 2008)
The previous version of the review included five trials involving 210 patients.
The conclusions of this review have not changed with the addition of the new
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